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Abstract 
This study investigated the role of tolerance induction in an inflammatory setting in regard to the 
early growth response genes Egr2 and Egr3. T cells robustly respond to pathogenic antigens during 
infection, but are tolerant to stimulation by self-antigens. The intrinsic mechanisms for self-tolerance 
in the periphery are still not clear. Egr2 and 3 are induced in tolerant T cells in response to antigen 
stimulation by NFAT-medicated tolerant signalling; however, their function in tolerant T cells is still 
unknown.  
The study demonstrated that Egr2 and 3, induced in tolerant T cells, are not directly involved in 
defective proliferation and IL-2 production, the hallmarks of T cell tolerance. However, they are 
essential for preventing inflammatory response of tolerant T cells. In the absence of Egr2 and 3, 
tolerant T cells show impaired proliferation and production of IL-2, but produce high levels of IFN-γ, 
a key inflammatory cytokine. This phenotype resembles CD4 T cells from autoimmune diseases such 
as lupus which show poor proliferative response, but hyper-inflammation. Our study demonstrated, 
for the first time, a distinctive mechanism to control inflammation from proliferative tolerance 
regulated by Egr2 and 3, which may be an important mechanism for the control of autoimmune 
diseases. 
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Chapter 1. Introduction 
1.1 Governance of the immune system  
The immune system is a group of specialised organs, tissues, cells and processes designed to 
protect the body against infection. This complex system is divided into two main functional 
groups: innate immunity, which takes place immediately following antigen encounter, and 
adaptive immunity which is triggered a number of days later (Delves and Riott, 2000). 
1.2 Innate immunity 
1.2.1 Cells of innate immunity 
Macrophages play a key role as they are not only capable of engulfing and killing bacteria by 
phagocytosis, but also present the antigen to CD4+ T cells as antigen presenting cells, 
triggering the adaptive immune response (Aderem and Ulevitch, 2000). Neutrophils are short-
lived cells and are only able to survive about 6 hours in circulation before undergoing 
apoptosis. They are a set of specialised killers that are able to destroy pathogens when 
recognised. Eosinophils and basophils are involved in the mediation of inflammation and 
remain responsive to cytokines produced by the adaptive immune system (Beutler, 2004). The 
innate immune system has adapted to the challenge of the recognition of a vast number of 
antigens by having receptors that are able to recognise conserved motifs. This is necessary as 
pathogens are able to mutate. The motifs are referred to as pathogen associated molecular 
patters (PAMPs). They include bacterial cell wall components such as lipopolysaccharide (LPS), 
yeast cell wall, and formulated proteins (Aderem and Ulevitch, 2000). These molecules are 
activators of the innate immune system. LPS is able to trigger the release of cytokines such as 
tumour necrosis factor (TNF), IL-1 and IL-6, causing symptoms such as hypotension, metabolic 
acidosis, organ failure and fever. LPS is recognised by toll-like receptors, which are adapters 
that help trigger an immune response. The humoral arm of the innate immune system 
includes components such as complement proteins, which are a set of proteolytic enzymes 
that cause inflammation, lysis of bacteria and phagocytosis, and antimicrobial peptides which 
are able to kill microbes and the acute phase response (Beutler, 2004). 
1.2.2 Cytokines 
Cytokine production by the innate immune arm provides an immediate response to 
inflammation and infection (Iwasaki and Medzhitov, 2010)(McGettrick and O'Neill, 2007)). 
Cytokines produced include IL-4, IL-10, IL-6, IFN-γ and TNF. Release of these cytokines can be 
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triggered by complement activation or by pathogens such as bacteria and fungus. For the 
system to be optimal, the release of cytokines is regulated. Initially cytokines mount allergic or 
inflammatory reactions which subside after the reaction is complete (Hu and Ivashkiv, 2009). 
Another set of cytokines is also able to activate T cells and allow for adaptive immune 
responses (Iwasaki and Medzhitov, 2010). Some of the cytokines released are shown in Table 1 
Cytokine Function Pro/anti-
inflammatory 
Reference 
TNF  Induces septic shock, recruits neutrophils and 
monocytes to inflammatory site 
Pro-inflammatory (Griffin et al., 2012) 
IL-1 Allows histamine production in mast cells. 
Increases cell adhesion expression on leucocytes 
Pro-inflammatory (Ben-Sasson et al., 2009; Carmi et 
al., 2009) 
IL-6 Causes acute phase protein release in the liver. 
Activates cytotoxic T cells and encourages 
differentiation of B cells  
Pro-inflammatory (Arango Duque and Descoteaux, 
2014) 
IFN-γ Secreted by natural killer cells and macrophages 
to elicit inflammatory response 
Pro-inflammatory (Schroder et al., 2004) 
IL-10 Suppresses macrophage activation, hinders 
production of inflammatory cytokines  
Anti-inflammatory (Fiorentino et al., 1991) 
TGF-β Supresses Th1 and Th2 activity Anti-inflammatory (Travis and Sheppard, 2014; 
Josefowicz, Lu and Rudensky, 2012) 
Table 1 Cytokine functions 
1.2.2.1 Complement pathway 
Complement is a host defence system developed within innate immunity that is triggered by 
the identification of pathogens via surface receptors (Janeway,Charles,A,Jr et al., 2005). It can 
be activated in 3 ways, and thus has three specific pathways. Firstly, the classical pathway is 
activated through the activation of the molecule C1q. Secondly, the lectin pathway is activated 
through non-self-recognition using pattern-recognition receptors. Finally, the alternative 
pathway takes place as a result of spontaneous hydrolysis of the molecule C3 (Walport, 2001) 
(Janeway,Charles,A,Jr et al., 2005).  
The three main effects are: priming the immune response by generating anaphylatoxins, the 
direct lysis of surfaces that have been targeted for destruction and opsonisation, and 
clearance of the target including the recruitment of cells such as macrophages and neutrophils 
(Janeway,Charles,A,Jr et al., 2005; Walport, 2001). 
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1.2.3 Adaptive immunity 
The adaptive immune system is primed to be able to deal with invading pathogens in a timely 
manner. A broad repertoire of T cells must be generated in order to respond to the large 
number of pathogens (Schartner, Fathman and Seroogy, 2007). The adaptive immune system 
has evolved to maximise the response to non-self-antigens and reduce response to self-
antigens. 
1.2.3.1 Cells; general function 
Adaptive immunity heavily relies on the ability of B and T lymphocytes to express a wide range 
of unique surface receptors created via somatic DNA arrangement and random chain pairing 
(O'Garra and Vieira, 2004). The adaptive immune response has a number of advantages. 
Firstly, it has a high diversity of antigen receptors meaning it has a high specificity for antigens, 
thus it is able to target a wide variety of antigens. Secondly, it has the capability of 
immunological memory due to the production of antibodies by B lymphocytes. Thirdly it 
allows for clonal expansion and specialisation to deal with district pathogens. In addition, the 
adaptive immune system has self- and non-self-discrimination functionality in order to avoid 
autoimmune disease development. The problem of self and non-self-discrimination is tackled 
by negative and positive selection in the thymus, which will be discussed later (Palm and 
Medzhitov, 2009).  
1.2.3.2 Cell mediated immunity 
Cell mediated immunity refers to the functions of T lymphocytes in the immune system; there 
are two main types, CD4+ and CD8+ T cells. The fate of the T cell during adaptive immunity 
depends on two major molecules: T cell receptors (TCR) and Major Histocompatibility 
Complexes (MHC) (O'Garra and Robinson, 2004). For T cells to be activated, these molecules 
must interact in the correct manner. Maintaining the right amount of these cells is crucial for 
optimal host defence. This works with the first step of the adaptive immune system to 
recognise where the infection is coming from and what kind of infection it is (Palm and 
Medzhitov, 2009). 
The consequences of TCR interaction with peptide-MHC ligands depend heavily on the quality 
of the interaction. TCR engagement is essential for an immune response. The extent to which 
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the TCR-ligand pair interacts with the CD4/CD8 co-receptor plays an important role in 
producing high quality signals (O'Garra and Robinson, 2004).  
1.2.3.3 Humoral mediated immunity 
Humoral immunity allows for the activation of B cells and thus antibody production. The 
antibody response that requires antigen specific T cell help are referred to as T cell dependant 
antigens (Janeway,Charles,A,Jr et al., 2005). The signal for B cell activation can either be T cell 
dependant or independent according to the pathogen encountered. Activation of B cells leads 
to clonal proliferation to produce plasma cells and memory cells. The plasma cells then 
produce antibodies that circulate in the body while the memory cells remain creating 
immunological memory in case of re-encounter with the pathogen (Janeway,Charles,A,Jr et al., 
2005).  
Figure 1: Innate and Adaptive Immunity  
The immune system is made up of two main parts., innate and adaptive. Innate immunity which takes place just 
hours after infection. It includes complement pathway activation inducing pathogen lysis, opsonisation and 
clearance. Phagocytosis is also induced causing cells such as macrophages to engulf invading pathogens. Adaptive 
immunity includes B and T lymphocyte function; B lymphocytes are able to produce antibodies and aid in 
immunological memory and T lymphocytes differentiate into effector subsets such as CD4+,CD8+ and T regulatory 
cells (Treg). With each subset having a specific role in immunological defence. 
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1.3 Central tolerance  
Central tolerance refers to the events in early life of a lymphocyte that focus the adaptive 
immune system against invading pathogens. Central tolerance is the process by which 
developing B and T cells are primed to be non-reactive to self. It includes the development of 
B cells within the bone marrow and that of T cells within the thymus. Central tolerance allows 
for the main development of self-tolerance, and includes all the mechanisms by which 
antigen-receptor recognition of self-antigens at specific sites result in the generation of 
tolerant B and T lymphocytes (Hogquist, Baldwin and Jameson, 2005).  
Around 90% of DP thymocytes express TCRs that interact so poorly with the available self-
peptide-MHC ligands that the signals required are not sustained, leading to cell death by 
neglect (Vieira, 2004). The hallmark of central tolerance is clonal deletion; this is the suicide of 
T cell progenitors that have a high affinity for self-peptides (Schietinger and Greenberg, 2014). 
Although central tolerance plays a large role in the development of self-reactive T and B 
lymphocytes, it is still possible for reactive lymphocytes to pass into other parts of the body 
because not all self-antigens are expressed within central tolerance sites. Thus the periphery is 
able to deal with these using peripheral tolerance mechanisms (Hogquist, Baldwin and 
Jameson, 2005).  
1.3.1 T cell development  
T cells originate from bone marrow haematopoietic precursors similar to B cells. They then 
lose their potential to become any other subset along the way. There are 4 main stages in the 
production of functional thymocytes: the entry of lymphoid progenitors into the thymus, the 
generation of double positive thymocytes in the outer cortex of the thymus, the selection of 
double positive (DP) thymocytes in the inner cortex and finally the interaction of positively 
selected thymocytes with medullary thymic epithelial cells.  
1.3.1.1 Generation of CD4+ and CD8+ thymocytes 
Lymphoid progenitors begin in the bone marrow and later migrate to the thymus; this is 
where T cell development takes place. The first step of T cell selection takes place in the 
thymic cortex. At this point thymocytes showing no affinity for peptide-MHC expressed by 
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cortical epithelial cells die (Xing and Hogquist, 2012; Palmer, 2003). Central tolerance depends 
on the presentation of self-antigens and is part of the thymic selection process. T cell 
differentiation takes place in a number of stages. In order for T cells to be active they must go 
from double negative to double positive T cells. Each T cell subset is identified by its surface 
receptors CD44 and CD25 (Germain Ronald N., 2002). There are 4 main double negative (DN) 
stages; (DN1, CD44+CD25-; DN2, CD44+CD25+; DN3, CD44-CD25+; and DN4, CD44-CD25-). Before 
T cells become double positive cells, they interact with MHC molecules to determine their 
fate, and this is referred to as active signalling. 
 
Figure 2: T cell development in the thymus 
T lymphocyte development takes place in the thymus, which is a primary lymphoid organ. The 
development involves the maturation of T cells from the double negative (DN) stages to the effector 
single positive (SP) T cells. The DN stage has 4 main phases,  DN1, CD44+CD25-; DN2, CD44+CD25+; 
DN3, CD44-CD25+; and DN4, CD44-CD25-, that take place into the cortex of the medulla. Following DN4, 
there is cells death due to neglect but surviving cells become double positive (DP) T cells. DP cells meet 
antigen presenting cells (APCs) that carry the antigen via major histocompatibility complexes (MHC’s) in 
the medulla of the thymus. This allows for either positive selection or negative selection. Positive 
selection results in the production of effector SP T lymphocytes such as CD4+ and CD8+, while negative 
selection results in cells death via apoptosis. Surviving cells move out of the cortex into the periphery. 
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1.3.1.2 T cell receptor (TCR) and antigen receptor diversity 
For a T cell to be functional it must have a TCR on its surface. These are transmembrane 
proteins that consist of heterodimers; α/β or γ/δ (Germain Ronald N., 2002); (Delves and Riott, 
2000; Delves and Riott, 2000; Delves and Riott, 2000)). The development of the TCR begins at 
the DN2 stage in the thymus from the Pre-TCR formation to mature TCR. The T cell receptor is 
made up of two main chains with a constant domain and variable region. There are two main 
classes of T cell receptor; the α/β and the γ/δ. During T cell maturation we see the 
development of the α/β TCR. Each the α and β chains are joined using a disulphide bond and 
anchored within the cytoplasm of the cell (Brownlie and Zamoyska, 2013). 
 
Figure 3: αβ T cell receptor structure  
The α/β TCR is showing two main regions, the variable region (V) and the constant region (C). Each chain 
is anchored in the cytoplasm and α and β chains joined via a disulphide bond. 
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The variable domain in the α/β TCR recognises complexes formed by the peptide and MHC 
molecule. The TCR must be diverse in order to allow for the identification of a vast array of 
pathogens. To increase diversity, a recombination process takes place which results in the 
modification of the variable genes. There are four regions in T cell receptor gene organisation: 
Variable (V), Diversity (D), Constant (C) and Joining (J) regions. The recombination process 
involves these segments. In order for recombination to occur, Recombination Activating Genes 
(RAG-1 and RAG-2) must be present to control the enzymatic processes that need to take 
place (Delves and Riott, 2000). This process gives rise to TCR-β; this then meets pre TCR 
(expressed in stages DN2-DN4) and forms a mature TCRαβ. The replacement of the TCR 
isotypes gives rise to double positive (DP) thymocytes (αβ-TCR+CD4+CD8+) (Germain Ronald 
N., 2002). Thymocte development allows for specialised reactions to specific antigens. The 
resulting large number of DP thymocytes must undergo positive selection in order to 
determine what subset would be most necessary for function. 
1.3.1.3 Antigen presentation 
T cells require peptide presentation in order to recognise the antigen; this is done with the 
help of antigen presenting cells or APCs. In order to present an antigen to T cells APCs must 
process the antigen; that is, to degrade the protein into recognisable peptide fragments. APCs 
can be divided into two main categories: professional APCs which include mature dendritic 
cells, monocytes, macrophages and B cells, and non-professional APCs include fibroblasts and 
epithelial cells (Holling, Schooten and van Den Elsen, 2004).  
In order for T cell maturation, APCs must present a peptide with the aid of a major 
histocompatibility complex or MHC. Only then can a T lymphocyte adequately become 
functional, as T cells are not able to recognise peptides that are not bound or loaded onto an 
MHC molecule (Holling, Schooten and van Den Elsen, 2004); (Janeway,Charles,A,Jr et al., 
2005). 
Major histocompatibility complex (MHC) 
The role of MHC molecules is to bind processed antigens (peptide fragments) to T lymphocytes 
via the TCR. There are two main types of MHC: MHC class I which present antigenic peptides 
to CD8+ T cells, and MHC Class II which present to CD4+ lymphocytes. MHC molecules are 
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glycoproteins and are part of the immunoglobulin superfamily. The MHC class I and II 
molecules are similar in structure and are made up of four domains. In the MHC class I three 
are α-chain domains and one is β, while MHC class II is made up of two α chains and two β 
chains. They each form a peptide binding cleft (Holling, Schooten and van Den Elsen, 2004) 
(see Figure 4). 
Human MHC genes are known as human leucocyte antigen or HLA, while in the mouse they 
are known as H2 genes. MHC molecules have adapted to their function in a number of ways to 
prevent pathogens from invading the immune system. Firstly, they are polygenic, that is there 
are several different MHC class I and class II genes allowing for wider ranges of peptide-
binding specificities; within humans, the MHC class I HLA (-A,-B and -C) and class II HLA (-DR,-
DP and -DQ). Secondly, they are highly polymorphic, meaning there are increased variants of 
each gene, and in fact MHC genes are the most polymorphic genes found (Holling, Schooten 
and van Den Elsen, 2004); (Janeway,Charles,A,Jr et al., 2005). 
 
Figure 4: Major histocompatibility complex (MHC) Structure 
Major histocompatibility complex (MHC) had two main types; MHC class I and MHC class II. Each are 
made from α and β chains. The MHC class I contains three α subunits and one β. While MHC class II 
contains two α subunits and two β subunits.  
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1.3.1.4 T cell fate  
For tolerance to be maintained, selection of mature T cells must take place from an array of 
immature thymocytes within the bone marrow, and three outcomes are possible: negative 
selection, positive selection or death by neglect (see Figure 5) (Palmer, 2003). It has been 
reported that death by neglect is due to a lack of the TCR to bind to the MHC-peptide complex, 
thus the cells do not receive a signal. It has been shown that 90% of the thymocyte population 
dies this way, leaving the remainder for further selection.  
 
Figure 5: T lymphocyte fate 
On selection T cells can undergo 3 possible fates: 1) Death by neglect, which happens to 90% of 
thymocytes, is due to a failure of the TCR to bind to/recognise the MHC-peptide complex. 2) Positive 
selection where double positive thymocytes (DP) mature into single positive (SP) thymocytes and takes 
place when the TCR recognises the self-peptide MHC complex producing self-MHC restricted self- 
tolerant T cells. 3) Negative selection when the TCR recognises the self-peptide MHC and self-antigen 
causing apoptosis.  
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T cell fate is highly dependent on the interaction between the TCR and the MHC-peptide 
complex. DP cells are able to interact through the mature TCR complex with peptide-MHC 
complexes that are expressed by stromal cells within the cortex (Takahama, 2006). Here the 
quality of interactions with these complexes dictates whether positive selection will take 
place. Once the TCR has recognised the MHC ligand at an adequate/low affinity and is able to 
interact with it, the DP thymocytes are able to receive signals for differentiation and survival 
giving rise to single positive (SP) lymphocytes (Takahama, 2006; Germain Ronald N., 2002; 
Germain Ronald N., 2002; Delves and Riott, 2000). 
Reports have shown this is dependent on the ‘affinity model’, meaning the strength of the 
signal. Negative selection is activated when the molecules interact with high affinity whereas a 
low/intermediate affinity interaction results in positive selection. If there is lack of affinity at 
all, cells will die by neglect. In addition, it was found that the mechanisms within the body are 
able to allow high-affinity self-reactive T cells to become T regulatory cells (T regs) (Klein et al., 
2009). Together these mechanisms make up central tolerance between TCR and MHC-peptide 
complex determines the fate of the T cell. It has been reported that intermediate signals lead 
to the production of T reg cells (see Figure 6) (Klein et al., 2014). 
 
Figure 6: Affinity thresholds in T cell selection 
The TCR can recognise the MHC-ligand at different affinities. Negative selection is activated when the 
molecules interact with high affinity whereas a low affinity interaction results in positive selection. High-
affinity self-reactive T cells become T regulatory cells If there is lack of affinity at all, cells will die by neglect 
(Klein et al., 2014). 
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1.3.1.5 Positive selection 
Thymocyte differentiation involves the transition of double positive thymocytes (DP) into 
single positive (SP) thymocytes. (Takahama, 2006)(Germain, 2002). Positive selection takes 
place when the TCR meets the self-peptide MHC complex with a low affinity interaction 
(Figure 7) allowing for the survival of the cell (Nakagawa et al., 2012). Reports have found 
positive selection to be dependent on the TCR and MHC-complex interaction within T cells but 
not in B cells (Baldwin et al., 2005). Positive selection has been reported to primarily take 
place within the cortex of the thymus and is assisted by specialised antigen presenting cells 
called cortical thymic epithelial cells (cTECs) (Nakagawa et al., 2012). cTECs were found to play 
an essential role in the processing of antigens and reports have suggested their role in multiple 
proteolytic pathways within positive selection (Nakagawa et al., 2012). 
 
Figure 7 : Positive selection in T lymphocytes 
Positive selection takes place in the cortex. It involves the selection of double positive thymocytes into 
single positive thymocytes. On the TCR recognising the MHC-self-peptide complex at an intermediate 
strength, the lymphocyte is allowed to survive and become a single positive lymphocyte. Cortical 
epithelial cells or cTECs are able to release proteases that aid in MHC stabilisation to encourage TCR 
binding.  
Positive selection involves the generation of single positive thymocytes from double positive 
ones, that is the generation of CD4+ and CD8+ T cells (Figure 7) (Hogquist, Baldwin and 
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Jameson, 2005). Antigen processing via cTECs in regard to CD8+ commitment requires MHC 
class II presentation. In this case, cTECs express a proteasome called β5t (Florea et al., 2010). 
In the case of the generation of CD4 T cells, with MHC class II interaction, cTECs express a 
different set of proteases, namely cathepsin L and thymus-specific sense protease (TSSP). Lack 
of cathepsin L results in inefficient CD4 T cell selection (Marrack and Kappler, 1987) with a 
reported 60-80% reduction in CD4 single positive T cell compartment within the thymus 
(Stritesky et al., 2013b). Caspesins protect against the improper loading of MHC class II 
molecules making it imperative for efficient positive selection. TSSP has been found to be the 
key protease that cTECs use in distinct pathways. It has been suggested it has a role in the 
generation of MHC class II bound peptides (Stritesky et al., 2013a). TSSP is encoded by Prss16 
and within Prss16-/- mice, the positive selection of MHC class II restricted to TCR was 
significantly reduced (). Once positive selection has taken place, cells are able to translocate 
into the medulla. 
1.3.1.6 Negative selection 
The process of negative selection contributes to the deletion of self-reactive T cells thus 
helping to avoid autoimmunity. In the event of a TCR recognising the self-peptide-MHC 
complex and the self-antigen at a high affinity (see Figure 8), negative selection prevails (Starr, 
Jameson and Hogquist, 2003)(Palmer, 2003). A small fragment of immature T cells bear TCR 
that are able to bind very well to self-ligands. High avidity interactions elicit signals that lead to 
the deletion of thymocytes. The death of T cells, known as clonal deletion, is a hallmark of 
central tolerance (Kyewski and Klein, 2006). Apoptosis is the process best characterised as the 
mechanism of negative selection as signalling on engagement of these TCRs with self-peptide 
MHC ligands promotes rapid cell death. Cortical DP thymocytes fail to receive TCR signals and 
are also programmed to die at this stage (Goldrath and Bevan, 1999)(Hogquist, Baldwin and 
Jameson, 2005). 
A large amount of research has gone into the studies of negative selection control, more 
specifically the importance of antigen presentation within this process. It has been reported 
that negative selection is able to take place both in the cortex and in the medulla of the 
thymus (Stritesky et al., 2013b; Stritesky et al., 2013b). However, the majority of reports state 
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the medulla is the main area for negative selection as it plays a crucial role in the antigen 
presentation via medullary thymic epithelial cells (mTECs). 
The thymic medulla is able to express a large array of tissue restricted antigens or TRAs. These 
are antigens usually expressed within peripheral organs (Klein et al., 1998). The expression of 
TRAs has been shown to play a major role in the deletion of self-reactive CD4 lymphocytes 
highlighting the medulla within central tolerance (Laufer, Fan and Glimcher, 1999; van 
Meerwijk and MacDonald, 1999). In fact, direct presentation of TRAs by mTECs has been 
shown to result in deletion of CD8+ T cells (Gallegos and Bevan, 2004). 
Interestingly, mTECs have been suspected to have alternative methods in antigenic 
presentation as they have been reported to have decreased efficiency in MHC class II 
presentation of extracellular antigens (Klein, Roettinger and Kyewski, 2001). A number of 
mouse strains have been shown to have impaired characteristics within the medulla; for 
example, nuclear factor kappa-light-chain-enhancer of activated B cells (NFkb) (Kappler, 
Roehm and Marrack, 1987) and TNF-6 (Cho and et, 2003) deficient mice show disturbed 
medullary patterns. Importantly, mTECs express the transcription factor autoimmune 
regulator (AIRE). Defects in AIRE lead to the multi-organ syndrome known as autoimmune 
polyendocriopathy candidiasis dystrophy syndrome (APECED) (Peterson et al., 1998). AIRE-
deficient mice develop spontaneous multi-organ disease (Anderson et al., 2002)(Peterson et 
al., 1998). mTECs also express B7 family of co-stimulatory molecules and can be helpful in the 
induction of clonal deletion of T cells that respond to TSAs (Xing and Hogquist, 2012). 
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Figure 8: Negative selection  
Negative selection takes place when the TCR recognises the self-peptide-MHC complex and the self-
antigen at a high affinity leading to apoptosis. This takes place in the medulla of the thymus. mTECs are 
able to act as antigen presenting cells for this process and express tissue restricted antigens. Co 
stimulation is also provided by mTECs as they express the B7 co-stimulatory molecule that aids in 
deletion via apoptosis. 
1.3.1.7 Molecular pathology of positive and negative selection 
Central tolerance has been shown to be directly upregulated by a number of factors. The 
mechanisms that govern both positive and negative selection have been widely studied. 
Within positive selection, a number of signals have been shown to be important in function. 
Positive section is dependent on TCR interaction at a low affinity. Thus investigation into 
factors downstream of TCR have been studied. Importantly it has been shown that 
cyclosporine A and FK506 can impair positive selection (Wang et al., 1995), meaning a calcium 
flux caused by TCR engagement plays a crucial role. It has also been found that NFAT (nuclear 
factor of activated T cells) activation is required for positive selection as it falls downstream of 
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the calcium flux. It was reported that in the absence of NFAT 4, positive selection was 
impaired (Oukka et al., 1998). LCK, a molecule downstream of signalling, was shown by 
Hashimoto to be required for positive selection (Hashimoto et al., 1996). Another such 
molecule is ZAP70; zap70-/- mice showed disturbed positive selection compared to wild type 
mice (Negishi et al., 1995). This means that TCR activation in positive selection is essential.  
The major factor in negative selection is that of apoptosis. There have been two apoptosis 
pathways suggested, and one is that of the Bcl-2 family. The Bcl-2 apoptosis pathway allows 
for the activation of caspase 9 after cytochrome c binds to APDF-1 (apoptosis death factor-1) 
(Adams and Cory, 2001). Cytochrome c thus allows for a number of cascades eventually 
leading to cell death. Significantly, the Bcl-2 family of genes plays an important role. For 
example, BIM deficient mice seem to have no negative selection mechanism in place (Bouillet 
et al., 2002). Apoptosis initiation can involve cell surface death receptors. They are able to 
initiate caspases via their death-effector domains (DEDs) leading to cell death (Palmer, 2003). 
They include Fas and tumour necrosis factor (TNF) (Nagata, 1997) (Figure 9). The activation 
allows for caspase activation and eventually leads to apoptosis (Tait and Green, 2010).  
Negative selection has also been found to link to the costimulatory signal. It was shown CD28-
/- mice do not undergo anti-CD3 induced apoptosis (Noel et al., 1998). In addition, it has been 
shown that CD28 can induce apoptosis (Palmer, 2003) suggesting that this signal is important. 
CD40 has also been shown to play a role as its deficiency results in blockade of negative 
selection (Foy et al., 1995). CD40L is a member of the TNF family, and decreased expression 
leads to incomplete deletion in self-reactive cells. The map-kinase pathway (MAP-K) has been 
studied within positive and negative selection. The activation of this pathway seems to 
influence the kinetics of signalling during positive and negative selection (Palmer, 2003). 
Introduction 
 
 
17 
  
 
1.3.1.8 Development of natural T regulatory (nT-reg) cells 
T reg cells are also produced in the thymus. They are CD4+ CD25+ cells that function to control 
the differentiation of CD8 and CD4 effector T cells. They make up about 5-10% of CD4+ T cells 
in healthy adult mice and humans (Vieira, 2004). Their function or activation only takes place 
in the periphery. Their production in the thymus relies heavily on the expression of 
transcription factor forkhead box P3( FOXP3) (Hsieh, Lee and Lio, 2012; Josefowicz, Lu and 
Rudensky, 2012). This transcription factor is thought to programme the development of this 
subset. Loss or alteration in this gene in mice caused a phenotype in mice with symptoms that 
included early onset type 1 diabetes, thyroiditis and autoimmune endocrinopathy (O'Garra 
and Vieira, 2004). Humans with FOXP3 mutations develop IPEX (Immunodysregulation, 
Figure 9: Bcl-2 apoptosis pathway 
The Bcl-2 apoptosis pathway is triggered by the activation of Bcl-2 family such as BIM and BAX. This is 
able to activate cytochrome c within the cytoplasm. Cytochrome c then binds to apoptosis factor 1 or 
APF1 causing the activation of caspase 9. at this point the apoptosome is formed and leads to caspase 7 
and caspase 3 activation to induce apoptosis. Death receptor domains within the cytoplasm can also 
cause apoptosis. They are able to trigger the activation of caspase 7 and caspase 3 and lead to 
apoptosis. 
(Tait and Green, 2010) 
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polyendrocrinopathy, enteropathy, x-linked syndrome) which is a severe multi-organ 
autoimmune disease that requires bone marrow treatment. Thus it is important to generate T 
reg cells as they help maintain immune tolerance and prevent autoimmunity (O'Garra and 
Vieira, 2004).  
 
The development of this subset in the thymus is not fully understood. There are many 
mechanisms that give rise to these cells. Thymocytes receive signals based on TCR; affinity to 
the TCR was of greatest concern although it has been found that an intermediate signal allows 
for the induction of FOXP3 expression with low affinity leading to negative selection and high 
affinity to positive selection (Hsieh, Lee and Lio, 2012). 
Downstream of the TCR there are a number of mechanisms that give rise to the development 
of T reg cells, including the activation of NFAT and NF-Kb. Among the many molecules 
activated it has been found that NF-Kβ plays the biggest role. Increased NF-Kβ expression via 
overexpression of IKKb was sufficient to bypass TCR stimulation as it results in the 
development of FOXP3+ T reg cells in the thymus of RAG deficient mice (Hsieh, Lee and Lio, 
2012). 
1.4 Peripheral T cell tolerance 
1.4.1 T cell Activation  
Once cells have reached the point of SP in the thymus they are still naïve. In order for CD8 and 
CD4 T cells to become functional a few things must take place. This process occurs in the 
periphery as these cells are transported out of the thymus into peripheral organs such as the 
spleen and lymph nodes where activation occurs.  
There are three main signals that have to take place in order for a T lymphocyte to be 
activated and become functional (Figure 10). The first is the antigen must be appropriately 
presented on the surface of an MHC molecule allowing for the identification of the antigen by 
the TCR. The second is the co-stimulatory signal which is a second interaction between the 
APC (antigen presenting cell) and the T cell. On T cells the receptor is known as CD28 and APCs 
are able to use the B7 receptor. The coming together of these two receptors allow for the 
second signal to stabilise T cell activation.  
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Figure 10: Signals required for T lymphocyte activation 
In order for activation to take place T cells need three signals; 1) T cell receptor (TCR) signalling is 
required for antigen recognition via the major histocompatibility complex (MHC) class II molecule that 
lays on the antigen presenting cell (APC), 2) Co-stimulatory signalling through CD28 on the T cell and 
CD80/B7 on the APC, 3) the production of cytokines by antigen presenting cells which is able to aid in T 
cell differentiation. 
(Gutcher and Becher, 2007). 
 
Co-stimulation, which is discussed later, also plays a role in the development of this subset; it 
was found that without co-stimulation there was an 80% drop in the number of FOXP3 T reg 
cells. The primary role of the CD28 is to enhance the survival of thymocytes undergoing 
differentiation and CD40, another costimulatory molecule, plays a role in the expansion of T 
reg populations (Hsieh, Lee and Lio, 2012). 
The third signal is the production of cytokines by the APC after the two initial interactions. The 
cytokine secretion is responsible for directing the differentiation of specific cells into the 
appropriate effector subtypes (Gutcher and Becher, 2007). The most important APC cells are 
the dendritic cells (DCs), and these are activated via the recognition of pathogenic antigens by 
cell surface pattern recognition receptors such as toll like receptors and intracellular pathogen 
sensing receptors which include nucleotide oligomerisation domain (NOD)-like receptors. It 
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has been reported that the priming of dendritic cells allows for the initiation of immune 
function. Mature DCs are able to allow the binding of an MHC class II molecule onto their 
surface in order for ample T cell activation. In addition, DCs have an enhanced ability to 
stimulate naïve T cells (Luckheeram et al., 2012a). DCs consist of different subsets and aid with 
co-stimulation to activate the T cell, for example the interaction between CD28 on the TCR and 
CD80 on the DC (Luckheeram et al., 2012b; Gutcher and Becher, 2007). DCs carry the ligands 
of CD28 that lay on the TCR that is CD80 (B7-1) and CD86 (B7-2) which are upregulated after 
DC activation. APCs such as dendritic cells are also the main source of cytokines following T cell 
activation. They are able to release different cytokines and aid T cell differentiation following 
successful activation which will be discussed later (Luckheeram et al., 2012a). One of the main 
cytokines produced by CD4+ T cells is IL-2, although other subgroups are able to produce it, 
such as CD8+ T cells and thymic cells (Nelson, 2004)(Nelson, 2004) 
. 
IL-2 is produced in the secondary lymphoid organs and production is strongly induced after T 
cell activation (Boyman and Sprent, 2012). IL-2 is responsible for clonal expansion of CD4 T 
cells into their functional subsets (Fathman and Lineberry, 2007). Its production allows for the 
activation of a number of transcription factors that in turn activate the production of cytokines 
that direct T helper expansion to the required subset. 
1.4.1.1 TCR signalling 
CD4 T cell activation requires signals from the antigen and the co-stimulatory molecule. Each 
signal produces a cascade that together allow for the production of IL-2 (Boyman and Sprent, 
2012; Fathman and Lineberry, 2007). TCR signalling is essential for T cell activation (Abraham 
and Weiss, 2004). In order to recognise the antigen α and β dimers of the TCR are put into 
place (Abraham and Weiss, 2004). TCR activation allows for a cascade of events that in turn 
activate proliferation and differentiation. On TCR activation via antigens presented on MHC, it 
has been found that changes in cytoskeletal arrangement are induced along with transcription 
factor expression (Brownlie and Zamoyska, 2013). Activation via TCR causes recruitment of the 
SRC family of kinase members Fyn and Lck. These molecules are able to promote the survival 
of naïve T cells (Seddon and Zamoyska, 2002). In addition, Fyn and Lck are important for 
transportation within the nucleus. They are able to phosphorylate ITAMs allowing for ZAP70 
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activation. It has been reported ZAP-70 then undergoes conformational changes and 
phosphorylates LAT or linker for activation of T cells, and SLP76 (Deindl et al., 2007).  
LAT activates a number of mechanisms such as mobilisation of transcription factors and 
expression of T cell growth genes (Brownlie and Zamoyska, 2013). LAT activation also results in 
activation of Ras via guanine nucleotide exchange factors or GEF’s, and phospholipase Cγ 
(PLCγ) on the Golgi apparatus (Quintana et al., 2005)(Bivona et al., 2003). RASGRP-1 or Ras 
guanyl-releasing protein 1 requires translocation to the Golgi membrane. Significantly, this is 
controlled by calcium (Ca2+). When the TCR recognises an antigen, ZAP70 is activated and this 
allows for a calcium flux within the cell. Ca2+ levels increase following TCR activation and Ca2+ 
levels have been emphasised in the control of transcription factor translocation (Feske, 2007). 
Along with DAG (Diacylglycerol), increased calcium levels allow translocation of RASGRP-1 to 
the Golgi membrane (Bivona et al., 2003). Activation of the Ras pathway activates a mitogen-
activated protein kinase or MAPK cascade which eventually leads to the activation of nuclear 
factor of activated T cells (NFAT). Map kinase activation causes the activation of activator 
protein 1 (AP-1) which is a heterodimer of FOS and JUN; Ras pathway activation is reported to 
induce Fos (Quintana et al., 2005). Increased calcium levels thus cause the activation and 
nuclear translocation of NFAT (Harris et al., 2004; Su et al., 1994b). These processes lead to 
proliferation and differentiation into effector T cells.  
1.4.1.2 Co-stimulatory signalling 
Full T cell activation requires help from co-stimulation. In the 1980s the two signal hypothesis 
where TCR signalling was found to be amplified by the CD28 co-receptor was described 
(Sharpe and Freeman, 2002). Signalling molecules fall into two main categories: the tumour 
necrosis factor superfamily (TNF) and the immunoglobulin superfamily (IgSF) (Chen and Flies, 
2013). CD28 expressed on T cells and B7 on antigen presenting cells belong to the IgSF family 
of receptors (Gonzalez et al., 2005; Sedy et al., 2005). 
CD28 has been reported to play a significant role in T cell activation with T cell responses being 
disturbed in CD28-/- mice and in CD80-/- and CD86-/- mice. CD80 and CD86 are ligands of 
CD28 (see Figure 11) (Sharpe and Freeman, 2002; Lenschow, Walunas and Bluestone, 1996). 
CTLA-4 or cytotoxic T lymphocyte antigen 4 is able to prevent interactions of CD28 and B7 that 
lays on the APC. Upregulation of CTLA-4 causes downregulation of CD28 following 
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endocytosis. CTLA 4 is only produced after T cell activation has taken place in order to 
suppress T cell immune responses (Chen and Flies, 2013). It was reported that lack of CD28 
mediated co-stimulation resulted in decreased T cell proliferation (Lucas et al., 1995; Green et 
al., 1994). Unlike TCR signalling, it was reported that CD28 signalling is not sensitive to 
cyclosporine A (June et al., 1987). CD28 signalling has been found to have many roles including 
cell cycle progression and clonal expansion. It also allows for the activation of downstream 
transcription factors such as NFAT, AP-1 and NF-kβ (Acuto and Michel, 2003). 
 
Figure 11: CD28 in T cell interactions  
A T cell becomes active after the T cell receptor (TCR ) meets a major histocompatibility complex (MHC) 
class II molecule loaded with and antigenic peptide. This allows for proliferation, differentiation and 
effector function. Anergy takes place when a T cells receives the signal from the T cell receptor (TCR) 
without that of the co-stimulatory (CD28). Cytotoxic T lymphocyte antigen 4 (CTLA4) has been shown to 
interact with the CD28 molecule on the T cell preventing the binding of CD80, this has been reported to 
cause cell cycle arrest to suppress the immune system. 
(Chen and Flies, 2013) 
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1.4.1.3 Cytokine signalling  
The production of IL-2 after TCR and co-stimulatory signalling allows for proliferation and 
differentiation. On T cell activation, cytokines are released to allow for the influence of T cell 
subset differentiation. Cytokines produced are able to influence differentiation via open 
receptors. In culture, T cells express IL-2; IL-2 receptors on T cells receive IL-2 and activate 
pathways that induce gene expression that aid in proliferation and differentiation into effector 
cells (Alberts, Johnson and Lewis, 2002). Cytokine medicated differentiation into multiple 
subsets is possible through similar mechanisms discussed later. 
1.4.1.4 Transcription network 
The three main transcription factors that are present following T cell activation are NFAT, 
NFKB and AP-1. Activation results in proliferation, differentiation and cytokine production as a 
result of transcription factor function. All the transcription factors are engaged downstream 
following TCR and CD28 stimulation (Gutcher and Becher, 2007). 
NFAT has been reported to be the most directly linked to Ca2+ influx. The NFAT family is made 
up of NFAT 1, 2, 3, 4 and 5, four of which are regulated by calcium (Macian, 2005). As 
regulation of NFAT is important, the calcium mechanism within TCR control has been heavily 
studied. Following TCR-dependant antigenic biding, DAG results in binding of InsP3. When 
InsP3 meets its receptor on the endoplasmic reticulum (ER) it allows the release of Ca2+ from 
Ca2+ stores, although this increase is not sufficient to raise levels significantly. ER also allows 
for the activation of the SOCE (store-operated Ca2+ entry) pathway that opens CRAC (Calcium 
release-activated channel) pathways (Feske, 2007) in the plasma membrane, and the Ca2+ flux 
using these channels are what truly elevate intracellular calcium (Crabtree and Olson, 2002). 
This flux activates calcineurin which in turn dephosphorylates NFAT, which allows for NFAT 
activation and translocation of NFAT into the nucleus (Crabtree and Olson, 2002).  
Once in the nucleus, NFAT is able to act with AP-1. CD28 has been implicated in AP-1 
expression, however the bulk comes from the TCR (Acuto and Michel, 2003). CD28 was 
reported to activate cJUN, which activates AP-1 leading to the production of IL-2 (Su et al., 
1994a). NFkB expression has, however, been primarily linked to CD28 signalling. Activation of 
PKC-θ (Protein kinase C) leads to the activation of NFkB. AP-1 is able to be activated by CD28 
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via the activation of Ras and MAP kinase proteins which allow for c-Fos and c-Jun expression 
(dimers of AP-1) and thus cells that are CD28-/- have a defect in IL-2 production (see Figure 12) 
(Acuto and Michel, 2003). 
 
 
 
 
Figure 12: T cell activation transcription network  
T cell receptor activation (TCR) is able to induce DAG expression and activate InsP3. Insp3 induces 
calcium (Ca2+) release from calcium stores and inducing calcium stores within the membrane (CRAC 
channels) to increase Ca2+ levels within the cell. Ca2+ release activates calcineurin (CaN) and activates 
nuclear factor of activated T cells (NFAT) and allows for its translocation into the nucleus. CD28 
activation triggers RAS activation alongside TCR and activated the MAPK pathway and AP-1 formation 
and translocation into the nucleus. CD28 also activates protein kinase C (PKθ) allowing for NFκβ 
expression and translocation into the nucleus. NFκβ, NFAT and AP-1 in the nucleus initiate the 
transcription of IL-2 which favours proliferation and differentiation. 
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1.4.2 T cell differentiation 
CD4 T cells are able to differentiate into a number of sub populations depending on cytokine 
production after stimulation. T helper (Th) subsets are distinguished by cytokine production 
and expression for specific transcription factors (Coomes, Pelly and Wilson, 2013). Each 
subgroup is specialised for a different purpose and a particular cytokine governs each subset. 
Previously it was reported that T helper cell differentiation is clear cut and divides into two 
main subsets, Th1 and Th2 (Mosmann et al., 2005; Heinzel et al., 1989). Since then other 
subsets have been described. It is important to note that some cytokines are produced by 
more than one subgroup. There are 5 main subgroups, they include Th1, Th2, Treg, Tfh (T 
follicular help) and Th17 (Zhu, Yamane and Paul, 2010). The first group, Th1, produces IFN-γ, 
IL-2, IL-3 and TNF-α. The governing cytokine is IFN-γ, thus these cells induce pro-inflammatory 
responses by activating macrophages, eliminating infection, and causing delayed type 
hypersensitivity. Th2 cells predominantly secrete IL-4 but also secrete IL-13 and IL-5. They are 
able to stimulate B cell activation and help humoral immunity activation. The Th17 subset 
mainly produces IL-17A and IL-17F while the T reg subgroup produces IL-10. This particular 
subgroup is referred to as induced T regulatory T cell (iTreg) which is distinct from the natural 
T reg cell. This subgroup is identified by its ability to produce IL-10. The final subset is that of T 
follicular helper cells. This is another B cell helper with the production of IL-6 and IL-21. These 
cells aid in immunoglobulin class switching within the germinal centre (Zhu, Yamane and Paul, 
2010; Gutcher and Becher, 2007). 
1.4.2.1 Transcription network for distinct T helper differentiation  
Th1 differentiation results in the production of IFN-γ and is initiated by the production of IL-12 
(Trinchieri, Pflanz and Kastelein, 2003). The most important and master regulator of Th1 
differentiation is the T box transcription factor (T-bet). It was reported that the expression of 
T-bet is dependent on signal transducer and activator of transcription 1 (STAT1) (Chen, 
Laurence and O'Shea, 2007). IFN-γ is also able to activate STAT1; this signal is amplified as T-
bet induces more IFN-γ expression and upregulates IL-12R expression (Afkarian et al., 2002). 
STAT4 also plays a role in Th1 differentiation. STAT 4 is induced by IL-12 and also leads to the 
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production of IFN-γ causing a positive feedback loop for IL-12R and T bet expression 
(Luckheeram et al., 2012a). 
Th2 differentiation is governed by the transcription factor GATA binding protein or GATA-3, 
with IL-2 and IL-4 being essential for functional differentiation. STAT6 is induced by the 
production IL-4 (Zhu et al., 2004; Kaplan et al., 1996) (Luckheeram et al., 2012a). GATA-3 
deficiency leads to incomplete Th2 differentiation. STAT-5 has also been implicated in Th2 
differentiation. IL-2 is able to activate STAT-5 independent of IL-4 and so without the 
activation of GATA-3, thus both GATA-3 and STAT-5 are required for full Th2 differentiation. It 
has been reported that GATA-3 and STAT-5 bind to the IL-4 locus at different sites 
(Luckheeram et al., 2012a).  
Th17 cell differentiation involves the master regulator retinoic acid receptor-related orphan 
receptor gamma-t or RORγt, and is governed by a number of cytokines, namely IL-6, IL-23 and 
TGF-β. It has been reported that the process can be divided into 3 parts: TGF-β and IL-6 in 
differentiation initiation, amplification of cells by IL-21, and the use of IL-23 in stabilisation 
(Luckheeram et al., 2012a). TGF-β signalling allows for RORγt activation inducting the 
production of IL-17F and IL-17A (Ivanov et al., 2006). RORγt expression is also governed by 
STAT-3 which is activated downstream of cytokine signalling (Bettelli et al., 2006).  
T reg cell differentiation is governed by FOXP3 expression and these cells are classified as 
CD4+CD25+. Following T cell activation, forkhead transcription factor (FOXP3) is expressed. T 
regs can be naturally occurring or induced (iTregs) in the periphery. IL-2 signalling allows for 
STAT-5 induction which in turn activates FOXP3 expression (Luckheeram et al., 2012a; Burchill 
et al., 2007). T follicular help cell differentiation has been reported to depend on the 
transcription factor Bcl6. IL-6 and IL-21 production allow for its activation (Luckheeram et al., 
2012a). 
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Figure 13: T helper cell subsets 
CD4+ T cells are able to differentiate into 5 main T helper (Th) subsets: T helper 1 (Th1) subset is 
influenced by the production of IFN-γ and IL-12. These cytokines induce T bet expression and in turn Th1 
cells produce IFN-γ. The T helper 2 (Th2) subset is influenced by the production of IL-4 and IL-2. this in 
turn causes the expression of transcription factor GATA-3 within the Th2 cells. Th2 cells produce IL-4 
and IL-13 and play a role in humoral immunity. The T helper 17 (Th17) subset is influenced by the 
production of IL-6 and TGF-B by CD4+ T cells, this allows for RORgt expression and production of IL-17A 
and IL-17F to aid in tissue inflammation. The T regulatory (Treg) subset is also influenced by the 
production of TGF-B with IL-2, this allows for transcription factor FOXP3 expression and production of 
IL-10 by the cells. Treg cells paly a major role in immune suppression and tolerance. The T follicular help 
(Tfh) subset is produced after increased levels of IL-6 and IL-21. this allows for the expression of Bcl6 
and production of IL-10 and IL-21 and play a role in the maintenance of germinal centre response.  
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1.4.2.2 T helper cell plasticity 
CD4+T cells have plasticity to enable them to adapt quickly and deal with pathogens including 
bacteria and viruses. Different subsets are thus sometimes able to influence others in order to 
best deal with the pathogen and restore immunological balance. Some groups have been 
shown to have increased plasticity compared to others. This has been attributed to a number 
of mechanisms that influence this such as epigenetics, cytokine signals, transcription factor co-
expression and the stability of the cell cycle as shown in Figure 14 (Coomes, Pelly and Wilson, 
2013). 
 
Figure 14: Mechanisms of T cell plasticity 
There are a number of mechanisms that have been found to play a role in T helper cell plasticity. They 
include; cell cysle progression, miRNA mediated regulation, immune cell function, cytokine signalling 
and DNA methylation.  
The relationship between Th1 and Th2 has been closely studied. The plasticity of these cells 
decreases with increased rounds of cell division (Grogan et al., 2001). That is in the early 
stages Th1 and Th2 can convert into one another as shown by the groups Murphy et al. (1996) 
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and Zhu et al. (2006). They showed partly differentiated Th2 cells can produce IFN-γ after IL-22 
induction while Th1 cells can also induce IL-14 (Zhu et al., 2006; Murphy et al., 1996). 
Th17 cells have also been found to have great plasticity. It has been reported that its inhibition 
or suppression can be achieved by IL-4, IFN-γ and IL-2 (Coomes, Pelly and Wilson, 2013). Cells 
that secrete IFN-γ potentially stemmed from Th17 cells (Hirota et al., 2011), and Th17 cells can 
become Th1 cells in vitro. Recent data collectively shows Th17 can influence Th1 secretion and 
T bet expression (Coomes, Pelly and Wilson, 2013). 
It has also been reported that Th17 cells can become Th2 cells if programmed properly 
(Coomes, Pelly and Wilson, 2013). Th17 cells were found to produce IL-4 after culture in Th2 
conditions (Panzer et al., 2012). T reg cells have also been shown to be unstable and have high 
plasticity. It was shown that FOXP3+ T reg cells could become Th1 cells. FOXP3 deletion in T 
reg cells results in high IFN-γ and IL-2 production (Coomes, Pelly and Wilson, 2013) indicating 
the Th1 subset. It was also reported that TGF-β promotes both RORγt and Foxp3 (Zhou et al., 
2008). It was reported that the development of Th17 or T reg is dependent on the presence or 
absence of IL-6 (Xu et al., 2007). 
1.4.2.3 T helper subset functions in adaptive immunity 
Each T helper cell subset plays an essential role in immunity. The effector T cell influences the 
type of immune response. Th1 cells play a big role in the elimination of pathogens (Del Prete, 
1992). This is through the effector function of IFN-γ production leading to an inflammatory 
response. They are able to activate macrophages and thus kill pathogens. IFN-γ receptors on 
the macrophage surface bind to IFN-gamma produced by Th1 cells. Macrophages then express 
CD40 on the T cell resulting in phagocytosis (Murray et al., 1985). CD8+ T cells can also be 
activated by the production of Il-2 from Th1 cells and encourage cytotoxic function. In 
addition, IL-2 promoted memory in CD8 T cells following infection (Williams, Tyznik and Bevan, 
2006).  
Th2 cells are able to produce a multitude of cytokines including IL-4, IL-9, IL-10, IL-25 and IL-5. 
They have been reported to stimulate B cells along with Th1 cells. Particularly, Th2 cells 
stimulate B cells during class switching of IgE via IL-4 (Luckheeram et al., 2012b). IL-4 and IL-6 
also allow for the inflammatory setting to be increased through activation of GMCSF 
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(granulocyte-macrophage colony-stimulating factor) (Doucet et al., 1998). IL-10 functions to 
clear immune cells following a heightened immune response thus maintaining homeostasis 
(Couper, Blount and Riley, 2008). Th17 cells respond mainly to fungi and bacteria. Their 
production of IL-17A also contributes to the development of autoimmune disease via 
induction of pro-inflammatory cytokines such as IL-6 and TNF-α (Luckheeram et al., 2012a). 
Th17 cells also produce IL-2 that is able to activate B cells to differentiate into memory cells. T 
follicular help cells function mainly in the germinal centre in the development of memory B 
cells (Fazilleau et al., 2009). 
1.4.2.4 Intrinsic mechanisms of tolerance 
Ignorance 
T cell ignorance takes place when a T cell presented to a self-antigen does not have a high 
enough affinity to result in stimulation, leaving the cell to remain ‘ignorant’ (Parish and Heath, 
2008; Parish and Cooke, 2004). These cells thus exist within the T cell repertoire in the 
periphery and are able to become reactivated and contribute to autoimmune disease later, 
especially after viral infection (Ohashi et al., 1991). 
Senescence 
Senescence is an irreversible state that relates directly to telomere shortening. It is a 
mechanism that results in the permanent cell cycle arrest which is due to the cells’ inability to 
divide and grow. Senescence that has recently been added as one of the mechanisms of 
tolerance (Schietinger and Greenberg, 2013). 
Exhaustion 
Exhaustion takes place when a T cell is exposed to an antigen repeatedly resulting in the cell 
gradually losing its effector function. This is most commonly seen during chronic infection. This 
process has been closely studied within CD8 T cells compared to CD4 and is associated with 
the expression of B Lymphocyte induced maturation protein 1 (Blimp-1) and Eomesodermin 
(Emoes) (Shin et al., 2009). This state is neither fixed or irreversible thus it lacks the ability to 
clear out the pathogen (Schietinger and Greenberg, 2014). It has been reported that there is a 
sustained expression of PD-1 within T cell exhaustion which is speculated to support tolerance 
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induction, and this has been found to be the case within chronic viral infection (Wherry et al., 
2007). 
CD4 T cell anergy  
T cell anergy is a tolerance mechanism wherein a lymphocyte is functionally inactivated 
following an antigen encounter in the absence of co-stimulation (see Figure 15). This is an 
active state, and the cell remains alive for an extended period of time, albeit in a 
hyporesponsive state. The state must be more than 24 hours long to exclude cells that have 
begun apoptosis (Shwartz, 2003). The hallmark of T cell anergy is the failure to synthesize the 
T cell growth factor IL-2 resulting in decreased proliferation (Wells, 2009). Anergic cells have 
been found to not only have a reduction in IL-2 secretion but in a number other cytokines 
including IFN-γ, TNF-α and IL-3 (Zheng, Zha and Gajewski, 2008). This state of clonal anergy 
was found to be reversible by the addition of IL-2 (Fathman and Lineberry, 2007). 
It has been found that disruption of the cell cycle can also lead to anergy. Cell cycle 
progression blocks have been used to prove this theory. For example, when rapamycin is 
added to fully stimulated T cell clones, it leads to anergy and this is a similar case with 
hydroxyurea. Since rapamycin blocks the cell cycle at G1 and hydroxyurea blocks at early S 
phase, it is hypothesised that G1 to S phase is where co-stimulation exerts its greatest effect 
(Shwartz, 2003). Induction of CD4 T cell clonal anergy can be achieved not only be giving a cell 
part of stimulation, but by competition and co-inhibition. Cytotoxic T lymphocyte antigen 
(CTLA-4) is able to compete with B7 for CD28 binding (Shwartz, 2003). B cell anergy has been 
thought to result from defective B cell receptor signalling and chronic antigen receptor 
occupancy leading to the downregulation of surface IgM (Gauld et al., 2005).  
Maintenance of CD4 T cell anergy-transcription networks 
The lack or absence of co-stimulation leads to anergy induction. This results in reduced 
efficiency of MAPK and other pathways, resulting in reduced AP-1 and NFKb activity within the 
nucleus and decreased IL-2 (Wells, 2009). A number of essential pathways have been 
proposed to maintain this state. In order for anergy to take place, a number of things must 
happen within the T cell: TCR activation leads to an increase in intracellular calcium via the 
molecule ZAP70; this calcium flux allows for NFAT translocation; and co-stimulation within the 
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T cell causes MAPK activation where the DAG which lies in the membrane activates RAS 
guanyl-releasing protein 1 (RASGRP-1) which phosphorylates RAS GTP to MAPK activation and 
AP-1 expression. Within tolerant cells the TCR activation is normal however with a lack of 
CD28, DAG is phosphorylated by diaglycerol kinase alpha (DGK-α) into phosphatidic acid. Thus 
there is lack of activation of RASGRP-1 and lack of MAPK activation and AP-1 formation 
(Shwartz, 2003). 
NFAT signalling and CD4 T cell anergy 
A very important part of T cell activation is the calcium flux caused by antigenic stimulation; 
this leads to the activation of NFAT more than any other signal. This particular signal has been 
found to be the most critical in the maintenance of CD4 T cell anergy; this must be able to take 
place even in anergic cells in order to allow NFAT mobilisation to the nucleus (Harris et al., 
2004). 
Map kinase pathway and anergy 
There have been multiple blocks in the map kinase pathway identified with anergy. It was 
found that the DNA binding of the activator protein-1 (AP-1) in anergic T cells was reduced in 
reporter assays. Studies of the signalling pathway found defects in the activation of the 
immediate upstream molecules of the mitogen activated protein kinase (MAP-K) families 
(DeSilva et al., 1996; Li et al., 1996). It was also found that in the lack of activation of MAPKs 
extracellular signal-regulated kinase 1 (ERK1) and or ERK2 in anergic T cells results from a 
defect in the GTP loading of RAS. Even though its guanine-nucleotide exchange factor (GEF) 
was activated normally via son of seven less homologue (SOS) (Fields, Gajewski and Fitch, 
1996).  
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Figure 15: Mechanism of CD4+ T cell anergy  
On activation of the T cell receptor (TCR) and costimulatory molecule (CD28), TCR is able to binding to 
activate ZAP70, this releases activated calcium (Ca
2+
) into the cytoplasm. This calcium flux causes 
activation of NFAT and allows for its translocation into the nucleus. CD28 activation allows for 
diacylglycerol (DAG) activation and its activation of RAS guanyl-releasing protein 1 (RASGRP-1), RASGRP-
1 phosphorylates RASGDP to form RASGTP and cause mitogen-activated protein kinase (MAPK) 
activation and formation of AP-1 through its dimers cFOS and cJUN. Its translocation into the nucleus on 
meeting NFAT allows for IL-2 transcription to take place leading to proliferation and differentiation. 
However during anergy there is lack of co-stimulation. DAG is phosphorylates by diacylglycerol kinase 
alpha (DGK-α) to form phosphatidic acid. Thus RASGRP-1 loading is not possible and there is a lack of 
MAPK activation and AP-1 formation leading to hindrance in IL-2 transcription. 
RAS has been found to be defective in anergic cells, thus the defect is in RAS activation. 
Therefore, downstream MAPK activation could be overcome by the addition of diacylglycerol 
(DAG) analogue phorbol 12-mysristate 1 acetate (PMA) to cultures of T cells during re-
stimulation (Fields, Gajewski and Fitch, 1996). Another pathway proposed for RAS activation in 
T cells is independent of SOS and activated by the protein kinase C (PKC) activator PMA 
(Downward et al., 1990). 
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RASGRP-1 is recruited to the Golgi membrane by increases in the levels of DAG and 
intracellular calcium following T cell activation. Once there, the RSGRP1 promotes the 
conversion of GDP to GTP on RAS leading to the activation of the MAPK pathway. Defects in 
the RASGRP-1 pathway may lead to the induction of T cell anergy as RASGRP-1 deficient mice 
are deficient in proliferation and maturation. DGKs (diaglycerol kinases) phosphorylate DAG 
into phosphatidic acid, reducing the amount of DAG that would be able to activate RASGRP-1. 
Its inactivation would interfere with the MAP kinase-AP-1 pathway blocking T cell activation 
and lead to anergy (Zheng et al., 2012). 
Anergy reversal and inhibition 
The need for a lack of co-stimulation for anergy induction is not the factor that dictates the 
avoidance of anergy. IL-2 is able to reverse the anergic state, meaning IL-2 signalling though 
the IL-2 receptor is the signal that allows the escape form anergy. Il-2 binding to the IL-2 
receptor induces activation of the Jak-Stat and MAPK pathway allowing for the reversal of 
anergy (Wells, 2009).  
NFAT translocation is controlled in a calcium dependant manner. The drug cyclosporine A has 
been reported to play a significant role in anergy inhibition. This immunosuppressive drug is 
able to inhibit the function of calcineurin, which is essential for NFAT translocation into the 
nucleus (Jenkins et al., 1990)(Shwartz, 2003). Studies have shown that when cyclosporine A is 
added to culture with cells receiving only an antigenic stimulation, anergy is inhibited and cells 
are able to produce a normal amount of IL-2 (Yamamoto, Hattori and Yoshida, 2007)(Jenkins, 
Schwartz and Pardoll, 1988)(Fathman and Lineberry, 2007).  
E3 ubiquitin ligases and anergy 
Ubiquitin ligases have been studied in the anergy setting recently. The five major ones under 
study are Cbl-b, Itch, Grail, c-cbl and Nedd4. These proteins are responsible for flagging 
proteins for degradation and destruction.  
Cbl-b expression is linked to calcium mobilisation and calcineurin activation during anergy 
induction (Heissmeyer et al., 2004). It plays an important role in the downregulation of TCR 
expression during antigen recognition (Naramura et al., 2002), with Cbl-b deficient mice 
developing spontaneous autoimmunity (Krawczyk et al., 2000). There is increased C-blb 
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expression within anergic T cells, leading to the recycling and ubiquitination of TCR in 
endocytic vesicles (Mueller, 2004). 
Grail expression is also increased within anergic T cells, and studies show increased mRNA 
levels in induction using calcium ionophore such as ionomycin (Mueller, 2004). Itch expression 
increases with anergy induced by ionomycin with levels similar to grail and Cblb. 
1.4.3 Extrinsic mechanisms 
1.4.3.1 T regulatory cells 
T reg cells are able to function by providing protection in the periphery. There are two main 
subsets of T reg cells described. These are the naturally occurring T regs and the adaptive/IL-
10 producing iT reg cells. 
Naturally occurring T regulatory (nTregs) cells CD4+CD25+ 
Naturally occurring T reg cells were first described by Sakaguchi et al. (2005). These T reg cells 
develop in the thymus and are generated during early events of T cell development. 
Phenotypically they are CD4+CD25+ and also express high levels of cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) and glucocorticoid-induced TNF receptor (GITR). These cells represent 5-
10% of CD4+ T cells in healthy human adults (O'Garra and Vieira, 2004)(O'Garra and Vieira, 
2004) 
. In the periphery, natural T reg cells function in a contact-dependant manner to stop the 
development of self-reactive T cells. nTregs are able to bind directly to either the T helper cell 
or the antigen presenting cell, inhibiting the development of autoimmunity (Bluestone and 
Abbas, 2003). 
Adaptive/inducible T regulatory cells (iTregs) 
Adaptive T reg cells are generated form mature T cells populations following specific antigen 
stimulation (O'Garra and Barrat, 2003). Adaptive T reg cells originate from the thymus but are 
derived from classical T cell subsets (Bluestone and Abbas, 2003). They receive additional 
differentiation after further antigenic stimulation, and may not require co-stimulation through 
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CD28 to be functional. They have been found to be cytokine dependant and once activated 
release cytokines such as IL-10 and TGF-β (O'Garra and Barrat, 2003).  
IL-10 producing T regs are known as T regulatory 1 (TR1) and function by inhibiting the 
production of TNF and IL-12 primarily produced by macrophages. CD8+ T regulatory t cells 
have also been identified. They are able to produce IL-10 or TGF-β- Figure 16(Bluestone and 
Abbas, 2003). 
 
Figure 16: Production of T regulatory T cells  
T regulatory cells (Treg) are first produced in the thymus. On meeting a double positive t cell meeting a 
self-antigen at an intermediate affinity, Natural Treg (nTreg) (CD4+CD25+FOXP3+) cells are produced. 
Naïve CD4+T cells are able to become inducible Treg (iTreg) cells within the periphery on meeting self or 
foreign antigens. iTregs include the TR1 subset and the TR2 subset. Naïve CD8+ T cells are able to 
produce CD8+ Treg cells following encounters with self or foreign antigens within the periphery. 
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1.5 Autoimmunity 
One of the roles of the immune system is to effectively prevent attack on self by reactive self-
antigens leading to autoimmunity. The main function of central tolerance being clonal deletion 
and peripheral to ensure self-reactive T cells are kept at bay. This system is robust although it 
occasionally breaks down. This breakdown can be due to a number of reasons that include 
altered apoptosis, decreased clearance of self-antigens, and reduced fitness of T reg cells that 
may in turn lead to the development of autoimmune disease (Wasterberg, Klein and Snapper, 
2008). The main cytokines that play a role in the induction of autoimmunity include IFN-γ, IL-
17 and IL-22, and if the productions of these cytokines are not monitored such as by the 
production of Treg cells, autoimmune disease ensues. 
1.5.1 Mechanisms of tolerance breakdown  
1.5.1.1 Environmental influence 
Environmental triggers play a large role in autoimmune disease development. Triggers that 
lead to tolerance breakdown include exposure to UV radiation, smoking, infection, toxins and 
antibiotics (Dooley and Hogan, 2003) and they have effects that lead to the development of 
autoimmune disease. Dysregulation of the immune system plays the primary role, wherein 
Treg cell production is compromised (Vojdani, 2014). Toxins have been much studied as 
factors that causes autoimmune disease, working to either induce aberrant cell death or by 
the mechanism of xenobiotics which are organic compounds that are able to induce antibody 
production against tissue protein following binding. It has been reported that chemicals as 
whole play a very large role in that they are able to alter proliferation and stimulate release of 
reactive oxygen species (Vojdani, 2014). Infection with certain viruses or bacteria may also 
trigger an increase in autoreactive antibodies or T cells leading to periods of exaggerated 
immune responses (Wucherpfennig, 2001). The mechanisms that can be induced include 
induced cell death which causes release of toxic material leading to inflammation. Molecular 
mimicry takes place, in which foreign antigens have similar structure to self-antigens leading 
to activation of T cells that are cross-reactive with self-antigens (Kivity et al., 2014). This can be 
seen in cases of herpes simplex virus antigen which cross-reacts with the cornel antigen 
leading to stromal keratitis. Epitope spreading can also take place where a protein changes 
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confirmation and later causes the induction of autoimmune disease as seen in the mouse 
model of encephalomyelitis (multiple sclerosis) (Dooley and Hogan, 2003) (Reeves et al., 
2009). Bystander activation and stimulation of pattern recognition receptors (PRRs) can also 
take place, where viral antigens stimulate PRRs, activation of these receptors leads to the 
release of inflammatory cytokines via the APC (Duke, 1989). Another factor is that of dietary 
components, and studies have shown that an increase in sodium intake can aggravate 
autoimmune disease by activation of Th17 cells (Kleinewietfeld et al., 2013). Sex has also been 
found to play a role with more women being susceptible to autoimmune diseases such 
systemic lupus due to high levels of oestrogen (Tiniakou, Costenbader and Kriegel, 2013). 
1.5.1.2 Genetics 
Genetic predisposition is a well-studied factor contributing to the development of 
autoimmune disease. It has been found that a large amount of predisposition has been 
attributed to association with the human leukocyte antigen (HLA) which encode for MHC 
genes. Rheumatoid arthritis is attributed to the HLA-DR4 while Type 1 diabetes is attributed to 
HLA-DR3. T regulatory cells are also affected and it has been reported a genetic defect in T 
regs leads to X-linked recessive disorder IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome) (Ray et al., 2012). 
1.5.1.3 Dendritic cells (DCs)  
Dendritic cells have recently been found to play a role in autoimmune disease development. It 
is well known that DCs, which are professional antigen presenting cells, are able to promote 
and maintain tolerance and aid in adaptive immune system response, thus they are 
immunogenic. The two types of DCs that are implicated in autoimmunity are the myeloid DC 
(mDC) also known as the conventional DC (Cheong et al., 2010) and plasmacytoid DCs which 
express CD45R and are generally quiescent (Reizis et al., 2011). Tolerogenic DCs work to 
sustain self-specific tolerance and promote anergy, deletion and apoptosis of T cells. Within 
rheumatoid arthritis it has been reported that mDCs and pDCs are highly expressed and 
activated. Leading to their production of interferons (IFNs) and increased expression of MHC 
class II encouraging T cell activation (Santiago-Schwarz, 2004). In EAE the which is the animal 
equivalent of Multiple sclerosis, it has been found that mDCs are involved in disease 
development and pDCs which are usually able to increase the production of Treg cells produce 
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IFNs (Bailey-Bucktrout et al., 2008). Clinical studies have shown increased frequency of MDCs 
within the central nervous system (CNS) which allows for reactivation of T cell responses to 
the myelin (Amodio and Gregori, 2012). In addition, the mDCs have been found to produce 
IFN-γ meaning the activated CD4 T cells are polarised toward Th1 responses by the activated 
mDCs (Vaknin-Dembinsky et al., 2008).  
1.5.1.4 Immune regulation 
Immune regulation plays a large role in the development of autoimmune disease 
development. If regulation of the well-established tolerance mechanisms breaks down, 
autoimmune disease will ensue. This is seen in the disruption of mechanisms such as anergy, 
deletion and ignorance which lead to autoimmune disease development. Natural T reg cells 
express FOXP3 and it has been shown that mutations in FOXP3 lead to the autoimmune 
disease IPEX immune dysregulation polyendocriopathy X linked syndrome (Refaeli, Van Parijs 
and Abbas, 1999) 
(Refaeli, Van Parijs and Abbas, 1999; (Gambineri, Torgerson and Ochs, 2003). Fas-FasL 
interaction allows for cell death within lymphocytes to take place, and mutations in Fas genes 
lead to the development of an autoimmune lymphoproliferative syndrome. CTLA-4, which is 
essential for T cell immunoregulation, has been found to play in a role in lupus development () 
and in type 2 diabetes (Chu et al., 1996) caused by polymorphisms in gene. It has also been 
found that CTLA-4-/- mice develop a lymphoproliferative disease (Refaeli, Van Parijs and 
Abbas, 1999). 
1.5.1.5 Inflammation 
Inflammation may play one of the largest roles in the development of autoimmune disease 
and is assisted by the maturation of dendritic cells (Ray et al., 2012). Danger signals can be 
presented by invading pathogens such as bacteria and viruses which result in inflammation. 
Inflammation induced maturation of DCs provides a pivotal role in autoimmune development 
following infection (Turley, 2002). T cells that escape tolerance against self-peptides in the 
thymus are possibly activated in the periphery when the peptides are altered due to outside 
stimulus, leading to T cell organ infiltration and inflammation (Skapenko, Lipsky and Schulze-
Koops, 2006). 
Introduction 
 
 
40 
1.5.2 Systemic and organ specific autoimmune disease 
Autoimmune diseases area particular problem in the world today as most lack a cure and are 
difficult to control. For this reason, a large amount of research is being carried out to better 
understand them (Rioux and Abbas, 2005). It has been reported that women are more 
affected by autoimmune disease than men, and show more severe symptoms (Whitacre, 
2001). Autoimmune disease can be classified as either organ specific or multisystem/systemic. 
Organ specific autoimmune diseases are recognised by attack on one specific organ while in 
systemic autoimmune disease autoantibodies are directed against multiple organs or 
molecules in the body (Sinha, Lopez and McDevitt, 1990). In organ specific autoimmune 
disease auto-antibodies are directed toward a specific organ, as seen in Type 1 diabetes where 
anti-insulin antibodies are found. Systemic autoimmunity has antigens that are present within 
most cells in the body, as in SLE (systemic lupus erythematosus) where there are anti-
chromatin auto-antibodies present which affect a wide range of cells (Janeway,Charles,A,Jr et 
al., 2005).  
 
Figure 17: Tolerance breakdown mechanisms 
Autoimmune disease can ensue due to a number of factors; environmental influence, Inflammation, 
Immune regulation, Genetic predisposition and alteration of dendritic cell function. These factors have 
been shown to aid in tolerance breakdown leading to autoimmune disease.  
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1.5.3 Autoimmune diseases with inflammation  
Inflammation plays a huge role in the development of autoimmune disease and has remained 
a hallmark in multiple disorders (Theofilopoulos and . Bona, 2002). Within rheumatoid arthritis 
the production of cytokines such as 1L-6, TGF-α and IL-17 are able to encourage tissue 
degradation by means of inflammation. In particular, IL-6 is able to call on neutrophils that 
greatly contribute to joint damage and inflammation by secretion of oxygen intermediates 
(Dayer and Choy, 2010). TNF-α causes increased monocyte activation and T cell apoptosis and 
TCR dysfunction (McInnes and Schett, 2007). Another inflammatory autoimmune disease is 
SLE, which is characterised by the production of auto-antibodies (Mok. C.C, 2003). Within 
systemic lupus self-reactive T cells which escape the thymus become activated. These T cells 
can then provide help to B cells for antibody production and secrete pro-inflammatory 
cytokines, both adding to tissue damage and release of self-antigens (Shlomchik, Craft and 
Mamula, 2001).  
 
1.6 Experimental settings for tolerance induction 
1.6.1 Induction of CD4 T cell clonal anergy in vitro 
In vitro anergy was first described by Schwartz and Jenkins in the 1980’s using CD4 + T cell 
clones. T cell clones were used and their reactions compared with chemically fixed APCs and 
normal APCs. They found that T cells reacting with the fixed APCs produced less IL-2 and 
proliferated poorly compared to the live APCs. Once they re-challenged them, they were 
found to be hyporesponsive (Jenkins et al., 1987a)(Schwartz et al., 1989) indicating an 
unresponsive tolerant state they named anergy. 
There are a number of ways to induce anergy in vitro. The most common is the delivery of a 
strong TCR signal in the absence of co-stimulation (Wells, 2009) using the plate bound peptide 
CD3 specific antibody alone to stimulate CD4 T cells (Fathman and Lineberry, 2007). Another 
method of inducing T cells anergy is the use of ionomycin. This is a calcium ionophore that 
functions by inducing the release of intracellular calcium stores, leading to the activation of 
NFAT proteins much like the CD3 stimulation although using an intracellular pathway 
(Fathman and Lineberry, 2007). 
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1.6.2 In-vivo tolerance induction 
Adoptive tolerance or in vivo anergy is described as the dysfunction of T cells induced by 
suboptimal in vivo stimulation (Schietinger and Greenberg, 2013)(Schietinger and Greenberg, 
2014; Schietinger and Greenberg, 2013) 
2014). There are a number of models that have been used to induce this state of 
unresponsiveness: the systemic delivery of superantigens; adoptive transfer of TCR transgenic 
T cells into hosts that express conjugate antigen as a self-antigen; and administration of 
soluble peptide antigen into TCR transgenic mice (Dubois et al., 1998; Pape et al., 1998; 
Kawabe and Ochi, 1990). 
1.6.2.1 Superantigens 
Superantigens are proteins that are able to bridge the surface of MHC class II molecules and 
make use of the TCR Vβ domain that lies outside the antigen recognition sites (see Figure 18) 
(Fathman and Lineberry, 2007; Kawabe and Ochi, 1990). Examples include staphylococcal 
enterotoxin A and B which are bacterial superantigens. The mechanisms of viral superantigens 
have not been as closely studied as bacterial, although have a similar mode of binding to cause 
T cell stimulation (Janeway,Charles,A,Jr et al., 2005). Unlike other proteins, superantigens 
recognised by T cells without the need for processing into peptides which are otherwise 
captured by MHC molecules because they are able to bind to the Vβ regions and the MHC 
class II molecules away from the complementary site formed by TCR and MHC molecules 
(Fraser, 2011). It has been reported that superantigens are able to stimulate 2-20% of all T 
cells. 
Stimulation via superantigens causes a massive production in cytokines by CD4 T cells, which 
in humans causes diseases such as food poisoning and toxic shock syndrome (Fraser, 2011). 
Bacterial superantigens are now being used within the tolerance mechanism to induce 
tolerance. It has been reported that multiple injections of bacterial superantigens are able to 
induce a state resembling that of in vitro anergy characterised by decreased cytokine 
production and decreased proliferation (Shwartz, 2003). Initial superantigen stimulation 
results in a large portion of T cells being activated resulting in increased expression of 
cytokines such as IL-2, IFN-γ and TNF-α. Once there is a surge, it is followed by a sudden 
decrease in T cell numbers over a period of about three days apparently due to the 
Introduction 
 
 
43 
mechanism of apoptosis. Huang et al. (2007) showed that the remaining T cells are 
hyporesponsive by a mechanism similar to that of anergy (Huang et al., 2007; Kawabe and 
Ochi, 1990). Multiple groups have used superantigens to maintain this form of tolerance that 
required continuous administration of stimulation in vivo (Huang et al., 2007).  
 
Figure 18: Comparison of TCR binding and superantigen binding 
TCR signalling takes place when the MHC Class II molecule carrying an antigenic peptide on the APC 
meets the TCR on the T cell. Superantigen binding is able to bind of outside of the peptide binging 
groove to the TCR and the MHC class II molecule in the absence of antigen recognition 
1.6.2.2  Repeated antigenic stimulation 
The use of peripheral models has become the hallmark for tolerance induction in vivo and TCR 
transgenic mice have been used as a major tool in these processes. It has been found that 
repeated antigenic stimulation leads to the induction of in vivo tolerance (Shwartz, 2003). The 
administration of soluble peptides has been used with cells from transgenic mice to induce 
anergy (Pape et al., 1998). Cells transferred from transgenic mice into normal hosts and 
repeatedly challenged with soluble peptides have been shown to firstly result in T cell death. 
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However, the remaining cells have been shown to be unresponsive to further stimulation, 
express perturbed IL-2 production and are less proliferative. On lack of constant peptide 
administration cells regained their ability to proliferate and produce IL-2 at normal levels 
(Rocha, Grandien and Freitas, 1995)(Shwartz, 2003). 
1.6.2.3 Oral tolerance induction 
Oral tolerance takes place when an orally administered antigen, such as OVA or anti-CD3, is 
able to supress immune responses, either locally and systemically. This is caused with the use 
of food antigens at different doses that are able to cause decreased proliferation when 
administered on a TCR transgenic (Tg) model which allows all T cells to have a common TCR. 
This results in antigen-specific tolerance (Pabst. and Mowat., 2012). Oral tolerance induction 
typically results in the reduction of cytokine production, T cell-proliferation, and systemic 
delayed-type hypersensitivity. This process involves the mucosal system that is the gut-
associated lymphoid tissue (GALT). Oral tolerance depends on this system for functionality. 
The mechanisms of the antigen intake play a significant role using sites such as Peyres’s patch 
(PP) and the gut-draining mesenteric lymph nodes (mLNs) for induction and effector sites such 
as the lamina propria (LP) and intestinal epithelium. Orally administered antigens are first 
recognised by dendritic cells (DC) in the mLNs. Studies have shown that uptake through the 
intestine depends on molecular weight, with low molecular weight material such as 
polysaccharides cross directly through the epithelium via diffusion while larger molecules pass 
via apical membrane transportation. Dissemination of the antigen has been speculated to take 
place via the liver (Pabst. and Mowat., 2012). There have been multiple forms of oral tolerance 
described and it has been reported that one of the main determinants is the antigenic dose. 
Studies have found that at low doses of antigenic feed the induction T regulatory cells are 
triggered while at high doses anergy is induced. Induction of oral tolerance has been found to 
result in the production of T regulatory cells such as IL-10 producing Tr1 cells, natural Treg cells 
and Th3 Treg cells (Pabst. and Mowat., 2012). Reports have shown oral tolerance requires β-7 
integrin gut homing of iTregs (Hadis et al., 2011).  
1.6.2.4 Adoptive transfer 
Like antigenic stimulation, adoptive transfer relies on transgenic models, especially those 
within a Rag 2-/- background. Mice that lack Rag 2 have been found to have no mature 
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lymphocyte population due to defects in VDJ arrangements; this allows them to act as a 
neutral background for immune response studies (Shinkai et al., 1992). Tanchot et al. (2001) 
first described this method. They took CD4 T cells from specific for pigeon cytochrome c (PCC) 
and transfected TCR transgenic T cells on a rag 2-/- background into CD3-/- mice in order to 
induce tolerance. They reported decreased levels of IL-2 by 10 fold and proliferation in 
remaining T cells along with decreased IFN-γ and IL-10 IL-4, IL-3 (Shwartz, 2003; Tanchot et al., 
2001). The use of Rag2-/- mice within oral tolerance can be seen in studies with antigens such 
as OVA. Where hypo responsiveness to a fed antigen is caused due to re-challenge with the 
same antigen; the Rag2-/- background allows for a neutral setting to monitor tolerance 
induction via proliferation (Faria and Weiner, 2006). Rag2-/- mice have been used in 
conjunction with other transgenic models in a similar mechanism to oral tolerance induction. 
Safford et al. adopted the use of 6.5 TCR transgenic (Tg) mice that are specific for the 
hemagglutinin antigen and C3-HA mice which express hemagglutinin as a self-antigen. These 
mice were backcrossed in the TCR Tg Rag2-/- B10.D2 background. To induce tolerance, they 
took T cells from the 6.5 TCR tg mice and adoptively transferred them into the C3-HA mice on 
the TCR Tg Rag2-/- B10.D2 background. This was successful as the self-peptide within the C3-
HA mice was able to recognise the hemagglutinin (homologous antigen) as it is an adjuvant 
resulting in antigen-specific tolerance. This allowed for the monitoring of gene upregulation 
and downregulation within a neutral tolerant background (Safford et al., 2005). 
 
1.7 Early growth response (Egr) genes  
1.7.1 Egr family 
The early growth response gene family is made up of four members: Egr1 (Krox24 and nerve 
growth factor inducible (NGFI)-A), Egr2 (Krox20), Egr3, and Egr4 (NGFI-C). They are a family of 
DNA-binding zinc finger transcription factors which are induced when T cells are activated (Eva 
L. Decker, 2003). All Egr members share a highly conserved zinc finger motif; they all contain 
three cys2his2 that bind to a GC rich consensus motif GCGGGGGCG (Carleton et al., 2002). 
Their DNA binding zinc finger domains are very closely related with about 82% homology, but 
their flanking regions are what differentiate them. This region is able to indicate the specific 
function of each EGR protein (Eva L. Decker, 2003; Carleton et al., 2002). These genes are 
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expressed in a large number of cells including B cells, neurons and thymocytes. A number of 
binding elements for EGR proteins have been identified in cytokines such as IL-2 and cell 
surface receptors such as FasL (Eva L. Decker, 2003). 
1.7.2 Egr function 
The early growth response genes have been studied closely, with each gene found to have a 
specific function within the body. Early studies of these genes were in relation to neurobiology 
with the Egr1 taking the lead in research (Beckmann and and Wilce, 1997). Egr1 was the most 
heavily studied with its functions linked to neurobiology. It was reported to be expressed after 
activation from injury, stress and even multiple growth factors (Pagel and Deindl, 2011). It has 
also been reported to be essential in the development of memory (Jones et al., 2001) with 
Egr1 deficient mice being unable to develop long term memory (Jones et al., 2001).  
Egr2 had been reported to have primary functions that lay in peripheral nerve myelation, 
where it has been found to be essential (Topilko et al., 1994). It also plays a role in bone 
formation (Levi, 1996) and hindbrain segmentation (Nonchev et al., 1996). Egr3 is reported to 
play a role in muscle spindle formation with Egr3-/-mice showing defects in this process 
(Tourtellotte and Milbrandt, 1998a). 
Egr1, 2 and 3 have all been linked to lymphocyte development; Carleton et al. (2002) first 
reported the transcription factors are upregulated during thymocyte differentiation once they 
are past the β selection stage in the DN4 stage. Egr4 however was not detected within this 
population. Li et al. (2011) also reported the upregulation of Egr1, 2, and 3 within thymocyte 
development. Egr4 has been reported to interact with NF-kβ and play a role in the production 
of inflammatory cytokines (Wieland et al., 2005). 
1.7.3 Egr2 knockout model  
Egr2 and 3 have become the main focus within the study of immunity. Thus mouse models for 
these genes have been generated and have allowed for better understanding of their function 
within B and T lymphocytes which are the main arms of the immune system.  
In 2008 Zhu et al. used a CD2-specific Egr2 knockout mouse to more clearly understand the 
role of Egr2. This group showed that Egr2 plays an important role in the prevention of 
autoimmune disease development. On deletion of Egr2 within lymphocytes, they found the 
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population of CD44 high T cells became hyper-responsive exhibiting increased proliferation 
and activation. This led to the accumulation of this population and with that, increased 
production of inflammatory cytokines IL-17 and IFN-γ both of which are associated with 
autoimmune disease SLE (Zhu et al., 2008). In order to further confirm the role of Egr2 within 
the development of T cells, Li et al. (2011) used a CD2 specific Egr2 knockout mouse and an 
Egr2 transgenic to investigate this. They reported the expression of Egr2 influences the 
development of B and T cells. They showed within developing thymocytes in transgenic mice, 
there is an increase in double positive cells that are able to mature into single positive cells 
compared to the WT equivalent. 
Miao et al. (2013) further looked at Egr2 expression in the control of inflammatory cytokine 
production. As it was previously reported that Egr2 knockout mice produce IL-17, they 
concentrated on the differentiation of Th17. They reported Egr2 as able to negatively regulate 
the expression of IL-17, As IL-17 expression is controlled Batf in CD4 T cells. They considered 
that Egr2 is able to control Th17 differentiation by inhibiting Batf. 
1.7.4 Egr2 and Egr3 knockout model 
Li et al. (2012a) carried out analysis on CD2-Egr2-/-Egr3-/- mice. The mice presented with early 
onset systemic autoimmunity, accompanied by increased by lymphocytic infiltration in 
multiple organs. IL-2 production and proliferation of B and T cells from CD2 Egr2- and Egr3- 
deficient mice was impaired on stimulation in vitro, showing that Egr2 and Egr3 are essential 
for efficient proliferation of naïve B and T cells. Production of inflammatory cytokines IFN-γ, IL-
21 and IL-17 was increased in Egr2-/-Egr3-/- CD4+ T cells. It was also found that Egr2 and Egr3 
induce SOCS-1 and SOCS-3 expression with activation of STST-1 and STAT-3 and there was 
reduced expression of SOCS-1 and SOCS-3 in Egr2/Egr3 Knockout mice. It has recently been 
reported that Egr2 and 3 are able to regulate T follicular help cell differentiation, and Ogbe et 
al. (2015) found that Egr2 and Egr3 are able to regulate the expression of Bcl6 (B cell 
lymphoma 6) which is required for the differentiation of Tfh cells. Egr2 and 3 absence results 
in defective expression of BCL6. The roles of Egr2 and 3 within T cells are shown in Figure 19. 
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Figure 19: The role of Egr2 and Egr3 in T cells 
The Egr2-/-Egr3-/- knockout mouse model first described by Zhu et al. has been shown to have 
decreased IL-2 and proliferation levels due to transcription factor Batf binding to AP-1 in the absence of 
Egr2, whereas in presence of Egr2, Batf would bind to Egr2. In addition, the Egr2-/-Egr3-/- mouse model 
has been reported to have increased levels of SOCS-3 and SOCS-1 expression, this resulted in decreased 
expression STAT-3 and STAT-1 respectively, this lead to increased production of pro-inflammatory 
cytokines IL-17 (A and F) and IFN-γ respectively. (Sumitomo et al., 2013) 
1.7.5 Egr2 in autoimmune disease  
Egr2 has recently been studied within autoimmune disease development. Egr2 knockout mice 
were found to have an increased production of inflammatory cytokine production, coupled 
with development of autoimmune disease in the later stages of life (Zhu et al., 2008). Miao et 
al. (2013) studied patients with multiple sclerosis and identified Egr2 as one of the factors that 
influenced differentiation. MS is primarily driven by Th17 mediated inflammation and the 
TH17 T cell subset also plays a major role with the production of IL-17 shown to contribute to 
tissue destruction during inflammation and found to be involved in the maintenance of 
chronic inflammatory disease in patients (Romagnani, 2008). Miao et al. (2013) found 
decreased Egr2 expression in patients with MS compared to healthy patients, showing Egr2 
expression plays a heavy role in mediation of inflammation. Egr2 has also been implicated 
within systemic sclerosis (SSC) which is characterised by autoimmune disease. There have 
been reports of increased expression of Egr2 from patients with SSC and within mouse models 
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(Fang et al., 2011). Similarly, it has been shown within the Japanese population that Egr2 was 
associated with susceptibility to systemic lupus erythematosus (SLE) (Myouzen et al., 2010). 
Systemic lupus has also been studied in regards to Egr2 the absence of Egr2 results in the 
increased production of inflammatory cytokines coupled with symptoms such as 
glomerulonephritis (Li et al., 2012b). There have also been genetic links to egr2 and the 
development of SLE, with polymorphisms in Egr2 identified in patients (Myouzen et al., 2010).  
1.7.6 Egr2 and 3 in tolerance  
The presence of Egr2 in anergic cells has recently been closely studied. Harris et al. (2004) 
found that Egr2 is required for full anergy induction. They looked at the expression of Egr2 in 
the cells and found anergic T cells maintain long term expression and this was the case 
following re-stimulation. Later studies by Zheng et al. (2012) have also proposed that Egr2 is 
needed for T cell anergy induction in vitro and in vivo. Anti-CD3 induction was used to induce 
anergy in vitro, however in vivo induction was measured after a single dose of superantigen 
administration. Diaglycerol kinases (DGKs) have been found to play a role in anergy induction. 
It has been demonstrated that DGK-α is upregulated following anergy induction and may be 
due to Egr2 expression (Zheng et al., 2012).  
Reports have shown an immediate target of the NFAT-mediated transcription following 
calcium flux in T cells is the EGR- early growth response transcription factors (Shwartz, 2003). T 
cell clones screening analysis showed Egr2 and 3 expression during anergy may be dependent 
on the activity of calcineurin and PKC (Safford et al., 2005).  
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1.8 Aim of study 
Early growth response genes (Egr) 2 and 3 have been found to be important for T cell 
development. Previously, we have shown that CD2-specific Egr2 and Egr3 knockout mice 
developed autoimmune diseases with hyper-inflammatory phenotypes. Recent studies have 
shown Egr2 and Egr3 play an important role in T cell tolerance, which allows for protection 
against autoimmune disease development. However, it is still unknown how Egr2 and 3 are 
able regulate T cell tolerance. This project aims to investigate the mechanism of Egr2 and 3 in 
T cell tolerance. The main objectives of the project fall under three areas. 
Firstly, it was important to investigate the induction of T cell tolerance in vitro in the absence 
of Egr2 and Egr3 through the use of antigenic stimulation without that of co-stimulation. This 
led to studies to examine the role of Egr2 and Egr3 induction in an NFAT dependant manner. In 
addition, well known markers of T cell tolerance such as ubiquitin ligase gene expression were 
assessed within the tolerant setting. 
Secondly we investigated in vivo tolerance induction in the absence of Egr2 and Egr3 using 
superantigens. IL-2 and proliferation studies were used and T cells populations within the 
tolerant setting assessed.  
Finally, we investigated the function of Egr2 and 3 in the control of inflammatory response 
within tolerant T cells; by looking at cytokine production following tolerance induction within 
the inflammatory setting provided by T cells from the Egr2/Egr3 knockout model.  
The hypothesis of this study is that Egr2 and 3 induced in tolerant T cells have distinct roles in 
controlling TCR signalling and inflammatory responses.  
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Chapter 2. General Methods and Materials  
2.1 Generation of Egr2-/-Egr3-/- mice 
2.1.1 Animal housing and care 
All mice used in the study were housed in Brunel University according to established 
institutional guidelines under the authority of the UK Home Office project licence (Guidance 
on the Operation of Animals, Scientific Procedures Act 1986) in the Biological Services Unit. 
Weights and animal wellness were recorded during all experiments carried out in accordance 
with the project licence guidelines registered to Dr. Su-Ling Li. All mouse controls were done 
using WT mice within each experiment. In-vitro stimulations used PBS (phosphate buffered 
saline) as controls.  
2.1.2 CD2 specific Egr2 knockout mice (CD2-Egr2-/-) 
Egr2 has been shown to be a crucial player in hind brain development and myelation of the 
peripheral nervous system (Tourtellotte and Milbrandt, 1998a). Systemic knockout of Egr2 
results in multiple defects leading to early death (Tourtellotte and Milbrandt, 1998a)(Nonchev 
et al., 1996). 
A conditional knockout of Egr2 was thus carried out in lymphocytes using the CD2 promoter 
and the cre-loxp system (Zhu et al., 2008). Cre is a recombinase enzyme, which was found in 
the P1 bacteriophage. The cre (cyclisation recombination) gene is attached to the CD2 
promoter in lymphocytes. Cre is able to recombine DNA substrates where lox-p (locus of X 
over P1) sites are present. Lox-p sites are 34 base pairs in length, and are usually placed on the 
ends of the target gene; this is called flanking.  
The cre loxp system is a method used for the targeted deletion of genes. Loxp is able to ‘flank’ the gene. 
When cre meets loxp p, it is able to ‘splice’ the regions the loxp sites have marked and result in the 
deletion of said gene. Diagram from (415 Sauer, Brian 1998). 
Figure 20 - Cre-Loxp system 
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Mice were generated with Egr2 flanked by lox-p sites and other mice were generated to 
express CD2 specific cre. These mice were crossed resulting in the inactivation of egr2 in the 
lymphocytes. Once this had been done the mice were then crossed in a C57BL/6 background 
to purify. The expression of cre and loxp was verified via polymerase chain reaction (PCR) (Zhu 
et al., 2008).  
CD2 specific Egr2-/-Egr3-/- mice. 
Egr3 -/- was carried out systemically using a neomycin cassette (Tourtellotte and Milbrandt, 
1998a). A vector containing Egr3 was flanked using Loxp and a neomycin resistant positive 
selection cassette was added to create a sequence of homology. The egr3 sequence was then 
replaced by neomycin. This vector was linearised and transferred in embryonic stem cells. The 
cells were then cloned and injected into blastocysts and then inserted into female mice. The 
offspring were backcrossed with C57BL/6 mice until a stable germline was established 
(Tourtellotte and Milbrandt, 1998a). 
In order to create CD2-Egr2-/-Egr3-/- mice, CD2-Egr2-/- mice (Zhu et al., 2008) and Egr3-/- 
(Tourtellotte and Milbrandt, 1998a) interbred on the non-autoimmune disease prone C57BL/6 
background (Li et al., 2012a).  
2.2 Genotyping 
In order to confirm Egr2 and 3 knoclout mice, genotyping was carried out. DNA extraction was 
carried out as follows. Mouse tails were collected into Eppendorf tubes and labelled. In each 
tube, 20µl of extraction buffer (Sigma Aldrich, Gillingham, Dorset, UK, E-7526) was added. 
Samples were vortexed and 5µl of tissue preparation solution (Sigma Aldrich, Gillingham, 
Dorset, UK T-3073) was added. Samples were vortexed for not less than 30 seconds, 
centrifuged at 14,462g for 1 minute, and incubated for 30 minutes at 55°c. Samples were then 
heated at 95°c for 3 minutes for enzymatic denaturation. 20µl of neutralisation buffer (Sigma 
Aldrich, Gillingham, Dorset, UK, N-3910) was added to the solution in the tubes, vortexed and 
centrifuged to mix contents. Distilled/autoclaved water was added to each sample: 150µl to 
knockout samples and 300µl to transgenic samples.  
The principle of Polymerase Chain Reaction (PCR) is to generate huge numbers of copies of a 
specified gene. This process incudes three major steps; denaturation, annealing and extension, 
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PCR was carried out as follows: Each PCR tube was prepared with master mix (Thermo 
scientific, Loughborough, UK) solution with primers. For all mixes: with 7.5µl master mix, 
0.25µl sense primer and 0.25µl antisense primer For Egr3 KO samples however we used 7.5µl 
master mix with 0.5µl Egr3 sense primer, 0.5ul Egr3 antisense primer and 0.5ul Neo primer. 
1.5µl of tissue (tail) sample was added into each PCR mix and ran on the required program. 
Programs are shown in Table 2.  
 
Genotyping 
Sample 
Primer sequence PCR protocol Band Size (bp) 
Egr2 Knockout 
LoxP 
Sense: 
GTG TCG CGC GTC AGC ATG CGT 
Antisense: 
GGG AGC GAA GCT ACT CGG ATA CGG 
95°C for 5min 
94°C for 40sec} 
65°C for 40sec} 30 Cycles 
72°C for 40sec} 
72°C for 5min 
4°C for 10min 
Upper Band = 
210bp 
Lower band = 
195bp 
Egr2-/- Cre Sense: 
CCA ACA ACT ACC TGT TCT GCC G 
Antisense: 
TCA TCC TTG GCA CCA TAG ATC AGG  
95°C for 5min 
94°C for 40sec} 
56°C for 40sec} 40 Cycles 
72°C for 40sec} 
72°C for 5min 
4°C for 10min 
150bp 
Egr3-/-  Sense: 
CTA TTC CCC CCA GGA TTA CC 
Antisense: 
TCT GAG CGG GCT GAA ACG 
Neo: 
GAT TGT CTG TTG TGC CCA GTC 
95°C for 5min 
94°C for 40sec} 
57°C for 40sec} 35 Cycles 
72°C for 40sec} 
72°C for 5min 
4°C for 10min 
Upper band = 
700bp 
Lower band = 
350bp  
Table 2: Polymerase chain reaction programmes, primers and band sizes 
 
 
 
 
Gels were made using 2g agarose powder (Invitrogen, cat. Number-15510-027) dissolved in 100ml of 
0.5% TAE buffer. This was heated until it dissolved and cooled for 2 minutes before adding 10µl 
ethidium bromide solution. The solution was poured into the moulding blocks and left to solidify. The 
samples were loaded into a container filled with 0.5TAE buffer with 1.5µl 100 base pair ladder: 100µl 6X 
loading dye (Fisher scientific, R0611, LE115RG,UK) and 50µl 100bp ladder (Invotrogen, cat.no-15628-
019, PA49RF,UK) and ran at their respective volts. Visualisation was via a Syngene Genesys:G-Box. 
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2.3 Organ collection and preparation 
Mouse organs were collected and fixed overnight with 4% paraformaldehyde (PFA) (at least 3 
times the amount of the sample) and then changed to 70% ethanol (Fisher scientific, 
LE115RG,UK- E/0650DF/17) until tissue processing. Samples were processed in a 22-hour 
process as follows: 
Solution Immersion Time 
(Hours) 
Drain Time 
(Seconds) 
70% Ethanol 2 15 
90% Ethanol 2 15 
95% Ethanol 2 15 
95% Ethanol 2 15 
95% Ethanol 2 15 
95% Ethanol 2 30 
100% Xylene 2 15 
100% Xylene 2 30 
Wax 2 60 
Wax 2 120 
Table 3: Tissue processor program 
Organs were then placed into cassettes (Thermo scientific, Loughborough, UK, Shandon- 
41743) and embedded in wax. Sample cassettes were left to harden for at least 6 hours at 
room temperature and then stored at -20 °C. Cutting of each sample was done using a 
microtome and samples cut to thickness between 5 and 7 microns and immediately placed in a 
water bath at 45°C and then transferred on slides and heated at 60°C for 8 minutes to allow 
the paraffin section to adhere to the slide, before putting slides at 37°C overnight. Frozen 
sections were snap-frozen in liquid nitrogen following tissue collection. Embedding was done 
in Tissue-Tek™ CRYO-OCT Compound (Thermo scientific) and sectioned with the use of a 
cryostat. 8μm-thick sections were cut and left at room temperature for 30 minutes. This was 
then followed by fixation in 1:1 acetone: methanol solution at -20˚C for 10 minutes. Sections 
were allowed to air dry for another 10 minutes before storing in -80˚C freezers. 
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2.4 Haematoxylin and Eosin (H&E) staining  
This is the most common form of staining. The affinity of dyes allows us to visualise different 
structures. We used a regressive method where we overstrained the tissue with haematoxylin 
and then washed and stained with eosin. The procedure used was follows.  
Slides were treated with 100% Xylene (Fisher scientific, LE115RG,UK- X/0200/17) for 3 
minutes. This was repeated twice, followed by treatment with 50% xylene and 50% ethanol for 
3 minutes. Slides were then treated with 100% ethanol (Fisher scientific, LE115RG,UK- 
E/0650DF/17) for 3 minutes twice, and then 90% Ethanol for 3 minutes twice. The slides were 
rinsed with distilled water and treated with haematoxylin for 6 minutes. They were then 
washed under running water for 5 minutes; dipped in acid alcohol until samples turned pink; 
washed again and treated with 0.2% ammonium solution for 40 seconds and washed again; 
treated with eosin for 45 seconds and washed again under running water; treated with 95% 
ethanol for 2 minutes three times; 100% ethanol for 2 minutes three times; 50-50 ethanol-
xylene for 2 minutes; and finally 100% xylene for 2 minutes 3 times. Slides were then mounted 
with histomount (National Diagnostics- HS-103) and cover slipped. Photos were captured 
with an Axiscope microscope  
2.5  Immunohistochemistry of frozen sections 
Immunohistochemistry was carried out on frozen sections incubated at room temperature for 
one hour with the directly labelled primary antibody Texas Red conjugated donkey anti-mouse 
IgG (Jackson ImmunoResearch Lab, UK) at a 1:200 dilution. Slides were then washed with 
1xPBS for 10 minutes and left to air dry. Mounting was done using Vectashield with DAPI 
(Vector laboratories, H-1200) and viewing done with a Zeiss fluorescence microscope with 
Smart capture software (Digital Scientific Cambridge, UK). 
2.6 Isolation of CD4 T cells  
Fresh spleen and lymph nodes were collected and homogenised in PBS (phosphate buffered 
saline) (Fisher Scientific Loughborough, UK) using a 40μm nylon cell strainer or mesh (Falcon, 
Stafford, UK). The cells were centrifuged at 124g and re-suspended in 0.8% ammonium 
chloride for 5 minutes at 37°C to lyse the red blood cells. Lysis was stopped by adding PBS and 
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centrifugation at 124g for 5 minutes. Cells were then re-suspended in beads buffer, a mixture 
of 50ml PBS and 3ml RPMI for adequate suspension of the magnetic beads. 
Using a positive selection kit, CD4 positive cells were then isolated by Magnetic Activated Cell 
Sorting (MACS) (Miltenyi Biotech, Almac House, Bisley. UK). Briefly, cells were suspended in 
beads buffer and 20 µl of CD4 beads per WT spleen and 25µl per Egr2-/-Egr3-/- spleen was 
added. The mix containing anti-CD4 antibodies (L3T4) attached to magnetic beads was 
incubated at 37°C for 20 minutes with shaking every 5 minutes with the labelled CD4 T cells 
present in the suspension. Beads buffer was added up to 10ml to allow washing of unlabelled 
anti-CD4, and cells were centrifuged at 124g for 5 minutes at room temperature. The 
supernatant was discarded and the cells re-suspended in 500µl beads buffer. The column was 
washed and 500µl of cells were added. This allowed for CD4+ T cells to be retained within the 
column and unlabelled cells to pass through the column by washing with 1.5ml beads buffer. 
The column was filled to the top with RPMI with 10% Foetal bovine serum (FBS), which 
contains basic nutrients, hormones and growth factors that cells require to survive (Thermo 
Fisher Scientific, Life technologies, Paisley UK), and plunged out to elute CD4 + T cells into a 
separate 15ml tube.  
2.7 Tolerance induction 
2.7.1 In-vitro CD4+ T cell anergy induction 
CD4+ T cells were cultured in RPMI 1640 medium (500ml) stored at 4°C (Gibco-Life 
technologies, Paisley, UK) supplemented with 50ml 10% FBS, 500µl 50μm β-mecaptoethanol, 
10ml sodium pyruvate, 500µl 50μg/ml gentamicin and 5ml 300mg/L L-glutamine all obtained 
from Gibco-Invitrogen, Life technologies, Paisley UK. To induce a state of anergy anti-CD3 
(eBioscience, clone 145-2C11) was used; plates were coated with 1μg anti-CD3/ml at 
300μl/well and activated plates coated with 1μg/ml anti-CD3 and 2μg/ml anti-CD28 
(eBioscience, clone 37.51). Control wells were coated with 300µl PBS. The coated plates were 
incubated for more than 60 min at 37°C to allow antibodies to adhere to the surface of high 
binding plates. Coating solution was discarded after an hour and 1ml PBS was added to each 
well to remove unbound antibody and immediately discarded. 2 x 106 cells per well in 300µl 
medium was added to the plate before 24-hour incubation. This was for anergy induction and 
control. Cells were re-suspended and transferred to a 96-well plate coated with 1μg/ml anti-
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CD3 and 2μg/ml anti-CD28, then re-stimulated for a further 72 hours. Alternatively, cells were 
transferred to an uncoated plate and left to rest overnight before re-stimulation.  
To test multiple concentrations of re-stimulation, plates were coated with anti-CD3 and anti-
CD28; 96 well flat bottom plates were coated with titration of anti-CD3 at 1μg/ml, 0.5μg/ml 
and 0.25μg/ml all with 2μg/ml anti-CD28 at 50μl/well. The plate was incubated for more than 
60 min at 37°C before seeding cells. Re-stimulated cell medium was collected after 48 hours 
for ELISA. After 72 hours, 3H-Tdr was added to each well and incubated overnight. 
 
2.7.2 In-vivo tolerance induction 
Age and sex matched CD2-Egr2-/-Egr3-/- mice were injected 6-8 times, twice a week with 
superantigen to induce in vivo tolerance. For each in vivo sample 6-8 mice were used, where 2 
were pooled together to make one sample. Superantigens are able to stimulate T cells outside 
of the peptide binding groove allowing stimulation of a larger array of the T cell population. 
Staphylococcal enterotoxin A (SEA) (Sigma Aldrich, Gillingham, Dorset, UK) was administered 8 
times with 20μg/ml SEA diluted in 100ml PBS per injection per mouse (fourteen mice were 
used on average per experiment) for anergy induction with a WT and CD2-Egr2-/-Egr3-/- 
sample injected once as an ‘active’ sample positive control (two mice used per experiment), 
and non-injected or PBS injected as negative controls (2 mice used per experiment). All mice 
were sacrificed on the same day and CD4 T cell isolation carried out. Mice weights were 
recorded before each injection.  
2.7.2.1 Ex-vivo culture 
CD4 T cell isolation was carried out after organ collection. Each sample had 2 mice pooled 
together, i.e. cells from two WT mice treated once with SEA made one (active) sample; cells 
from 2 WT mice treated with SEA multiple times made one (tolerant) sample and similarly 
with Egr3-/-Egr3-/- mice. WT CD4 negative cells were used as antigen presenting cells (APCs). 
Briefly, cells were collected and rested in RPMI medium for 30 mins at 37°C. Antigen 
presenting cells were collected and treated with mitomiycin for 30 minutes at 37°C to stop 
intracellular DNA production, thus stopping cell function. Prior to culture at 37°C, APCs were 
loaded with SEA for 3 hours at a concentration of 10μg/ml and washed twice to remove 
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unbound SEA with PBS before culturing with CD4+ T cells (APCs from ‘active’ samples were 
used for active cell culture and APCs from tolerant samples were used for tolerant culture). 
Culture was done in a 50-50 ratio with 50% APC with 50% CD4+ T cells for 48-72 hours. CD4 T 
cells from each sample were stained with the appropriate cell surface markers immediately 
after the culture was complete (refer to chapter on flow cytometry). All other cells were 
cultured with APCs overnight in RPMI with loaded APC (controls were cultured without SEA).  
2.8 Cell viability 
Trypan Blue staining was used to assess cell viability. Briefly, 10µl of CD4 T cell suspended in 
RPMI was mixed with 10µl of trypan blue and cells counted. The following equation was used 
to determine cell viability using a countess automated cell counter (Invitrogen): 
Cell Viability (%) = total viable cells (unstained) ÷ total cells (stained and unstained) × 
100 (http://www.sigmaaldrich.com/technical-documents/articles/biofiles/cell-viability-
and-proliferation.html#sthash.UdUP75eK.dpuf). 
2.9 Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme Linked Immunosorbent Assay or ELISA is a widely used technique useful for 
determination of antigen and antibody concentration (Gan and Patel, 2013). In this case we 
carried out a sandwich ELISA, which takes place when an antigen is detected between two 
specific antigens (Gan and Patel, 2013), for the detection of IL-2 and IFN-γ levels. Both were 
carried out using kits: IL-2 (eBioscience, Altrincham, Cheshire. UK) and IFN-γ (BD, Oxford 
Science Park, Oxford, UK). The following reagents were prepared: Wash buffer made from PBS 
+ 0.05% tween-20, 1x Coating buffer made from 1ml of 10x coating buffer + 9ml Deionised 
water, 1x assay diluents for dilutions or blocking buffer made from 1 part 5x assay diluents + 4 
parts water and Stop solution: 2N H2SO4. 
2.9.1 Interleukin 2 (IL-2) ELISA 
IL-2 ELISAs were carried out according to manufacturer’s instruction and all reagents obtained 
from the kit unless otherwise stated. Briefly, plates were coated by adding 100µl/well of 
capture antibody at a dilution of 250X per well in coating buffer on a high binding plate 
(Granier Bio One, Stonehouse, UK) and incubated overnight at 4°C to allow adherence of 
antibodies. Dilution for IL-2 standard was calculated from certificate of analysis provided with 
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the kit. The next day, wells were washed 5 times with at least 250µl of wash buffer for 5 
minutes, on a shaker. Wells were blocked with 200µl per well of 1x assay diluents (blocking 
buffer) for at least 2 hours at room temperature to avoid unspecific binding, washed 5 times 
with 250µl wash buffer for 5 minutes, and thoroughly blotted and 100µl of sample added per 
well. The standard was added using serial dilution with the highest concentration of 200pg/ml 
down to 0pg/ml in blocking buffer. Plates were incubated overnight at 4°C. Wells were washed 
5 times with at least 250µl of wash buffer on shaker for minutes, the next day. 100µl of the 
detection antibody was added at a concentration of 250x per well and the plate incubated at 
room temperature for 1 hour. Wells were washed and 100µl of Avidin enzyme HRP at a 
concentration of 250x to each sample well for 1 hour. Wells were washed 7 times for 5 
minutes on a shaker, the plate was properly blotted, and 100µl of 1xTMB solution added to 
each sample well. Readings were taken after 15 minutes, 30 minutes and 1 hour after 
development in the dark.  
2.9.2 Interferon gamma (IFN-γ) ELISA 
In the case of IFN-γ, plates were coated with 100µl capture antibody at a concentration of 
250x in coating buffer at 4°C overnight. The next day wells were washed with no less than 
250µl wash buffer (0.05% Tween 20 in PBS) for 1 minute each. This was repeated 5 times and 
100µl/well blocking buffer (10% FBS in PBS) added for 1 hour at room temperature. Wells 
were then washed with wash buffer 5 times for 1 minute each and 100µl samples added; the 
standard was diluted according to certificate of analysis with the highest dilution of 
2,000pg/ml to 0pg/ml and incubated for 2 hours at room temperature on a tightly sealed 
plate. The plate was washed with wash buffer 5 times for 1 minute each and 100µl of 
detection and Avidin enzyme HRP at a concentration of 250x was added for 1 hour before 
washing 10 times with wash buffer for 1 minute per wash. Plates were properly blotted and 
100µl TMB of solution added. Plates were read after 30mins incubation at 450nm and the 
results analysed according to manufacturer’s instruction. 
2.10 Flow cytometry 
Flow cytometry is a technique used to investigate multiple parameters simultaneously within a 
cell population or a single cell. Single cell suspensions were obtained from homogenised 
spleen tissues. Surface staining with fluorescent marked antibodies was carried out first. The 
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flow cytometry kit was obtained from eBioscience, Altrincham, Cheshire, and staining carried 
out according to the manufacturer’s instruction. Cells were centrifuged at 1,844g for 5 
minutes and supernatant discarded. Pellets were re-suspended in a solution with 2μl/antibody 
diluted in wash/permiabilisation buffer and incubated for 20 minutes In the dark. Cells were 
then fixed with fixation buffer from the kit. 
For IFN-γ, measurement cells were first stimulated with 200ng/ml PMA and Ionomycin per 
well in 300μl RPMI in order to bypass barriers into the nucleus and simulate the cells, and 
Golgi stopper (BD Bioscience, Oxford Science Park, Oxford, UK) was added at a 1/100 dilution 
per well to prevent the escape of intracellular cytokines. The cells were incubated for 3 hours 
at 37 degrees. Nuclear staining followed where, cells were collected and centrifuged at 1844g 
for 5 minutes and supernatant discarded and fixed using Fixation/permiabilisation solution for 
20 minutes at 4°C. Samples were centrifuged and 300µl permiabilisation buffer added for 10 
minutes at room temperature. 300µl permiabilisation/wash buffer was added to the same 
tube and immediately centrifuged at 1,844g for 5 mins. Antibody dilutions were prepared and 
pellets re-suspended and incubated in the dark for 20 minutes. Pellets were washed with 
300µl wash buffer and centrifuged for 5 minutes at 1,844g and finally re-suspended in PBS 
ready for flow cytometry analysis.  
Samples were run through a 6 channel flow cytometer on a LSRII or Canto (BD 
Immunocytometry Systems) by Professor Ping Wang at the London School of Medicine and 
Dentistry, Queen Mary University of London. For flow cytometry analysis, single cell 
suspensions were analysed using FlowJo (Tree Star).  
2.10.1 Flow cytometry antibodies  
The following antibodies were used: fluorescein isothiocyanate (FITC)-conjugated antibodies 
to CD4, Vβ3; IFN-γ Phycoerythrin (PE)-conjugated antibodies to, CD4, CD62L, CD69, IL-2, Vβ3, 
Egr2; allophycocyanin (APC)-conjugated antibodies to CD44, Egr2, CD69, IFN-γ; and PEcy7-
conjugated antibodies to CD44, T-bet, IFN-γ. All antibodies were obtained from E-bioscience. 
2.11 Proliferation measurement 
Proliferation was assessed using thymidine (3[H]-TdR). It is able to metabolically integrate into 
the DNA of each new cell, allowing for proliferation to be monitored. To carry out proliferation 
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studies, CD4 T cells were isolated and the respective treatment administered. Cells were then 
plated on a 96-well plate at 2.5x105 cells/well and stimulated with 1μg/ml anti-CD3 and 
2μg/ml anti-CD28 for 72 hours. Following this, 0.5μCi of per well of 3[H]-TdR Tritium diluted in 
RPMI was added, and the plate further incubated at 37°C for 8 hours. Plates were read using a 
scintillator; tritium is able to emit radiation that in turn excites a fluid during scintillation. This 
allows for the production of light which is measured when detected (Madhavan, 2007). 
2.12 Electronic mobility shift assay (EMSA) 
The electronic mobility shift assay or EMSA is a method used to detect protein-nucleic acid 
interactions. All EMSA were completed at Queen Mary University London by Dr. Miao. EMSA 
represents the binding of a transcription factor with the promoter region of a gene. Definition 
of binding sites allows for probe designs, and probes were designed as published by Li et al. (Li 
et al., 2012a). All probes were marked with a fluorescent marker, known as the hot probe, and 
one unlabelled probe (cold probe) was also used as a control. Prior to carrying out EMSA, CD4 
T cells were stimulated with 1μg/ml anti-CD3 and 2μg/ml anti-CD28 for 3 hours or with 1μg/ml 
anti-CD3 overnight followed by re-stimulation with 1μg/ml anti-CD3 and 2μg/ml anti-CD28 for 
3 hours.  
2.12.1 EMSA protein extraction  
Protein extraction was performed as follows. 1ml of cytoplasm lysis buffer (Sigma Aldrich, 
Gillingham, Dorset, UK) was added to each sample for 15 minutes and inverted every 3-5 
minutes. Samples were centrifuged at 14,462g for 1 minute and supernatant discarded. 150µl 
lysis buffer and 1.5µl proteinase buffer was added to each sample pellet and placed on a 
shaker at 4°C for 30 minutes. Samples were then sonicated for 2 minutes 30 seconds and 
centrifuged at 124g for 10 minutes, and the concentration of protein was assessed using 
bovine serum albumin (BSA) assay. 
2.12.2 Bradford assay-protein quantification 
Protein quantification using a BSA assay was performed using 100XBSA reagent (New England 
Biolabs). BSA is able to form a complex when bound to protein lysate, and this allows for a 
shift in absorbance. Serial dilution was carried with BSA was prepared on a 96-well plate from 
a concentration of 5mg/ml down to 0mg/ml at 200μl per well. A similar amount of protein 
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extraction diluted in water and Bradford reagent was added to other wells on the same plate. 
The plate was incubated at room temperature for 5 minutes before being passed through a 
KC4 Luminometre (Bio Tech Inc.). A standard curve was produced with BSA readings and 
protein concentrations.  
Acrylamide gels were made using 1ml 30% acrylamide (Flowgen Bioscience, Nottingham, UK), 
300μl 10x TBE (Amresco, Cleveland, USA), 100μl 10% APS (Sigma Aldrich, Gillingham, Dorset, 
UK), 20μl TEMED and 2.6ml water. Gels were pre-run for 1 hour at 100V in 0.5x TBE.  
2.12.3 EMSA Binding reactions 
For binding reaction steps, 10x binding buffer was used containing 100nM Tris, 500mM KCl, 
35mM DDT, pH 7.5, 2.5% Tween20, Poly-Di-dc 0.5μg/μl in TE, pH 7.5 (Sigma Aldrich, 
Gillingham, Dorset, UK). Binding reactions were made with 2μl of 10x reaction buffer, 1μl 
polyDidc, 2μl of 50% glycerol (Sigma Aldrich, Gillingham, Dorset, UK), 1μl of labelled probe, 
5μg of nuclear extract and water for a total volume of 20μl per sample. After mixing, orange 
dye was added to samples and the samples loaded on the gel and run at 100V. Gels were 
scanned using a Typhoon 9400 imager (Amersham Biosciences).  
 
 
Probes used were as follows: 
AP-1  5’-CGCTTGATGACTCAGCCGGGA-3’  3’-GCGAACTACTGAGTCGGCCTT-5’. 
NFAT 5’-CGCCCAAAGAGGAAAATTTGTTTCATA’-3’  3’-
GCGGGTTTCTCCTTTTAAACAAAGTAT-5’ (Sigma Aldrich, Gillingham, Dorset, UK).  
2.13 RNA extraction 
Cells were collected from their respective samples, pelleted and suspended in 500μl Trisol (Tri) 
reagent (Sigma Aldrich, Gillingham, Dorset, UK) to allow for the extraction of total RNA. Trisol 
is able to aid the precipitation of DNA and RNA from cells (Chomczynski, 1993). Cells were 
vortexed for 30 seconds and 400μl chloroform to aid homogenization. Samples were vortexed 
and incubated at room temperature for 15 minutes, allowing the protein to denature and 
General Methods and Materials 
 
 
63 
become soluble in the organic phase. Samples were vortexed for a further 30 seconds and 
spun down at room temperature for 10 minutes at 12,470g to separate the phases. These are 
the lower red organic phase, interphase (which is in the middle) and the aqueous upper phase. 
The RNA dissolves into the aqueous phase while protein and DNA remains in the interphase 
and the organic phase. The upper aqueous phase was then transferred to a new tube and 
300μl of isopropanol added to precipitate, and the samples incubated at room temperature 
for 10 minutes. Samples were then spun down at 4°C for 10 minutes at 124g and the 
supernatant discarded. Pellets were washed with 80% ethanol and spun down for 5 minutes at 
4,150g. Supernatant was discarded and the pellets left to air dry for 5-8 minutes. Finally, 
samples were re-suspended in RNase-free DEPC.  
The RNA quality and quantity was assessed using a spectrophotometer nanodrop 2000c. 
2.14 cDNA production 
After RNA concentration was assessed, cDNA synthesis was carried out. RNA was converted to 
cDNA using the Superscript TMIII Reverse transcriptase enzyme. This allows for the formation 
of a cDNA strand from a complementary RNA template. To do this, random primers are used 
together with total RNA primers. Each sample was heated at 70°C to denature the RNA which 
was collected and cooled at 4°C to allow binding of random primers. 1μl dNtTP and 4μl of 
MgCl2 were added to each sample along with 4μl 5x running buffer and 1μl of the reverse 
transcriptase enzyme. Samples were spun and treated at 25°C for 5 minutes for denaturation, 
42°C for 1 hour for annealing, and 70°C for 15 minutes for the elongation step. This resulted in 
multiple copies of cDNA. Once ready the cDNA was diluted ready for the RT-PCR mix. 
2.15 Primer design 
The length of the average primer should be 18-24 nucleotides. To produce the programme, 
PerlPrimer was used. 20-23 nucleotide primers were designed with the sense and antisense 
designed to anneal to the exons of the sequence of interest to allow differentiation between 
amplification of cDNA and potential contaminating genomic DNA by melting curve analysis. 
The 5’ (forward) or sense primer included the recognition site of the required restriction 
enzyme, while the 3’ (backward) or antisense primer included the stop codon if needed. To 
deduce the melting temperature of each primer we used the Wallace rule (Tm=4x (G+C) +2X 
(A+T)) and the melting temperature set to Tm - 2°C and altered as necessary. A blast search 
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was then carried out to check each primer was correct. For the endogenous gene, mouse β-
actin was used (Table 4). 
Primer Sequence 
Egr2 TCAATGTCACTGCCGCTGAT 
AGAAATGATCTCTGCAACCAGAA 
IFN-γ CCATCAGCAACAACATAAGC 
AGCTCATTGAATGCTTGGCG 
Il2  GCATGTTCTGGATTTGACTC 
CAGTTGCTGACTCATCATCG 
Egr3  GATCCACCTCAAGCAAAAGG 
CGGTGTGAAAGGGTGGAAAT 
Tbet pcr5  CATTGCAGTGACTGCCTACC 
CACTCGTATCAACAGATGCG 
Batch 2 GCTAACCTCAGAACAGTTGAA 
GTGATTCCTCTCCGACAACAG 
Tcf1 ATAGACAGCACTTCCCTGCC 
TTCTCTGCCTTGGGTTCTGC 
Bhlhe40 
 
ACGTTGAAGCACGTGAAAGC 
GAAGTACCTCACGGGCACAA 
Itch GCTCTAGTCGCTGTAGTCGG 
CAAACCTGAAGTTCTCAATGGCT 
Cblb GAGCTTTTTGCACGGACTAAGA 
GGTCCGACTGCATCCTGAAT 
Dgk alpha CTGGGCACTGGAAATGATCT 
AATCTTTCTCAAATTCTCACCTTCATA 
Table 4: RT-PCR primer sequences 
2.16 Real Time PCR  
Real time PCR (RT-PCR) has the ability to monitor the progress of DNA/RNA amplification. It 
works on the same principle as the PCR, although this particular technique is able to use cDNA 
in order to determine relative gene expression or RNA levels within a sample. RT-PCR is able to 
use a ‘housekeeping gene’ that is not expected to change under experimental conditions as an 
internal standard or reference in comparison to the target gene. Quantification is made 
possible by the use of fluorescent probes. In this case we used SYBR Green I, which is able to 
bind to the minor groove of double stranded DNA and emit 1,000-fold greater fluorescence 
than when it is free in solution (Morrison, Weis and Wittwer, 1998).  
After each round of synthesis, the amount of fluorescence was measured. We used a 
QuantiTect SYBR Green PCR kit (Quiagen, Manchester, UK). As per manufacturer’s instruction, 
each sample had 1μl cDNA and a primer concentration of 5μM of each sense and anti-sense 
primer in a 1xSYBR Green master mix. A Rotor-Gene system (Corbett Robotics) was used to 
carry out the Real Time PCR for a total of 40 cycles 
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 Denaturation: 95°C for 15 seconds  
 Annealing: 60°C for 20 seconds 
 Elongation:72°C for 30 seconds  
RT-PCR also has its limitations, such a SYBR green unspecific binding, thus it is important to 
produce a melting curve, and analysis must be performed using the Tm (the temperature at 
which 50% of a particular DNA duplex dissociates and becomes a single stand DNA) to 
show any unspecific products such as primer dimers.  
2.17 RT-PCR data analysis 
Rotor Gene software was used for RT-PCR analysis. RT-PCR products are measured at each 
cycle. The use of fluorescent dyes allows for the yield of increasing fluorescent signals. Each 
result has an exponential phase, a linear phase and a plateau phase reached when reactants 
are consumed. The monitoring of the reactions can be seen during the exponential 
amplification phase, allowing for the determination of the initial quantity of the target. During 
the exponential phase the amount of fluorescence emitted is higher than that of the 
background fluorescence and this is known as the Ct (cycle threshold) value. It represents the 
starting copy number of the original template. The linear phase of the reaction is the phase in 
which the optimal amplification is achieved and in an ideal reaction, the PCR product doubles 
after each cycle. The final phase is the plateau that indicates the end of a reaction; the 
components of the reaction are consumed, meaning the reaction is slowing down and the 
products are degrading (Wong and Medrano, 2005). Following this result after RT-PCR, a 
threshold value was determined after samples were run in the exponential phase. The 
numbers of cycles (Ct) from the samples were compared with those of the reference gene in 
this case, mouse gapdh was used. This was done in order to normalise the data. The following 
formula was used: 
Ct (gapdh)-Ct (target gene)x10000. 
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Figure 21: Phases of PCR amplification curve 
There are 3 main phases of the PCR amplification curve: the exponential phase which allows for the 
quantification of the cycle threshold where the fluorescence emitted is higher than that of the 
background fluorescence; the linear phase which is the optimal point of PCR amplification with product 
doubling after each cycle; and finally the plateau phase where the reaction comes to an end.  
Derived from (Wong and Medrano, 2005). 
2.18 Statistical analysis 
Student’s T test was used to calculate significance to determine tolerance induction. P value of 
<0.05 was considered to be significant. 
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Chapter 3. In-vitro tolerogenic induction in Egr2 and Egr3 
knockout CD4 T cells 
3.1 Introduction  
Immunological tolerance is described as the lack of immune response to a foreign antigen 
(bacteria, viruses) or to a self-antigen, which prevents the induction of autoimmune disease. 
Tolerance is divided into central and peripheral mechanisms; central tolerance embodies the 
generation and maturation of T lymphocytes within the thymus which plays the role in the T 
cells being able to distinguish self-antigens from foreign antigens. This results in the 
production of CD4+, CD8+ and T regulatory cells (Xing and Hogquist, 2012).  
Peripheral tolerance takes place within secondary lymphoid organs such as the spleen. There 
have been a number of mechanisms described within peripheral tolerance. Exhaustion, which 
is often confused with anergy, takes place when CD8+ T cells become gradually unreactive due 
to persistent antigenic stimulation (Schietinger and Greenberg, 2013). Ignorance takes place 
when self-reactive T cells are unaware of antigen due sometimes due to low level expression. 
T cell anergy, which has mainly been studied within CD4 T cells, is induced by the activation of 
a T cell through antigenic stimulation in the absence of co-stimulation (Jenkins et al., 1987b). It 
is described as an unresponsive state characterised by a decrease in IL-2 and proliferation and 
expression of T cell markers such as CTLA4 and is the cetral mechanim studied in this chapter 
(Jenkins et al., 1987b)(Shwartz, 2003). 
Egr (early growth factor response genes) 2 has been reported to be necessary for T nerve 
myelation (Topilko et al., 1997). In addition, it has been found that Egr2 is necessary for T cell 
development. Mouse model Egr2-/-Egr3-/- has shown that Egr2 and 3 play a role in the 
development of autoimmune disease, with Egr2-/-Egr3-/- mice exhibiting lupus-like symptoms 
coupled with increased inflammatory cytokine production (IL-17A,IL-17F and IFN-γ) (Li et al., 
2012b). More importantly Egr2 has been studied within the peripheral mechanism of CD4+ T 
cell anergy. It has been found to play an important role within the induction of anergy (Safford 
et al., 2005) and it has been reported that the mechanism of anergy is accompanied by 
increased expression of a number of genes namely cblb and itch. Cblb-/- and itch-/- mice 
develop autoimmune disease similar to Egr2-/-Egr3-/- (Safford et al., 2005; Mueller, 2004). 
Within this chapter we investigate; the role of Egr2 and Egr3 within the tolerance setting, 
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starting with the induction of tolerance within the Egr2-/-Egr3-/- mouse model and the 
functionality of tolerance induction within the high inflammatory cytokine environment 
provided by the Egr2 and Egr3 knockout CD4 T cells in vitro.  
3.2 Methods 
To investigate the mechanisms of Egr2 and Egr3 in in vitro tolerance we used well established 
modes of tolerance induction. In order to do this, we used a number of techniques. 
3.2.1 Organ collection, preparation and staining 
Mice were housed in the animal unit in Brunel University as described in Section 2.1.1. WT and 
Egr2-/-Egr3-/- mice were culled and organs were collected at 4 weeks and 8 weeks for each. 
Spleens and lymph nodes were weighed and mouse weights recorded. Graphs were generated 
according to number of mice used per organ, and statistical analysis performed using 
Student’s T test.  
Kidneys were treated with 4% PFA overnight before organs were processed in a 22-hour 
process. Organs were embedded in wax and slides cut to between 5-7 microns thick. Organs 
underwent Haematoxylin and Eosin staining and were dewaxed with xylene three times 
treated with descending concentrations of Ethanol at 100% and 90% three times and treated 
with haematoxylin and then eosin before passing through ascending concentrations of Ethanol 
and 100% xylene.  
Frozen sections were incubated at room temperature for one hour with the directly labelled 
primary antibody (Texas Red conjugated donkey anti-mouse IgG), washed with 1xPBS for 10 
minutes and left to air dry. Mounting was done using Vectashield with DAPI (Vector 
laboratories, H-1200) and viewing with a Zeiss fluorescence microscope with Smart capture 
software (Digital Scientific Cambridge, UK). 
3.2.2 CD4 T cell isolation 
For this project it was important to isolate T cells directly from WT and Egr2-/-Eg3-/- mice for 
full use of primary cells. Cells were collected and red blood cells removed by the addition of 
0.8% ammonium chloride for 5 minutes at 95°C. Cells were then treated with CD4 beads for 20 
minutes in 1ml beads buffer (50ml PBS and 3ml RPMI) and using a positive selection kit, CD4 
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positive cells were then isolated by Magnetic Activated Cell Sorting (MACS) according to 
manufacturer’s instruction.  
3.2.3 Cell stimulation 
In order to induce tolerance in vitro, we used plate bound anti-CD3 simulation alone at 
1μg/ml. For comparison we used samples treated with anti-CD3 at 1μg/ml and anti-CD28 at 
2μg/ml, and for negative controls we stimulated cells with 1xPBS. Cells were first incubated 
with plate bound antibodies for 24 hours at 37°C, washed and re-stimulated with plate bound 
anti-CD3 at 1μg/ml and anti-CD28 for 72 hours. IL-2 quantification was carried out using ELISA 
after 48 hours of incubation, and proliferation was carried out using a beta counter after 
addition of 3[H]-TdR 72 hours following re-stimulation. RT-PCR was carried out after collection 
of cells following re-stimulation and flow cytometry similarly (refer to main methods chapter). 
 
Figure 22: In-vitro tolerance induction 
CD4+ T cells were isolated form Egr2-/-Egr3-/- and WT mice and stimulated with anti-CD3 1μg/ml and 
anti-CD28 2μg/ml (active), anti-CD3 alone at 1μg/ml (tolerant) or PBS (control). Cells were then 
incubated at 37°C for 24 hours to induce tolerance. cells were the re-stimulated with anti-CD3 and anti-
CD28 for a further 48 hours at 37°C after which supernatant was collected for IL-2 and IFN-γ analysis via 
ELISA. The plate was then incubated for a further 24 hours and 3H-TdR/tritium was added. The plate 
was further incubated at 37°C and proliferation values assessed.  
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3.2.4 EMSA-electronic mobility shift assay 
In order to determine the presence of transcription factors we used EMSA. Protein extraction 
was done first before quantification using a BSA assay and nanodrop. EMSA relies on the basis 
of the transcription factor binding to the promoter region. Once the binding probe is designed 
within the known promoter region, it is marked with a fluorescent marker or hot probe. Once 
the probe is added to the sample it binds to the desired promoter. Acrylamide gels were 
prepared and pre-run for 1 hour before samples were loaded. The consensus probes for AP-1 
(5′-AGCTTCGCTTGATGAGTCAGCCG-3′) and NFAT (5′- CTGTATCAAACAAATTTTCCTCTTTGG-3′) 
were labelled and used in binding reactions with nuclear extracts from lymphocytes 
stimulated with anti-CD3 and anti-CD28, for CD4+ T cells and run on polyacrylamide gels.  
3.3 Results 
3.3.1.1 Confirmation of Egr2 and Egr3 Knockout Mice 
In order to generate Egr2 and Egr3 knockout mice for this project, our group first developed 
Egr2 knockout mice in lymphocytes using the CD2 promoter (CD2-Egr2-/- )(Zhu et al., 2008). 
This was done because Egr2 deficient mice have a number of abnormalities including problems 
with peripheral nerve myelination (Topilko et al., 1994). Once CD2-Egr2-/- mice were 
developed, they were crossed with Egr3 knockout mice (Egr3-/-) mice to yield Egr2-/- Egr3-/- 
mice. For this study only Egr2-/- Egr3-/- mice were used unless stated otherwise. 
Determination of CD2-Egr2-/-/Egr3-/- mice 
Deletion of Egr2 using CD2 specific promoter was established using the Cre/ Lox-p system and 
confirmed using PCR. PCR results for CD2-Egr2-/- mice showed Cre at 195 base pairs and Lox- P 
homozygous at 210 base pairs.  
In order to generate Egr3-/- mice, embryonic stem cells were used to carry out targeted 
mutagenesis by homologous recombination. Briefly, the Egr3 transcript was cloned into a 
pBluescript vector and disrupted using a fragment that contained a neomycin resistance 
selection cassette. The cassette deleted a fragment of the gene that encoded for the entire 
zinc finger binding domain resulting in Egr3-/- mice (Tourtellotte and Milbrandt, 1998b).  
In-vitro tolerogenic induction in Egr2 and Egr3 knockout CD4 T cells 
 
 
71 
To create Egr2-/-/Egr3-/- mice, the Egr2-/- were crossed with Egr3-/- mice. We crossbred to 
from the first generation and used littermates to form the second generation. At this stage, 
mice that were homozygous for Egr3, Lox-p heterozygous for Egr2 and cre positive were 
selected for further breeding the C57BL background (Li et al., 2012a). PCR results showed Egr2-
/-/Egr3-/- mice with a positive Cre band, homozygous Lox-p band and a homozygous Egr3 band 
(Figure 23).  
 
Figure 23: PCR verification of CD2-Egr2-/-Egr3-/- Mice 
To create CD2-Egr2-/-Egr3-/- Mice Egr2-/- and Egr3-/- mice were crossed. PCR results show Egr2 
knockout bands for lox-p allele at 210bp, WT allele at 195 bp and cre at 150bp. Egr3 knockout result 
shows the Neo allele at 800bp and the WT at 400bp. Lane 1 shows Egr2+/-Egr3-/-, Lane 2 shows Egr2-/-
Egr3-/-, Lane 3 shows Egr2-/+Egr3-/+ and lane 4 shows Egr2-/-Egr3-/+. All mice used in this project were 
Egr2-/-Egr3-/- in lane 2 (indicated in red rectangle) unless stated otherwise. 
In order to confirm protein expression of Egr2 Splenocytes were collected from Egr2-/-Egr3-/- 
mice and WT mice were stimulated and stained with CD4 FITC and Egr2 APC (Figure 24). Flow 
cytometry was carried out by Professor Ping Wang.  
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Figure 24: Confirmation of Egr2 Protein WT and expression in Egr2-/-Egr3-/- mice  
Flow cytometry confirmation of Egr2 Protein WT and expression in Egr2-/-Egr3-/- mice Results show 
decreased Egr2 expression in Egr2-/-Egr3-/- compared to WT 
 
3.3.1.2 Induction of anergy in Egr2 and 3 deficient T cells  
Egr2 and 3 have been reported to be important for T cell tolerance and knocking them down 
renders T cells resistant to anergy induction in vitro (Zheng et al., 2012). Previously, we 
discovered that Egr2 and 3 knockout mice develop severe autoimmune diseases suggesting 
that Egr2 and 3 deficient T cells lose self-tolerance (Li et al., 2012a). The previous results are 
from single deficiency of Egr2 or 3 (Zheng et al., 2012). We adopted the use of Eg2-/-Egr3-/- 
mice developed as previously described by Li et al. (Li et al., 2012a). Within this chapter; in 
order to confirm the tolerogenic function of Egr2 and 3 in T cells, naïve CD4 T cells with 
deficiency of both Egr2 and 3 were assessed for the induction of anergy in vitro.  
Egr2 and Egr3 are not involved in the induction of T cell anergy 
T cell anergy is described as a tolerance mechanism that induces a state of functional 
underactivity recognised by decreased IL-2 and proliferation levels (Shwartz, 2003). It is largely 
due to the lack of ‘second signal’ or co-stimulatory signal after antigen stimulation (Shwartz, 
2003). The role of Egr2 in this mechanism has recently been closely studied. Transfection of 
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Egr2 in Th1 cell line in vitro renders cells resistant to T cell receptor (TCR) stimulation by 
measuring proliferation and IL2 production (Zheng et al., 2012)(Chai and Lechler, 1997) 
 Chai and Lechler, 1997 which are the hallmarks for T cell anergy (Jenkins et al., 1987a). 
Using well-established protocols for induction of anergy in vitro, naïve CD4 T cells from WT 
and CD2-Egr2-/-Egr3-/- mice were treated with anti-CD3 at different doses in the absence of 
costimulatory signals. The induction of anergy was compared to the T cell activation induced 
by both anti-CD3 and anti-CD28. Consistent with previous observations, Egr2 and 3 deficient 
CD4 T cells respond to anti-CD3 and anti-CD28 poorly in both proliferation and production of 
IL2 (Li et al., 2012a). The proliferation was 2.5-fold less than wild type counterparts (Figure 
25), together with the impaired IL-2 production in response to anti-CD3 and anti-CD28 
stimulation (Figure 26). This observation is consistent with reported findings from other 
groups in previous Egr2 knockdown experiments (Zheng et al., 2012).  
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Figure 25: Deficiency of Egr2 and Egr3 impairs proliferative responses of CD4 T cells  
 
CD4 T cells isolated for WT and Egr2-/-Egr3-/- mice were stimulated with or without anti-CD3 (1μg/ml) 
and anti-CD28 (2μg/ml) for 48 hours before pulsing with 3H-Trd for 8 hours. Proliferation was measured 
by β-counter. The data presented is a mean of four replicates from four mice and represent three 
independent experiments with similar results. Error bars calculated from standard error values. 
Statistical analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, 
P<0.001***, NS-not significant. 
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Figure 26: Deficiency of Egr2 and Egr3 impaired IL-2 production of CD4 T cells 
CD4 T cells isolated for WT and Egr2-/-Egr3-/- mice were stimulated with or without anti-CD3 (1μg/ml) and 
anti-CD28 (2μg/ml) for 48 hours. IL-2 production in supernatant was assessed by ELISA. The data presented 
is a mean of four replicates from four mice and represent three independent experiments with similar 
results. Error bars calculated from standard error values. Statistical analysis was calculated using students T-
test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not significant 
To induce anergy, naïve CD4 T cells from wild type and CD2-Egr2-/-Egr3-/- mice were 
stimulated with different doses of anti-CD3 in the absence of anti-CD28. Following anergy 
induction, we viewed the cells; we found ‘clusters’ of cells that we thought to be indicative of 
the cells proliferative ability thus we called them ‘proliferation clusters’. The proliferation 
clusters had reduced in number within samples treated with anti-CD3 alone compared to 
those treated with anti-CD3 and anti-CD28, indicating reduced proliferation (Figure 27). 
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Figure 27: Visualisation of impaired proliferation levels in naïve CD4 T cells from wild type and CD2-
Egr2
-/-
Egr3
-/-
 mice in response to anergic stimulation  
CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 at (A,D)1μg/ml, (B,E) 
0.5μg/ml (C,F) in the absence of anti-CD28 for 24 hours for anergy induction, then re-challenged for a 
further 48 hours with anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml). Cells were captured under x10 
magnification. The data represent three independent experiments with similar results -Red arrows point 
to proliferation clusters. 
 
To confirm this, we measured the proliferation using a beta counter and found the 
proliferation of wild type CD4 T cells was severely reduced, as was the production of IL-2 in 
comparison to the T cells activated by both anti-CD3 and anti-CD28. To our surprise, the 
proliferation of Egr2 and 3 deficient naïve CD4 T cells was also significantly reduced in 
comparison to the activation condition induced by both anti-CD3 and anti-CD28 (Figure 28). 
Consistent with the reduced proliferative response, the production of IL-2 was also impaired 
(Figure 29), indicating tolerance induction similar to that within the WT sample. This finding 
challenges the importance of Egr2 and 3 in anergy induction.  
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Figure 28: Impaired proliferative response in WT and Egr2-/-Egr3-/- CD4 T cells in response to anergic stimulation 
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with or without anti-CD3 at (A)1μg/ml, (B) 
0.5μg/ml (C) and PBS in the absence of anti-CD28 for 24 hours for anergy induction, re-challenged for a further 48 
hours with anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) before pulsing with 3H-Trd for 8 hours. Proliferation was 
measured by β-counter. The data presented is a mean of four replicates from four mice and represent three 
independent experiments with similar results. Error bars calculated from standard error values. Statistical analysis 
was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not 
significant. 
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To exclude the possibility that the reduced IL-2 and proliferation was not due to increased cell 
death in Egr2 and 3 deficient cells, the percentage of live and dead cells were compared. The 
reduced cell number in anergy cells compared to activated cells in wild type similar to Egr2 and 
3 deficient CD4 T cells further indicated that Egr2 and 3 deficient T cells can undergo anergy 
induction at a similar level as the wild type counterpart (Figure 30).  
The Induction of anergy in Egr2/3 deficient CD4 T cells is mediated by the NFAT 
pathway 
The mechanism for induction of anergy in vitro with lack of secondary signal is due to partial 
activation of TCR mediated by the NFAT pathway (Fathman and Lineberry, 2007). Therefore, 
anergy is reversible if the NFAT pathway is blocked (Shwartz, 2003)(Fathman and Lineberry, 
2007). Early studies have shown that for in vitro anergy to take place there is over activation of 
NFAT compared to transcription factors such as NFκβ. In addition, anergy induces the 
upregulation of a number of genes however the upregulation of these genes is not seen within 
NFA-/- mice and neither is anergy induction. Chai and Lechner (1997) showed the induction of 
 
Figure 29: Impaired IL-2 production in WT and Egr2-/-Egr3-/- CD4 T cells in response to anergic stimulation 
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 at (A)1μg/ml, (B) 0.5μg/ml (C) 
and PBS in the absence of anti-CD28 for 24 hours for anergy induction, washed and re-challenged for a further 48 
hours with anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml). IL-2 presence was measured using ELISA using culture 
medium collected after 48 hours. The data presented is a mean of four replicates from four mice and represent 
three independent experiments with similar results. Error bars calculated from standard error values. Statistical 
analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not 
significant. 
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anergy can be blocked by the addition of cyclosporine A, which blocks NFAT dependant 
signalling (Jenkins, Schwartz and Pardoll, 1988). 
 
Figure 30: Negligible cell death within anergic WT and Egr2-/-Egr3-/- CD4 T cells  
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) in the absence 
of anti-CD28 for 24 hours for anergy induction, washed and re-challenged for a further 48 hours with anti-
CD3 (1μg/ml) and anti-CD28 (2μg/ml). Cells were diluted with trypan blue at a ratio of 1:1 and viability 
assessed using a countess automated cell counter to establish cell viability. The data presented is a mean of 
four replicates from four mice and represent three independent experiments with similar results. Error bars 
calculated from standard error values. Statistical analysis was calculated using students T-test and p values 
set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not significant. 
To assess the mechanisms for the induction of anergy in wild type vs Egr2 and 3 deficient CD4 
T cells, we used cyclosporine A to block the NFAT pathway. Cyclosporine A is an 
undecapeptide isolated form the fungus Hypocladium inflatum gams and has been used for 
the treatment of allograft rejection (Borel et al., 1977). It has been reported that CsA is able to 
inhibit T cell activation and prevent in vitro anergy by blocking the NFAT pathway (Shwartz, 
2003). Safford et al. (2005) found that the addition of CsA to cells under anergy condition 
results in the production of increased levels of IL-2 similar to normal stimulation.  
To assess this, naïve CD4 T cells from wild type and CD2-specific Egr2-/Egr3- mice were 
stimulated with activation or anergy conditions by anti-CD3 and anti-CD28 or anti-CD3 alone. 
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In another sample treated with anti-CD3 alone, CsA was added to investigate its effect on the 
induction of anergy. In the absence of CsA, anergy was induced in both wild type and Egr2 and 
3 deficient CD4 T cells which exhibited reduced IL-2 concentrations coupled with decreased 
proliferation. However, addition of CsA effectively prevented anergy in both wild type and 
Egr2 and Egr3 deficient CD4 T cells (Figure 31 and Figure 32). Consistently, both proliferation 
and IL-2 production were reversed to similar levels compared to levels after a full antigenic 
stimulation using anti-CD3 and anti-CD28 in both wild type and Egr2 and 3 deficient CD4 T 
cells. These results not only confirmed the induction of anergy in Egr2 and 3 deficient CD4 T 
cells but also indicated that NFAT pathway activated by partial activation of TCR is the 
mechanism for both wild type and Egr2 and 3 deficient T cells. Thus, we have now discovered 
that Egr2 and 3 are involved in TCR mediated activation, but not in TCR mediated anergy.  
 
Figure 31: Cyclosporine A rescues IL-2 production in WT and Egr2-/-Egr3-/- anergic CD4 T cells 
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with either anti-CD3 (1μg/ml) in the absence of 
anti-CD28, anti-CD3 (1μg/ml) and 0.01μM CsA in the absence of anti-CD28 or with anti-CD3(1μg/ml) and anti-CD28 
(2μg/ml) for 24 hours for anergy induction, re-challenged for a further 48 hours with anti-CD3 (1μg/ml) and anti-
CD28 (2μg/ml). IL-2 presence was measured using ELISA using culture medium collected after 48 hours. Cells 
without stimulation served as negative control. Error bars calculated from standard error values. The data 
presented is a mean of four replicates and represent three independent experiments with similar results.  
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Figure 32: Cyclosporine A recovers proliferative responses of WT and Egr2-/-Egr3-/- anergic CD4 T cells  
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with either anti-CD3 (1μg/ml) in the absence of 
anti-CD28, anti-CD3 (1μg/ml) and 0.01uM CsA in the absence of anti-CD28 or with anti-CD3(1μg/ml) and anti-CD28 
(2μg/ml) for 24 hours for anergy induction, then re-challenged for a further 48 hours with anti-CD3 (1μg/ml) and 
anti-CD28 (2μg/ml), Before pulsing with 3H-Trd for 8 hours. Proliferation was measured by β-counter. The cells 
without stimulation served as negative control. Error bars calculated from standard error values. The data 
presented is a mean of four replicates and represents three independent experiments with similar results. 
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3.3.2 The effect of anergy induction in Egr2-/-Egr3-/- mice 
3.3.2.1 The production of inflammatory cytokines in anergic Egr2 and Egr3 
deficient CD4 T cells 
The activation of T cells with TCR and co-stimulatory signals plays a crucial role in their 
eventual fate, however an additional signal is required, which is the cytokine influence 
((Shwartz, 2003)). CD2 specific Egr2 deficient CD4 T cells were already reported to have 
accumulations of cells which produced high levels of inflammatory cytokines such as IL-17A 
(Miao et al., 2013)(Li et al., 2012a) Zheng et al., 2012). Zheng et al. (2012) confirmed a similar 
result in CD4 T cells from Egr2 and 3 deficient mice. Egr2 and 3 deficient CD4 T cells treated 
with anti-CD3 and anti-CD28 for a full antigenic stimulation express much higher levels of IFN-γ 
compared to naïve wild type CD4 T cells (see Figure 33). Li et al. (2012a) found the CD2-Egr2-/-
Egr3-/- mice presented with early onset autoimmune disease development with symptoms 
that included splenomegaly (Figure 34) and glomerulonephritis (Figure 35). Spleen and lymph 
node weights were taken from WT and Egr2-/-Egr3-/- mice at 4 and 8 weeks of age with lymph 
nodes and spleen weights at 8 weeks increasing at least two fold in Egr2-/-Egr3-/- mice (Figure 
34). Kidneys from WT and Egr2-/-Egr3-/- mice were assed using haematoxylin and eosin 
staining and immunohistochemistry; we found increased cellularity in Egr2-/-Egr3-/- kidneys 
along with IgG deposits (Figure 35). 
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Figure 33: Deficiency of Egr2 and Egr3 results in increased IFN-γ production in CD4 T cells  
CD4 T cells isolated for WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) and anti-
CD28 (2μg/ml) or left unstimulated for 48 hours and supernatant collected. IFN-γ production was 
measured in supernatant by ELISA. The data presented is a mean of four replicates from four mice and 
represent three independent experiments with similar results. Error bars calculated from standard error 
values. Statistical analysis was calculated using students T-test and p values set as follows –P<0.05 *, 
P<0.01 **, P<0.001***, NS-not significant. 
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Figure 34: Egr2-/-Egr3-/- mice exhibit splenomegaly 
A, C; Increased size and weight of lymph nodes and spleen in Egr2-/-Egr3-/- mice. B, D; Increased spleen 
size and weight in Egr2-/-Egr3-/- mice at 4 and 8 weeks compared to WT. The data represent 15 mice 
examined at each time points (4 weeks and 8 weeks). Probability was calculated using Student’s T test, 
p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not significant. 
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Figure 35: Glomerulonephritis in Egr2-/-Egr3-/- mice kidneys 
Kidneys collected were stained with haematoxylin and Eosin; Egr2-/-Egr3-/- kidneys showed increased 
cellular deposition compared to WT kidneys (B). Immunostaining revealed IgG deposits within Egr2-/-
Egr3-/- kidneys (D). 
A hallmark of anergic CD4 T cells is the decreased expression of IL-2 compared to CD4 T cells 
treated with both antigenic and costimulatory signals. Evidently, IL-2 is the most important 
cytokine with its measure determining the state of the cells. Inflammatory cytokine production 
has not been investigated in the anergy setting, and the role of tolerance induction within an 
inflammatory or autoimmune disease environment has yet to be studied. In order to address 
these questions, we used Egr2-/-Egr3-/- mice as CD2-Egr2-/-Egr3-/- CD4 T cells have increased 
inflammatory cytokine production on full stimulation, we have shown anergy is inducible in 
Egr2 and Egr3 null CD4 T cells, we were curious about the effect anergy induction would have 
on inflammatory cytokine production. IFN-γ was shown to have the most dramatic increase in 
expression in CD2-Egr2-/-Egr3-/- CD4 T cells compared to other cytokines such as IL-17A after 
receiving full antigenic stimulation (Li et al., 2012a).  
To examine the expression of IFN-γ in anergic conditions, CD4 T cells from naïve WT and CD2-
Egr2-/-Egr3-/- deficient mice were thus treated with anti-CD3 at a dose of 1μg/ml over 24 
hours and re-stimulated over 48 hours before assessment of IFN-γ levels via ELISA. In 
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accordance with previous results, the Egr2-/-Egr3-/- CD4 T cells treated with anti-CD3 and anti-
CD28 had increased expression of IFN-γ compared to the WT. To our surprise, IFN-γ levels 
within anergic CD4 T cells from Egr2 and 3 deficient CD4 T cells remained increased (Figure 36) 
Compared to those treated with anti-CD3 and anti-CD28. Interestingly as we earlier attempted 
to reverse anergy using cyclosporine A, we had found a similar result in IFN-γ. Addition of CsA 
allowed for high IFN-γ levels similar to samples treated without CsA in the anergy setting 
(Figure 37). 
 
 
Figure 36: Increased IFN-γ concentration in anergic Egr2-/-Egr3-/- CD4 T cells 
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) in the absence 
of anti-CD28 for 24 hours for anergy induction, washed and re-challenged for a further 48 hours with anti-
CD3 (1μg/ml) and anti-CD28 (2μg/ml). IFN-γ production was measured using ELISA using supernatant. The 
data presented is a mean of four replicates from four mice and represent three independent experiments 
with similar results. Error bars calculated from standard error values. Statistical analysis was calculated 
using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-not significant. 
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Figure 37: CsA addition results in high IFN-γ production in naïve CD4 T cells from wild type and CD2-Egr2-
/Egr3- mice  
CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with either anti-CD3 (1μg/ml) in the absence 
of anti-CD28, anti-CD3 (1μg/ml) and 0.01uM CsA in the absence of anti-CD28 or with anti-CD3(1μg/ml) and 
anti-CD28 (2μg/ml) for 24 hours for anergy induction, washed and re-challenged for a further 48 hours with 
anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml). IFN-γ presence was measured using ELISA using culture medium 
collected after 48 hours. The data presented is a mean of four replicates from four mice and represent three 
independent experiments with similar results. Error bars calculated from standard error values. Statistical 
analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, 
NS-not significant. 
These results, along with our previous findings, highlight the role of Egr2 and Egr3 in control of 
inflammatory cytokine production. As IFN-γ levels are still increased in Egr2 and 3 knockout 
CD4 T cells, including those in the anergic setting, the results show that anergy induction has 
little to do with Egr2 and Egr3 expression (as shown by Jenkins et al in 1987 during the first 
experaiments with anergy induction). Rather, it highlights the possible role of Egr2 and 3 in 
effector T cell differentiation and in turn, inflammatory cytokine production within the 
tolerant setting.  
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3.3.3 The impact of TCR signalling on Egr2 expression in the tolerance 
setting  
3.3.3.1 Egr2 expression within mitogenic conditions 
Egr2 is not expressed in naïve T cells, but is induced in response to TCR stimulation in vitro or 
in vivo (Li et al., 2011). In contrast to previous reports (Safford et al., 2005; Harris et al., 2004), 
we have now demonstrated that Egr2 and 3 are involved in promoting TCR medicated 
proliferation, but dispersive for anergy induction. It has been reported that Egr2 and 3 are 
induced by TCR stimulation in both naïve and tolerant T cells (Zheng et al., 2012). However, 
the differences in Egr2 and 3 expression in partial or mitogenic TCR stimulation is unknown, 
which may explain their function in naïve, but not tolerant T cells for regulation of 
proliferation.  
 
To assess if the expression of Egr2 in tolerant T cells is solely based on the absence of co-
stimulatory signal, naïve CD4 T cells from wild type mice were stimulated with different doses 
of anti-CD3 or combined stimulation of anti-CD3 and anti-CD28. Egr2 was rapidly induced in 
naïve CD4 T cells in response to anti-CD3 stimulation (Figure 38). However, the level of 
expression was dose dependent and we see the lower concentration the bigger the difference 
in Egr2 expression (Figure 39).  
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Figure 38: Induction of Egr2 expression in WT CD4+ T cells by TCR stimulation is dose dependent 
Naïve CD4 T cells from four wild type mice were stimulated with different doses of anti-CD3 (1μg/ml, 0.5μg/ml, 
0.25μg/ml) or combined stimulation of anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) for 24 hours. CD4 T cells were 
stained for Egr2 and expression monitored using Flow cytometry (A) Dot plot showing Egr2 expression 
correlated with anti-CD3 concentration within the WT CD4+ T cells. (B) Egr2 in WT with varying TCR stimulation 
Flow cytometry histogram, showing the kinetic shift of different samples treated with different concentrations 
of anti-CD3 in the naïve WT and Egr2-/-Egr3-/- CD4 T cells. Cells were gated on the CD4+ population. Data are 
representative of three individual experiments. 
The levels of TCR signalling directly affect the proliferative responses of naïve T cells (Figure 40). The 
results further demonstrate the importance of Egr2 in promoting naïve T cell proliferation justified to 
the levels of TCR stimulation. The association of Egr2 with strength of TCR signalling in promoting 
proliferative responses is further supported by increased expression of Egr2 when naïve CD4 T cells 
were stimulated with a combination of anti-CD3 and CD28. These results also indicate that Egr2 is 
induced at high levels in naïve T cells by both TCR and co-stimulation and at low levels in the absence 
of co-stimulation. 
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Figure 39: Change of Egr2 expression in response to different doses of anti-CD3 stimulation 
Fold change from naïve CD4 T cells from wild type mice were stimulated with different doses of anti-CD3 
(1μg/ml, 0.5μg/ml, 0.25μg/ml) or combined stimulation of anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) for 24 
hours. CD4 T cells were stained for Egr2 and expression monitored using Flow cytometry. Fold change was 
calculated in comparison to samples treated with anit-CD3+anti-CD28. Cells without stimulation served as 
control. The figure shows increasing fold change with decreasing anti-CD3 concentration. 
 
Figure 40: TCR signalling strength directly affects proliferation levels in naïve CD4 T cells from Wild type and 
Egr2-/Egr3-/- mice  
Naïve CD4 T cells from wild type mice were stimulated with different doses of anti-CD3 (1μg/ml, 0.5μg/ml, 
0.25μg/ml) or combined stimulation of anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) for 24 hours. Cells were 
washed and re-challenged for a further 72 hours and proliferation assessed by addition of 3H-Trd for 8 hours. 
Error bars calculated from standard error values. Data is representative of three experiments. 
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3.3.3.2 The levels of cytokine expression in naïve T cells is regulated by the doses 
of TCR signalling 
T cell receptor signalling plays a crucial role in the T cell activation; in order for in vitro T cell 
anergy to take place a TCR signal is essential while the costimulatory as from CD28 is usually 
absent (Shwartz, 2003). As TCR plays such a crucial role in the mechanism of induction of 
tolerance, we looked at the effects of antigenic strength in vitro using cytokine production on 
stimulation. Using a sample treated with anti-CD3 and anti-CD28 as a control which showed 
increased IL-2 expression, we assessed the effect of anti CD3 concentration, specifically the 
strength of antigenic stimulation on IL-2 production within CD2-Egr2-/-Egr3-/- CD4 T cells.  
On treating cells with increasing doses of anti-CD3 and a stable CD28 at 5μg/ml, IL-2 
expression increased with increasing anti-CD3 concentration (Figure 41). However we did not 
find a similar correlation with varying anti-CD28 stimulation with anti-CD3 at 1μg/ml (Figure 
42), whereas varying anti-CD3 stimulation gave a clear relationship with IL-2, anti-CD28 
concentration was unrelated to IL-2 production highlighting the role of TCR stimulation in T 
cell proliferation.  
 
Figure 41: IL-2 expression increased according to increasing anti-CD3 concentration within WT and Egr2-/- 
Egr3 -/- CD4+ T cells  
Naïve CD4 T cells from wild type mice were stimulated with 5μg/ml anti-CD28 and varying concentrations of 
anti-CD3 (0, 0.5ug, 1ug, 2ug, 4ug and 8ug) for 48 hours before medium collection. IL-2 concentration was 
measured using ELISA. Data is representative of three individual experiments 
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Figure 42: IL-2 expression unaffected by co-stimulatory signalling in Egr2-/-Egr3-/- CD4 T cells  
Naïve CD4 T cells from wild type mice were stimulated with 1μg/ml anti-CD3 and varying concentrations of 
anti-CD28 (0, 0.5ug, 1ug, 2ug, 4ug and 8ug) for 48 hours. Medium was collected and IL-2 measured by ELISA. 
Error bars calculated from standard error values. Data shown is representative of three individual 
experiments.  
With CD2-Egr2-/-Egr3-/- CD4 T cells producing increased amounts of IFN-γ, we were curious to 
see if the correlation applies in regard to inflammatory cytokine production. Since within Egr2 
and 3 null mice the T cells are skewed toward the production of Th1 predominant cytokines (Li 
et al., 2012), we hypothesised that, like the production of IL-2, the production of IFN-γ would 
correlate with TCR stimulation. We found the highest production of IFN-γ was seen after a full 
stimulation of Egr2-/-Egr3-/- CD4 T cells (Figure 43A). On treatment using only anti-CD3 at 
different concentrations we found a decrease at 1μg/ml in IFN-γ production compared to 
treatment with anti-CD3 and anti-CD28. This production then gradually decreased with 
decreasing concentration of anti-CD3 in a linear manner B). These results correlate with 
(Yamamoto, Hattori and Yoshida, 2007) where they monitored the expression of IFN-γ with 
varying concentrations of TCR stimulation within TH1 cells. They found decreasing 
concentrations of IFN-γ with decreasing antigenic stimulation. We showed a clear correlation 
between IFN-γ production and antigenic strength by generating a linear graph from the flow 
cytometry results obtained previously shown in Figure 44. 
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Figure 43: Induction of IFN-γ producing Egr2 and 3 deficient CD4 T cells in response to both active and tolerant 
stimulation 
CD4 T cells from wild type and Egr2-/-Egr3-/- mice were stimulated with different doses of anti-CD3 (1μg/ml, 
0.5μg/ml, and 0.25μg/ml) or combined stimulation of anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) for 24 hours. CD4 T 
cells were stained for IFN-γ and expression monitored using Flow cytometry. (A) CD4 cells after gating as side scatter 
(SSC) and forward scatter (FSC) (B) IFN-γ producing CD4 T cells under indicated stimulation conditions displayed as 
SSC and IFN-γ. (C) MFI of IFN-γ in wild type and Egr2 and 3 deficient CD4 T cells under indicated stimulation 
conditions. Data are from pooled cells of four mice and representative of three independent experiments. 
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Figure 44: Linear reduction of IFN-γ producing cells in anergic Egr2 and 3 deficient CD4+ T cells challenged by 
different doses of anti-CD3 
Linear graph adapted from FACS values obtained in Figure 43 ; where Naïve CD4 T cells from wild type and Egr2-/-
Egr3-/- mice were stimulated with different doses of anti-CD3 (1μg/ml, 0.5μg/ml, and 0.25μg/ml) or combined 
stimulation of anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml) for 24 hours. 
Our results show Egr2 expression, IL-2 production and IFN-γ expression is all dependant on 
TCR stimulation in a dose dependant manner. These results in fact show that different 
antigenic stimulation results in altered effects and thus altered functionality of CD4 T cells, 
including proliferation and inflammation, emphasising the importance of TCR signalling 
strength in the production of effector cytokines.  
3.3.3.3 Downstream effects of TCR signalling in tolerant Egr2-/-Egr3-/- CD4 T cells 
Having shown the importance of TCR signalling in T cell activation, we concentrated on factors 
downstream of immediate TCR activation. For the activation of NFAT (nuclear factor of 
activated T cells) and the production of IL-2, a calcium flux must take place after the TCR 
meets the antigen. The importance of the calcium flux has been highlighted by multiple groups 
with the use of calcium ionophore ionomycin to induce anergy (Macian et al., 2002)(Shwartz, 
2003). Ionomycin is able to bypass the TCR and cause a calcium flux, thus ionomycin treatment 
alone is often used for CD4 T cell anergy induction in TH1 cells (Macian, 2005). This still results 
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in reduced IL-2 and proliferation, although studies with Th1 cells showed induction with 
ionomycin requires a longer time to induce compared to achieve than with anti-CD3 (Macian 
et al., 2002). Our attempted anergy induction using ionomycin in Egr2-/-Egr3-/- CD4 T cells 
resulted in decreased IL-2 and although proliferation decreased it was not significantly viable 
in ionomycin induction. It is not as reliable or robust as the most commonly used plate bound 
anti-CD3 induction and is often very easily reversible over time (Fathman and Lineberry, 2007). 
Li et al. earlier reported a defect in AP-1 expression within Egr2-/-Egr3-/- CD4 T cells, resulting 
in decreased IL-2 production (Li et al., 2012a). Similarly, we showed this using and EMSA 
(Figure 45A) and confirmed deceased expression by measuring the density of the bands 
(Figure 45B). EMSA or electronic mobility shift assay is a technique used to represent the 
binding of a transcription factor with the promoter region of a particular gene. Once 
identification of the gene was achieved, an AP-1 probe was designed. CD4 T cells were then 
stimulated with 1μg/ml anti-CD3 and 2μg/ml anti-CD28 overnight and protein extracted. A 
binding mix was then prepared for each sample with fluorescence markers and probes. The 
samples were run on a polyacrylamide gel as viewed in Figure 45 A and B, and measurements 
were then taken to confirm intensity.  
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Figure 45: Decreased AP-1 expression within Egr2-/-Egr3-/- CD4 T cells 
CD4 T cells from WT and CD2-Egr2-/-Egr3-/- were stimulated with anti-CD3 and anti-CD28 overnight and 
following protein extraction the expression of AP-1 assessed using EMSA (A). Results showed decreased 
expression in Egr2-/-Egr3-/- CD4 T cells. AP-1 density measure was carried out on bands from the EMSA 
experiment (B). The data are representative of 3 individual experiments using four mice per setting. 
Following the calcium flux, activation of NFAT must take place to allow the dephosphorylation 
and mobilisation of NFAT into the nucleus (Harris et al., 2004). We wanted to examine the 
expression of nuclear factor NFAT within active and tolerant wild type and Egr2 and 3 
knockout CD4 T cells. To achieve this we once again used an EMSA carried out by Dr. Tizong 
Miao at QMUL to visualise NFAT expression. First, cells were treated with 1μg/ml anti-CD3 and 
2μg/ml anti-CD28 and compared this to CD4 T cells stimulated with anti-CD3. NFAT probes 
were designed and once protein extraction was achieved, a reaction mix was prepared. An 
acrylamide gel was run to visualise each sample as shown in Figure 46. This showed NFAT 
signalling is similar within Egr2 and 3 knockout CD4 T cells and WT in both the active and 
tolerant states and confirmed by measuring the density of both the NFAT bands (Figure 47). 
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This result emphasises the importance of calcium signalling and NFAT activation within in vitro 
tolerance induction and proves it is not affected by the absence of Egr2 or 3.  
 
Figure 46: NFAT is activated in both active and anergic CD4 T cells 
Naïve CD4 T cells form WT and Egr2-/-Egr3-/- mice were stimulated overnight with anti-CD3 overnight and 
re-stimulated with anti-CD3 and anti-CD28 for 3 hours to induce anergy. Activated samples were stimulated 
with anti-CD3 and anti-CD28 for 3 hours before harvesting. 
Nuclear extracts were analysed for NFAT transcription factor expression by EMSA. Anergic samples in WT 
and Egr2-/-Egr3-/- CD4 T cells show decreased expression compared to their respective active samples. 
Representative of a single experiment.  
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Figure 47: NFAT band binding reduced in tolerant CD4 T cells 
Density measurement of the NFAT upper band was taken from NFAT EMSA from Figure 46. Results showed 
reduced levels of NFAT expression in the WT and Egr2-/-Egr3-/- tolerant cells. (A) NFAT upper band binding 
reduced in tolerant CD4 T cells. (B) NFAT lower band binding reduced in tolerant CD4 T cells.  
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3.3.4 Gene expression during in vitro tolerance induction  
3.3.4.1 Tolerogenic gene expression in T cells 
Egr2 and 3 have been shown to regulate a number of anergy genes that aid in the 
maintenance of this hyporesponsive state (Safford et al., 2005). On TCR stimulation and 
calcium flux during anergy, NFAT dephosphorylation allows for the expression of such genes, 
including Egr2 and 3 (Shwartz, 2003); whereas the lack of MAPK activation by lack of co-
stimulatory signalling allows for the expression of CBLB, GRAIL and ITCH (Fathman and 
Lineberry, 2007). These genes are upregulated during tolerance and include a multitude of 
functions: dyglycerol kinase alpha or DGK-alpha generates phosphatic acid, reducing the 
availability of dyglycerol after anti-CD28 stimulation and the two forms of DGK-α have been 
found to be upregulated during anergy. Zha et al. (2006) found the expression of DGK-α to be 
five times more in anergic TH1 clones as compared to cells treated with anti-CD3 and anti-
CD28(Zha et al., 2006) 
. DGK-α expression was found to increase within wild type CD4 T cells treated in the anergic 
conditions compared to fully activated samples (Figure 48). Intriguing was the increased 
expression of DGK alpha within the anergic Egr2-/-Egr3-/- CD4 T cells compared to the cells 
treated with anti-CD3 and anti-CD28. According to our results, there was increased expression 
of DGK-alpha within the Egr2 and Egr3 knockout anergic CD4 T cells similar to that of the wild 
type. 
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Figure 48: Dgk-α expression upregulated in anergic CD4 T cells from WT and Egr2-/-Egr3-/- mice 
CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) in the absence of anti-
CD28 for 24 hours for anergy induction, washed and re-challenged for a further 24 hours with anti-CD3 
(1μg/ml) and anti-CD28 (2μg/ml) prior to harvesting. Following RNA extraction RT-PCR was carried out to 
measure expression of DGK-alpha and data normalised against gapdh. Error bars calculated from standard 
error values. The data presented is a mean of four replicates and represent three independent experiments 
with similar results.  
3.3.4.2 Ubiquitin ligase gene expression within anergic CD4 T cells  
Along with DGK-α, a large number of genes upregulated downstream of TCR activation during 
anergy are ubiquitin ligase genes. During T cell activation ubiquitin serves as a key molecule 
controlling the process of ubiquitination. The attachment of these genes targets proteins for 
degradation among other targets anergic T cells have been associated with increased 
expression of ubiquitin genes Cblb, Itch and Grail (Fathman and Lineberry, 2007). These genes 
act to degrade key signalling molecules such as PLC-gamma and PKC-theta. Cblb functions as 
an E3 ubiquitin ligase via its RING domain. Multiple studies have been carried out on cblb-/- 
mice, with mice exhibiting spontaneous autoimmune diseases. More importantly cblb-/- mice 
are completely resistant to T cell anergy (Chiang et al., 2000).  
CD4 T cells were treated in anergic settings over 24 hours revealed increased levels of Cblb 
expression in the wild type and in the Egr2-/-Egr3-/- CD4 T cells compared with their 
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respective fully activated counterparts treated with anti-CD3 and anti-CD28 (Figure 49). Of 
note, the Cblb expression within the Egr2-/- Egr3-/- CD4 tolerant T cells was much higher than 
that in the WT, exhibiting a 2-fold increase. On the analysis of ITCH, we found similarly 
increased expression within anergic CD4 T cells from both the wild type and the Egr2 and 3 
knockouts compared to their counterparts treated with anti-CD3 and anti-CD28 (Figure 50). 
Itch-/- mice have also been found to develop autoimmune disease associated with scratching, 
thus mice are referred to as ‘itchy’. The role of Egr2 or 3 expression has not been directly 
studied in regard to ITCH expression within the anergy setting. 
 
Figure 49: Cblb expression upregulated in tolerant CD4 T cells from WT and Egr2-/-Egr3-/- mice 
CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) in the absence of anti-
CD28 for 24 hours for anergy induction, washed and re-challenged for a further 24 hours with anti-CD3 
(1μg/ml) and anti-CD28 (2μg/ml) prior to harvesting. Following RNA extraction, RT-PCR was carried out to 
measure expression of Cbl-b. Error bars calculated from standard error values. The data is relative 
expression against housekeeping gene gapdh and presented is a mean of three replicates and represent 
three independent experiments with similar results. 
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3.3.4.3 Egr2 and 3 tolerance induction has no effect on T regulatory cell 
production 
There are a number of peripheral mechanisms that allow for the evasion of autoimmunity. 
One T cell subset that contributes to this is T reg cells (T regulatory) cells. It is known T reg cell 
development is dependent on the expression of the transcription factor FOXP3 (Hsieh, Lee and 
Lio, 2012; O'Garra and Vieira, 2004). Another transcription factor has recently been identified 
that aids in the governing of T reg cells, Bach2 (Roychoudhuri et al., 2013). Recently Bach2 has 
been found not only to be expressed within B cells but also in T regulatory cells where it is 
been found to be essential for the development of both naturally occurring T reg cells and 
induced T reg cells produced within the periphery (Roychoudhuri et al., 2013). Egr2 and 3 have 
been found to have no effect on the production of T reg cells, and studies carried out on Egr2-
 
Figure 50: Itch expression is upregulated in tolerant CD4 T cells from WT and Egr2-/-Egr3-/- mice 
CD4 T cells from WT and Egr2-/-Egr3-/- mice were stimulated with anti-CD3 (1μg/ml) in the absence of anti-
CD28 for 24 hours for anergy induction, washed and re-challenged for a further 24 hours with anti-CD3 
(1μg/ml) and anti-CD28 (2μg/ml) prior to harvesting. Following RNA extraction RT-PCR was carried out to 
measure expression of Itch. Error bars calculated from standard error values. The data is relative expression 
against housekeeping gene gapdh and presented is a mean of three replicates from four mice and represent 
three independent experiments with similar results.  
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/-Egr3-/- found the function of CD4+CD25+ regulatory T cells (T reg) were not changed (Li et 
al., 2012a). 
We then sought to find out if the induction of tolerance would affect the production of T reg 
cells using Bach2 as a marker. To do this we treated WT and Egr2-/-Egr3-/- with anti-CD3 and 
anti-CD28 as an activated sample and with anti-CD3 alone as a tolerant sample. We then re-
stimulated the samples with anti-CD3 and anti-CD28 before assessing the expression of Bach2. 
Our results showed WT samples had unchanged expression between the activated and the 
tolerant. The Egr2-/-Egr3-/- tolerant samples had an insignificant change between the 
activated and tolerant samples similar to that of the WT (Figure 51). This result confirms 
earlier studies that the function of T reg cells is not affected by the lack of Egr2 and Egr3. It 
also highlights this within the expression of peripheral T reg cells, that iTreg cells are not 
affected, even in the tolerant state. The induction of T reg cells remains unchanged within the 
tolerant state in CD2-Egr2-/-Egr3-/- mice.  
 
Figure 51: Bach 2 expression in active or tolerant CD4 T cells  
Naïve CD4 T cells from wild type and Egr2 and 3 deficient mice were induced to anergy with 1μg/ml 
anti-CD3 for 24 hours. This was followed by re-stimulation with 1μg/ml anti-CD3 and 2μg/ml anti-CD28. 
Expression was assessed using RT-PCR where gapdh was used as the housekeeping gene. Error bars 
calculated from standard error values. The data is representative of three individual experiments. 
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3.3.4.4 TCF-1 is downregulated within tolerant Egr2-/-Egr3-/- CD4 T cells 
T cell differentiation is one of the factors that influence tolerance and so T cell fate lays an 
essential role. Egr2 has been reported to regulate the development of T cells (Li, 2011). During 
T cell development, T cells can be influenced toward specific fiats. One transcription factor 
that has been found to play a role in differentiation regulation is TCF-1 (T cell receptor factor 
1) (Choi, 2013). TCF-1 has been found to play an essential role in the regulation of the 
commitment to the CD4 T cell linage (Steinke, 2014). To investigate the role of Egr2 and 3 
within differentiation and during tolerance, we used RT-PCR to measure the expression of TCF-
1 within tolerant CD4 T cells.  
CD4 T cells from Egr2-/-Egr3-/- mice were treated with anti-CD3 or anti-CD3 plus anti-CD28 
before re-stimulation (Figure 52). Levels of TCF-1 decreased between the WT activated and 
the WT tolerant. Interestingly the Egr2-/-Egr3-/- activated sample had high levels of TCF-1, but 
the levels decreased by 14 fold within the anergic Egr2-/-Egr3-/- cells. This result indicates Egr2 
and 3 may play a role in the control of TCF-1 expression and TCF-1 seems to be downregulated 
within anergic CD4 T cells. Therefore, Egr2 and 3 may play a key role in the control of T cell 
differentiation within the tolerant state. 
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Figure 52: Defective Tcf1 expression in tolerant CD4 T from CD2-Egr2-/Egr3- mice 
Naïve CD4 T cells from wild type and Egr2 and 3 deficient mice were induced to anergy with 1μg/ml 
anti-CD3 for 24 hours. This was followed by re-stimulation with 1μg/ml anti-CD3 and 2μg/ml anti-CD28. 
Expression was assessed using RT-PCR where Egr2-/-Egr3-/- CD4 T cells treated with anti-CD3+anti-CD28 
increased tcf-1 expression compared to WT samples. With tcf expression dropping in the anergic 
samples both in the WT and Egr2-/-Egr3-/- compared to their activated counterparts. Error bars 
calculated from standard error values. The data is representative of three individual experiments. 
3.3.4.5 Bhlhe40 is upregulated in activated Egr2-/-Egr3-/- T cells  
Egr2 and 3 knockout mice have been found to have increased proliferation and differentiation 
toward the TH1 CD4 T cell subset causing increasing production of inflammatory cytokine IFN-
γ (Li et al., 2012a). We have found a similar situation within tolerant Egr2-/-Egr3-/- CD4 T cells. 
Bhlhe40 is a transcriptional regulator expressed on T cells on TCR stimulation and is known to 
regulate a number of processes such as apoptosis and differentiation (Miyazaki et al., 2010), 
and has also been found to control cytokine production in T cells (Lin et al., 2014). As Egr2 and 
3 have also been found to control inflammatory response and they may play a role in 
differentiation, we sought to find any possible link between Egr2 and 3 and bhlhe40. On 
induction of in vitro anergy, we quantified expression of bhlhe40 by fully activating CD4 T cells 
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with anti-CD3 and anti-CD28 or treating cells with anti-CD3 alone followed by re-stimulation 
with anti-CD3 and anti-CD28 for anergy induction. As with TCF-1 we found increased levels of 
bhlhe40 expression within activated samples in Egr2-/-Egr3-/- CD4 T cells (Figure 53). This 
reduced by 4 fold in the anergic sample. However, Blhe40 expression within tolerant Egr2-/-
Egr3-/- cells decreased. This result shows that Egr2 and 3 possibly play a double role in the 
influence of bhlhe40 expression in the regulation of T cell differentiation and that of 
inflammatory cytokine production.  
 
Figure 53: Bhlehe40 expression is increased in active, but not tolerant Egr2 and 3 deficient CD4 T cells 
Naïve CD4 T cells from wild type and Egr2 and 3 deficient mice were induced to anergy with 1μg/ml anti-CD3 
for 24 hours. This was followed by re-stimulation with 1μg/ml anti-CD3 and 2μg/ml anti-CD28. Expression 
was assessed using RT-PCR where gapdh was used as the housekeeping gene. Error bars calculated from 
standard error values. The data is representative of three individual experiments. 
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3.4 Discussion  
This chapter explored the role of Egr2 and Egr3 within mitogenic and tolerogenic conditions in 
vitro. Both Egr2 and 3 are induced under mitogenic conditions to allow for proliferation and 
effector function of T cells (Du et al., 2014). We found Egr2 and Egr3 knockout T cells are able 
to undergo tolerance induction, even though they have been implicated in tolerance induction 
(Safford et al., 2005). The mechanisms for the induction of T cell anergy involve T cell 
stimulation through the TCR in the absence of co-stimulation, essentially this is the activation 
of NFAT in the absence of NFkb and AP-1 (Fathman and Lineberry, 2007)(Shwartz, 2003). The 
major hallmarks of T cell tolerance being reduced IL-2 production coupled with decreased 
proliferation (Shwartz, 2003), which is what we viewed on In vitro induction of tolerance in 
Egr2 and 3 knockout CD4 T cells using anti-CD3. However, it has been reported that Egr2 and 3 
are upregulated on anergy induction (Harris et al., 2004). Although most studies carried out 
have been performed on cell lines (Harris et al., 2004) or in single knockout mice (Zheng et al., 
2012) which in one way or another affect the outcome. We on the other hand adopted the use 
of primary CD4 T cells isolated for CD2-Egr2-/-Egr3-/- mice allowing for a more physiological 
state of T cell response Figure 28and Figure 29. 
On TCR activation there is a calcium influx within CD4 T cells allowing for the activation of 
NFAT and its transcription into the nucleus (Feske, 2007; Crabtree and Olson, 2002). NFAT 
activation lies downstream of a calcium flux initiated on TCR signalling. This is the reason in 
vitro tolerance can also be induced using the calcium ionophore ionomycin (Heissmeyer et al., 
2004). As reported by Safford et al. (2005), we found the addition of cyclosporine A to Egr2 
and 3 knockout T cells with anti-CD3 alone prevented tolerance induction resulting in 
increased IL-2 and proliferation within Egr2-/-Egr3-/- CD4 T cells (Figure 31 and Figure 32). This 
has been shown to be one of the trademarks of anergic T cells (Chai and Lechler, 1997). 
Reports added that reversal could be achieved with the addition of IL-2 to the culture 
(Shwartz, 2003). Soto-Nieves et al. (2009) found NFAT to be key in the induction of T cell 
anergy, as we have seen within tolerant Egr2-/-Egr3-/- CD4 T cells. In addition, it has recently 
been reported that Deltex-1(DTX-1) which is upregulated during anergy, is a transcription 
target of NFAT with dtx-/- mice being more resistant to anergy induction and being more 
susceptible to autoimmune disease development (Hsiao et al., 2009) proving the importance 
of NFAT within in vitro anergy induction.  
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TCR signalling plays an essential role in T cell proliferation and differentiation (Abraham and 
Weiss, 2004). We have shown a novel relationship between Egr2 and TCR stimulation, wherein 
Egr2 expression decreases and increases in relation to antigenic strength (Figure 38). Egr2 and 
3 deficient T cells are impaired in proliferation response and IL-2 production in response to 
antigen stimulation. This is due to a defect in AP-1 activity (Li et al., 2012a). On analysis of 
Egr2-/-Egr3-/- T cells with varying TCR stimulation and Egr2 expression, we also found 
proliferation to alter in relation to Egr2 expression. This implies over-expression or under-
expression of Egr2 or Egr3 has a direct effect on T cell proliferation and IL-2 production. It has 
been shown that T cells from Egr2 transgenic mice increased proliferation while the lack of 
Egr2 and 3 exhibited the opposite (Li et al., 2012a). In addition, Harris et al. (2004) showed 
over-expression of Egr2 and Egr3 within transfected cell lines are able to inhibit T cell function 
and result in decreases IL-2 and proliferation resembling those from in vitro tolerant T cells, 
where we found a similar result after tolerance induction within Egr2 and 3 knockout CD4 T 
cells. Therefore, the expression of Egr2 that is governed by TCR signalling can influence 
proliferation of T cells and in doing so alter effector cytokine production. 
On establishing anergy induction in our model, the defect in AP-1 within the Egr2-/-Egr3-/- 
mice evidently has no effect on tolerance induction. Unlike NFAT, which we have shown to be 
expressed within anergic T cells, AP-1 formation within anergic T cells is diminished (Sundstedt 
et al., 1996). It was found that Ras activation which lies upstream of the MAP-K pathway that 
is activated after co-stimulatory signalling via CD28 is incomplete within tolerant T cells in vitro 
(Zha et al., 2006). AP-1 is not activated under tolerogenic conditions and we have shown 
proliferation and cytokine production to be primarily dependent on TCR signalling. Therefore, 
Egr2 and 3 expression, which lie downstream of AP-1 activation, remain unchanged within the 
tolerant setting thus allowing NFAT mediated T cell tolerance induction to take place in the 
absence of Egr2 and Egr3. Significantly, we thus show T cell proliferation is defective in 
tolerance settings and by extension Egr2 and 3 mediated T cell proliferation is also defective 
based on the fact that formation of AP-1 is inhibited, proving Egr2 and Egr3 are not essential 
for the induction of proliferative tolerance. 
Activation of NFAT without that of MAPK and NFkb allows for the activation of E3 ubiquitin 
ligases which are able to attach to molecules and flag them for degradation. These ubiquitin 
ligase genes have been studied recently within anergic T cells (Fathman and Lineberry, 2007). 
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On tolerance induction we found increased expression of Cbl-b and ITCH reported by 
(Heissmeyer et al., 2004) and (Fathman and Lineberry, 2007) to be increased during anergy. 
The expression of cbl-b has been linked to that of Egr2, with reports indicating expression of 
Cbl-b may be directly influenced by Egr2 expression (Safford et al., 2005). However, we found 
the highest levels of Cblb were viewed within Egr2/3 knockout tolerant CD4 T cells. The 
expression of cbl-b is clearly an important factor within in vitro tolerance induction in CD4 T 
cells with cblb-/- mice being resistant to tolerance induction in vitro (Chiang et al., 2000). As 
cbl-b and Itch expression is increased in tolerant T cells within our model, it would indicate an 
alternative role for Egr2 and 3 in the control of ubiquitin ligase gene expression (Tamiya et al., 
2011). The role of Egr2 and Egr3 within the control of ubiquitin ligase expression still has some 
way to go. With recent reports of DGK-alpha upregulation within anergic T cells (Zha et al., 
2006), a link between Dgk and Egr2 was discussed by Zheng et al. linking egr2 expression to 
DGK expression during tolerance (Zheng et al., 2012), once again bringing into question the 
role of Egr2 within the control of ‘anergy associated genes’. A summary of studies within 
anergy induction and Egr2 is given in Table 5.  
In conclusion, we report that Egr2 and Egr3 do not play a major role in the induction of T cell 
anergy in vitro, with the successful induction in their absence and NFAT upregulation within 
the CD4 T cells. The expression of Egr2 is governed by TCR signalling strength thus influencing 
effector cytokine production.  
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Reference Mouse model/ cell 
line 
Factor involved in 
tolerance control 
Factor 
upregulated 
during tolerance 
Summary of findings 
Zha, 2006 TCR-Rag-/- mice 
and IL-2 luc mice 
TH1 clones 
Ras,dgk-alpha, cblb Dgk-alpha  Ras reverses anergy in Th1. DGK-alpha 
upregulated in anergic th1 cells 
Harris, 2004 AE7 Egr2 - Anergy cannot be induced in T cells without 
Egr2 
Safford, 2005 A.E7 6.5 TCR 
transgenic C3-HA 
Egr2,Egr3,Cblb Egr3 and  
Cblb  
Overexpression of Egr2 and Egr3 inhibit T cell 
function. Egr2 and Egr3 upregulated in anergy 
in vivo and in vitro. Egr3-/- not capable of 
anergy induction. CsA can hinder anergy 
induction 
Hsiao, 2009 CD4+CD25- cells 
primed into Th1 
clone from Deltex-
1 -/- mice  
dtx,cblb,Egr2 DTX-1 and cbl-b  Overexpression of dtx1 suppresses T cell 
activation. Dtx1 is a transcription target for 
NFAT. Dtx1 deficiency does not affect t cell 
development. Egr2 unchanged in dtx1 
overexpression but cblb decreased. Deltex 1 
addition adds increases Egr2-Cblb expression. 
Cblb regulated by deltex1 via Egr2 
Zheng, 2012 Egr2-/- - th1 
clones, and mice 
dgk, Egr2 dgk  Egr2 is needed for anergy induction in vitro 
and in vivo. Egr2 regulates Dgk expression on 
anergy induction 
Oh, 2015 A.E7 and Ndrg1-/- 
mice CD4 T cells 
Ndrg1, Egr2 Ndrg1  Ndrg1 upregulated during anergy,Ndrg1 
overexpression mimics anergic state. Ndrg1 is 
degraded by CD28 signalling. Ndrg1 is a 
downstream target of transcription factor 
Egr2. Ndrg1-/- mice resistant to anergy 
induction  
Egr2-/-Egr3-/- 
knockout 
model 
Egr2-/-Egr3-/- CD4 
T cells  
Egr2, Cbl-b, Itch, 
Dgk-alpha, Egr3 
 Cbl-b, Itch, Itch, 
Dgk alpha  
Egr2 and 3 do not play a role in tolerance 
induction. Egr2 and 3 play a role in 
inflammatory cytokine production within the 
tolerant setting.  
Table 5 In-Vitro anergy induction with anti-CD3 studies 
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Chapter 4. In-vivo tolerogenic induction in Egr2 and 
Egr3 knockout CD4 T cells 
4.1 Introduction 
Self-reactive T cells are still able to bypass central tolerance mechanisms creating a need for 
peripheral tolerance. This may be due to self-antigens being poorly presented by the MHC 
molecule, self-antigens being presented at too low an avidity, or some foreign antigens cross 
reacting to self-antigens resulting in the development of autoimmune disease (Wasterberg, 
Klein and Snapper, 2008)(Romagnani, 2006; Zehn and Bevan, 2006). 
Anergy, the state of functional unresponsiveness, results when the T cells are stimulated in the 
absence of co-stimulation. As anergy has been studied widely in vitro, there have been a 
number of proposed mechanisms in vivo which is induced in a different manner (Shwartz, 
2003). These mechanisms include repeated antigenic stimulation, adoptive transfer, oral 
induction through proteins, and the use of superantigen toxins. In the in vivo or adoptive 
tolerance model, antigen challenge results in a large amount of T cell death with the remaining 
cells being classified as anergic (Sundstedt et al., 1996). Like in vitro anergic cells, these cells 
have decreased levels of proliferation and decreased production of IL-2. Superantigens have 
been reported to stimulate T cells outside of the peptide binding groove, allowing for a much 
larger T cell number to be activated (20%). Superantigens are primarily toxins that are able to 
cause diseases such as toxic shock syndrome in humans, but they do not have the same effect 
in mice. They include staphylococcal enterotoxin A and B (Sundstedt et al., 1994). Reports 
have shown repeated administration of superantigen to mice will result in a state of in vivo 
tolerance or adoptive tolerance. However, it has been reported that the mice must be 
constantly treated to maintain the tolerant state, and if treatment is stopped the mice regain 
their ability to produce high levels of inflammatory cytokines such as IFN-γ and IL-2. 
Proliferative function would also be returned. Therefore the use of superantigens is a 
reversible mode of tolerance induction (Anderson et al., 2006; Sundstedt et al., 1996).  
Egr2 has recently been studied in the tolerance condition with some groups also looking at it 
within the in vivo mechanisms (Zheng et al., 2012), with Egr2-/-Egr3-/- mice exhibiting high 
levels of inflammatory expression cytokines such as IFN-γ and IL-17. In order to assess the 
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function of Egr2 and 3 in tolerance, we sought to induce adoptive tolerance within our CD2-
Egr2-/-Egr3-/- mouse model to investigate the role of Egr2 and Egr3 in vivo using superantigen 
staphylococcal enterotoxin A (SEA) to induce tolerance. 
4.2 Methods 
4.2.1 In-vivo mouse treatment  
Mice were housed in the animal unit in Brunel University according to established institutional 
guidelines under the authority of the UK Home Office project licence. All WT and Egr2-/-Egr3-
/- mice were age and sex matched before each experiment and WT mice used as controls.  
In order to induce tolerance WT and Egr2-/-Egr3-/- mice were injected interperionatally (IP) 6-
8 times with 20μg/ml SEA diluted in 100ml PBS per injection per mouse (16 mice were used on 
average per experiment). This was done twice a week or 3 days apart. For an activated sample, 
mice were injected just once 24 hours before experiment end. Control samples went either 
uninjected or were injected with 100μl 1XPBS. All mice were culled at the same time and 
samples collected.  
4.2.2 Ex-vivo cell culture 
Spleens were collected the day after the activation injection and red blood cells removed by 
the addition of 0.8% ammonium chloride. Cells were then treated with CD4 beads for 20 
minutes and using a positive selection kit, CD4 positive cells were isolated by Magnetic 
Activated Cell Sorting (MACS). CD4- T cells and APCs were then treated with mitomiycin to 
stop intracellular function for 30 minutes at 37°C. APCs were loaded with SEA at 10μg/ml SEA 
for 3 hours, washed and cultured with CD4+ T cells at a 50:50 ratio. Some cells were collected 
here for flow cytometry and RT-PCR (see Chapter 2). Cells were stimulated for 48 hours before 
supernatant collection for ELISA and 72 hours later were treated with 3[H]-TdR for 16 hours.  
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Figure 54: Ex-vivo cell culture 
WT and Ehr2-/-Egr3-/- mice spleens were collected and CD4 T cell isolation carried out. CD4- T cells 
were used as antigen presenting cells (APCs). They were firstly treated with mitomiycin and then loaded 
with superantigen staphylococcal enterotoxin A (SEA) at a concentration of 10μg/ml. APCs were then 
cultured with CD4+ T cells at a 50-50 ratio for 48 hours at 37°C before collection of supernatant for 
ELISA. After 72 hours 3H-TdR (tritium) was added for 16 hours and proliferation values assessed.  
 
4.3 Results 
Once we determined in vitro anergy within CD2-Egr2-/-Egr3-/- mice, we looked into in vivo 
anergy induction. In vivo anergy induction is often referred to as adoptive tolerance and 
anergy has been shown to differ in a number of ways compared to the in vitro process. One 
similarity though is that Egr2 and 3 have also been found to play a critical role in the in vivo 
process, with previous publications showing increased levels of Egr2 and Egr3 in tolerant T 
cells (Zheng et al., 2012).  
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4.3.1.1 Egr2 and Egr3 have no effect on the CD4+Vβ3 T cell subset  
Adoptive tolerance or in vivo anergy is a state that causes the functional underactivity within T 
cells in vivo (Schwartz, 2004; Shwartz, 2003). This is due to the continuous stimulation of T 
cells with superantigens.  
CD2-Egr2-/-Egr3-/- mice were developed in the C57BL/6 background (Li et al., 2012a). This 
allowed for the use of superantigens staphylococcal enterotoxin A or B to stimulate T cells 
within mice. Superantigens are able to affect the V beta regions within T cells, thus the 
superantigen used is dependent on this crucial factor. It is known that superantigens activate T 
cells expressing certain TCR variable region beta chains (Vβ). Binding of the superantigens to 
MHC class II does not require processing and the sequences on the MHC ii and TCR vβ involved 
are distinct from the parts engaged in interaction with conventional peptide antigens 
(Dellabona et al., 1990).  
To confirm normality of the CD4+ Vβ3 region within Egr2-/-Egr3-/- CD4 T cells, the cells were 
stimulated with SEA and Vβ3 expression assessed via flow cytometry. A similar level of Vβ3 
expression within the WT and Egr2-/-Egr3-/- CD4 T cells was shown (see Figure 55). Thus Egr2 
and 3 deficiency does not alter the TCR variable region 3 allowing for optimal stimulation using 
superantigen staphylococcal enterotoxin A (SEA).  
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4.3.1.2 Egr2 and Egr3 are not essential in the induction of T cell tolerance in vivo 
Adoptive tolerance or in vivo anergy is induced by continuous stimulation of a TCR Vβ region 
using a superantigen. Egr2 and 3 have been found to play a critical role in the in vivo process 
with previous publications showing increased levels of Egr2 and Egr3 in tolerant T cells (Safford 
et al., 2005).  
Previously it has been demonstrated the induction of adoptive tolerance is due to repeated 
injections of superantigens to mice. It has been found that superantigens induce an 
exaggerated initial T cell reaction, with high production of cytokines such as IFN-γ, TNF and IL-
2 (Huang et al., 2007). Similarly, on treating both WT and CD2-Egr2-/-Egr3-/- CD4 T cells with SEA 
for 24 hours, there was a dramatic increase in IL-2 compared to samples with CD3 and CD28 
(Figure 56). As we have shown, Egr2 and 3 do not affect the activation of Vβ subsets. We 
injected WT and Egr2-/-Egr3-/- mice with SEA at 20μg/100μl PBS once. We collected serum from 
the mice on days 0, 1 and 4 in order to establish the optimal tolerance induction setting. In 
accordance with previous publication, IL-2 concentration was at its highest 24 hours post 
injection. The initial exaggerated reaction is then followed by decrease in effector cytokines 
(Huang et al., 2007). Indeed by day 4 we found decreased expression of IL-2 (Figure 56).  
 
Figure 55 Vβ3 population in naïve Egr2-/-Egr3-/- mice and WT mice 
CD4 T cells were isolated from WT and Egr2-/-Egr3-/- mice were collected and stained with Egr2 and 
Vb3 before FACS analysis. Figure is representative of gating performed before FACS analysis. 
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We adopted a well-used protocol whereby sex and age matched mice were treated with 
superantigen SEA twice a week for 4 weeks at a dose of 20μg/100μl PBS via intraperonatal 
injection or just once as an activated sample. Mice were culled after multiple injections and 
mice injected just once were used as a positive control. CD4 T cells isolated were further 
cultured in 10μg/ml SEA ex vivo before analysis. For an optimal activation protocol with 
antigen presenting cells, we treated both WT and CD2-Egr2-/-Egr3-/- APCs with mitomiycin to 
stop any DNA replication and cultured the cells at a concentration of 10μg/ml with CD4 + T 
cells. Testing of Egr2-/-Egr3-/- APCs and WT APCs gave a similar result in terms of IL-2 
production, thus we carried on with WT APCs as our antigen presenting cells. Antigen 
presenting cells were then loaded with 10μg/ml SEA for 3 hours before culturing alongside 
CD4 T cells to allow optimal stimulation and production of IL-2 and proliferation (see Figure 57 
and Figure 58). 
 
Figure 56 Decreasing IL-2 concentration in serum from wild type and Egr2-/-Egr3-/- mice treated once 
with SEA  
WT and Egr2-/-Egr3-/- mice were treated once with 20μg SEA and serum collected on days 0, 1, 4. IL-2 
levels were measured from serum by ELISA. The data presented is a mean of three replicates from two mice 
and represent three independent experiments with similar results. Error bars calculated from standard 
error values. Statistical analysis was calculated using students T-test and p values set as follows –P<0.05 *, 
P<0.01 **, P<0.001***, NS-not significant 
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Figure 57 Acceptable IL-2 concentration in CD4 T cells from WT and Egr2-/-Egr3-/- loaded with APCs  
Naïve CD4 T cells from WT and Egr2-/-Egr3-/- were cultured for 48 hours with addition of 10μg/ml SEA 
without loading, loaded first with APCs for 3 hours with 10μg/ml SEA and washed before culture with 
CD4 T cells or without SEA. After 48 hours, medium collected was assessed for IL-2 production using 
ELISA. Error bars calculated from standard error values. The data presented is representation three 
independent experiments with similar results. 
 
 
Figure 58 Increased proliferation levels in CD4 T cells from WT loaded with APCs  
Naïve CD4 T cells were cultured for 48 hours with addition of 10μg/ml SEA without loading, loaded 
first with APCs for 3 hours with 10μg/ml SEA and washed before culture with CD4 T cells or without 
SEA. After 72 hours, proliferation was assessed by addition of 3H over 8 hours. Error bars calculated 
from standard error values. The data presented is representation three independent experiments 
with similar results. 
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Using this protocol wild type and Egr2 and 3 knockout mice were injected 8 times using SEA. 
CD2-Egr2-/-Egr3-/- CD4 T cells have already been shown to have reduced IL-2 levels. In 
accordance with this previous in vitro observation we found decreased levels of IL-2 in the WT 
CD4 T cells from mice treated with 8 injections of SEA cells compared to the WT after 
treatment with one injection of SEA (Figure 59), we also found reduced proliferation levels 
within samples treated with 8 injections compared to one injection (Figure 59). Importantly 
we observed a similar view within the Egr2-/-Egr3-/-CD4 T cells. The reduction of IL-2 and 
proliferation is significant between the active and tolerant samples, indicating tolerance 
induction is taking place in the WT and Egr2-/-Egr3-/- CD4 T cells.  
 
Figure 59 Impaired IL-2 production in WT and Egr2-/-Egr3-/- CD4 T cells in response to tolerogenic 
stimulation with SEA  
WT and Egr2-/-Egr3-/- CD4+ T cells from mice injected ip with SEA once (active) or 8 times (to induce 
tolerance) or without an injection (unstimulated) and cultured ex vivo in 10μg/ml SEA for 48 hours and 
supernatant collection. IL-2 production was assessed using ELISA. The data presented is a mean of three 
replicates from twelve mice per experiment and represent six independent experiments with similar results. 
Cells without stimuli served as negative controls. Error bars calculated from standard error values. Statistical 
analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-
not significant. 
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B  
 
Figure 60 Impaired IL-2 production and proliferation in WT and Egr2-/-Egr3-/- CD4 T cells in response to 
tolerogenic stimulation using 6 injections of SEA 
CD4 T cells from WT and Egr2-/-Egr3-/- mice injected ip with SEA once (active) or 6 times with a three days 
interval (to induce tolerance) or without an injection (unstimulated) and cultured in ex vivo with SEA-
preloaded APCs at ratio of 1:1. After 24 hours, IL-2 production was assessed by ELISA (A). After 72 hours and 
3H-Tdr added for a further 16 hours to quantify proliferation (B). The data presented is a mean of three 
replicates from twelve mice per experiment and represent six independent experiments with similar results. 
Cells with stimuli served as negative control. Error bars calculated from standard error values. Statistical 
analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, P<0.001***, NS-
not significant. 
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4.3.2 Phenotypic identification of in vivo tolerised T cells  
The induction of in vivo anergy involves the constant exposure of the antigen to the cell and as 
a result apoptosis ensues leaving behind an unresponsive group of cells. Egr2 and 3 have been 
reported to play a significant role in T cell activation and proliferation. There are specific 
markers to allow for the identification of specific T cell subsets. These markers include CD44 
and CD69 for activated memory T cells, and CD62L for identification of naïve T cells (Oehen 
and Brduscha-Riem, 1998). Anergic T cells can be distinguished from the lack of IL-2 and 
proliferation but anergic cells can also be identified from non anergic cells using phenotypic 
expression. To establish this, we used in vivo tolerance induction of WT and CD2-Egr2-/-Egr3-/- 
mice and identified surface markers using flow cytometry. CD2-Egr2-/-Egr3-/- T lymphocyte 
subpopulation within tolerant T cells exhibited decreased levels of T lymphocyte activation 
marker CD69 compared to the activated sample (Figure 61); this result mirrored the situation 
within WT samples. We found increased levels of CD44-CD62L+ within the tolerant T cells in 
both WT and Egr2 and 3 knockout (Figure 63A). We found the tolerant Egr2-/-Egr3-/- CD4 T 
cells had a larger decrease in CD44-CD62L+ expression compared to the WT tolerant (Figure 
63B) showing a 2.3 fold increase compared to a 1.5 fold increase in the WT. 
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Figure 61 Decreased activation of CD4 T cells from tolerant WT and Egr2-/-Egr3-/- mice 
Flow cytometry phenotypic analysis of CD69 and CD62L population in naïve CD4 T cells from WT and 
CD2-Egr2-/-Egr3-/- mice that were either Naïve (untreated), Active (treated once with SEA at 
20μg/injection ip), or Tolerant (treated 8 times with SEA at 20g/injection ip). The data presented is a 
representation of one of three experiments. Cells were gated on CD4+Vb3+ population.  
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Figure 62 CD69 expression showed tolerant phenotype of CD4 T cells.  
(A)Graphical presentation from Figure 61. Flow cytometry phenotypic analysis of CD69 population in 
naïve CD4 T cells from WT and CD2-Egr2-/-Egr3-/- mice that are: Naïve (untreated), Active (treated once 
with SEA, or Tolerant (treated 8 times with SEA).(B) Fold change analysis of CD69 expression which 
decreases by 7.5 fold in the WT and 2.5 fold in the Egr2-/-Egr3-/- tolerant CD4 T cells. The data 
presented is a representation of one of three experiments. Cells were gated on CD4+Vb3+ population 
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Figure 63 CD62L+ population in CD4 tolerant T cells  
(A)Flow cytometry phenotypic analysis, adapted from Figure 61, of CD62L population in naïve CD4 T 
cells from WT and CD2-Egr2-/-Egr3-/- mice that were either Naïve (untreated), Active (treated once with 
SEA at 20μg/injection ip), or Tolerant (treated 8 times with SEA at 20g/injection ip). (B) Fold change 
analysis of CD44-CD62L+ expression, which increases by 1.5 fold in the WT and 2.3 fold in the Egr2-/-
Egr3-/- tolerant CD4 T cells. The data presented is representative of three experiments.  
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We then went on to look at another T lymphocyte activation marker, CD44. On treating CD4 T 
cells with either 8 injections of SEA (tolerant) or one injection (active). Cells were stained with 
CD44, CD69, Egr2 and CD62L and flow cytometry analysis carried out on the CD4+Vβ3 
population (Figure 64). The CD44 population within tolerant T cells reduced significantly 
compared to the activated, indicating tolerance induction within our CD2-Egr2-/-Egr3-/- T cells 
similar to that of the WT (Figure 65). These results therefore highlight in vivo T cell tolerance 
induction is not fully dependant on Egr2 or Egr3. They also show Egr2-/-Egr3-/- CD4 T cells are 
able to maintain the tolerant condition of increased naïve T cells and decreased activation 
markers. 
 
 
Figure 64 Phenotypes of tolerant CD4 T cells In-vivo 
Flow cytometry phenotypic analysis of CD69,Egr2,CD44 and CD62L population in naïve CD4 T cells from WT and 
CD2-Egr2-/-Egr3-/- mice that were either Naïve (untreated), Active (treated once with SEA at 20μg/injection 
ip), or Tolerant (treated 8 times with SEA at 20g/injection ip). Cells were gated on the CD4+Vb3+ population. 
The data presented is a representation of one of three experiments with similar results.  
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Figure 65 CD44 Expression in CD4 tolerant T cells decreases 
(A)Flow cytometry phenotypic analysis, adapted from Figure 64, of CD69 population in naïve CD4 T cells 
from WT and CD2-Egr2-/-Egr3-/- mice that are: Naïve (untreated), Active(treated once with SEA), or 
Tolerant (treated 8 times with SEA). Fold change analysis of CD44 expression which decreases by 2 fold in 
the WT and 1.5 fold in the Egr2-/-Egr3-/- tolerant CD4 T cells. The data presented is a representation of 
one of three experiments with similar results.  
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4.3.3 Inflammatory cytokine production within in vivo tolerant CD4 T cells 
Superantigen stimulation has been shown to induce an exaggerated cytokine response within 
CD4 T cells. As in vivo anergy induction is dependent on peptides such as superantigens, the 
increase in cytokines included those of the inflammatory nature (Sundstedt et al., 1994). On 
treatment of CD4 T cells from WT and Egr2-/-Egr3-/- mice once with SEA, we observed 
increased levels of IFN-γ within WT and Egr2-/-Egr3-/- CD4 T cells. Egr2/3 knockout mice have 
already been reported to have increased levels of IFN-γ which is evident in our results (Figure 
66). As Egr2 and 3 have been found to play a role within in vivo anergy induction (Safford et 
al., 2005), there has been no speculation of their roles within the control of cytokine 
production.  
In vivo tolerance is maintained by repeated injections of the antigen, with a decrease in 
cytokine expression taking place after a number of injections (Pape et al., 1998). Interestingly, 
after inducing tolerance or activating mice we observed increased levels of IFN-γ in Egr2-/-
Egr3-/- CD4 T cells after multiple injections of SEA (Figure 66). This was a completely opposite 
outcome to the WT where activated samples treated once with SEA showed increased 
concentrations of IFN-γ within both samples. The WT drastically reduced by 8 fold after 6 
injections of SEA whereas the Egr2 and 3 knockout CD4 T cells remained higher. On flow 
cytometric analysis of CD4 T cells treated either once with SEA or multiple times we further 
confirmed high levels of IFN-γ production within tolerant Egr2-/-Egr3-/- CD4 T cells compared 
to WT (see Figure 67 Figure 68).  
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Figure 66 Increased IFN-γ concentration in tolerant naïve CD4 T cells from CD2-Egr2-/Egr3- mice  
WT and Egr2-/-Egr3-/- CD4+ T cells from mice treated with once (active) or 6 times with a three-day 
interval (tolerant) with SEA at 20μg in vivo and cultured with SEA-reloaded APCs in ex vivo for 48 hours 
before collection of supernatant. IFN-γ quantification was done by ELISA. Cells cultured without stimuli 
served as negative controls. The data presented is a mean of three replicates from and represent three 
independent experiments with similar results. Error bars calculated from standard error values. 
Statistical analysis was calculated using students T-test and p values set as follows –P<0.05 *, P<0.01 **, 
P<0.001***, NS-not significant 
In-vivo tolerogenic induction in Egr2 and Egr3 knockout CD4 T cells 
 
 
128 
 
Figure 67 High IFN-γ expression in naïve CD4 T cells from CD2-Egr2-/Egr3- mice treated with SEA 8 
times 
IFN-γ levels in naïve WT and Egr2-/-Egr3-/- CD4+ T cells from mice treated with once (active) or 8 times 
(tolerant) with SEA at 20μg/injection and cultured ex vivo with 10μg/ml of SEA for 24 hours before re-
stimulation with PMA and INO before flow cytometry analysis. Cells were stained with CD4 and IFN-γ 
and gated on the Vb3+ population. The data presented represent three independent experiments with 
similar results.  
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Figure 68 High IFN-γ expression in naïve CD4 T cells treated once or multiple times with SEA. 
IFN-γ levels in naïve WT and Egr2-/-Egr3-/- CD4+ T cells from mice treated with once (active) or 8 times 
(tolerant) with SEA and cultured ex vivo for 24 hours. Adopted from Figure 67. Before flow cytometry 
analysis. Cells were stained with CD4 and IFN-γ and gated on the Vb3+ population. The data presented 
represent three independent experiments with similar results. 
4.3.4 T-bet induction in anergic T cells 
We have shown Egr2-/-Egr3-/- tolerant CD4 T cells to have increased levels of IFN-γ, which has 
not been reported in other studies. With increased IFN-γ expression within tolerant T cells due 
to Egr2 deficiency, we investigated the control of the inflammatory cytokine production. T bet 
or T box expressed in T cells is a transcription factor responsible for the TH1 program of naïve 
CD4 T cells. T bet is responsible for the activation of IFN-γ after its activation by STAT1 (Jenner 
et al., 2009). Egr2-/-Egr3-/- mice showed increased activation of STAT1 (Li et al., 2012a). By 
inducing IFN-γ, T bet is able to control multiple aspects of inflammation (Jenner et al., 2009). 
As T bet expression has not been investigated within anergic CD4+ T cells, we treated WT and 
Egr2-/-Egr3-/- CD4 T cells with either one injection of SEA or with 8 injections of SEA. 
Surprisingly, we found T bet expression in tolerant Egr2-/-Egr3-/- CD4+CD44+ T cells treated 8 
times with SEA to be similar to that to WT tolerant CD4 T cells (Figure 69). Activated samples 
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had increased levels of T bet in the Egr2-/-Egr3-/- CD4 T cells compared to WT. As confirmed in 
histograms provided via flow cytometry in Figure 70 and Figure 71. The result within the 
tolerant samples highlights the realisation that T-bet control is essential within the 
autoimmune disease or inflammatory settings. These results therefore suggest that Egr2 and 3 
function to influence the activity of T bet and most importantly the inflammatory cytokine 
production within tolerant CD4 T cells.  
 
Figure 69 T-bet is co-induced in tolerant CD4+CD44+ T cells from WT and CD2-Egr2-/-Egr3-/- mice 
WT and Egr2-/-Egr3-/- deficient mice were treated with 8 injections of SEA ip (20μg per injection) to induce 
tolerance and compared to samples treated with 1 injection SEA (active) or untreated. CD4 T cells were 
isolated and stained for T-bet and CD44 and expression checked by flow cytometry. This result is 
representative of 1 of 3 similar experiments. The data presented is a result of three individual experiments. 
Cells were gated on the CD4+Vb3+ population. 
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Figure 70 WT and Egr2-/-Egr3-/- T-bet kinetic shift 
Flow cytometry histogram, showing the kinetic shift of different samples. WT and Egr2-/-Egr3-/- 
deficient mice were treated with 8 injections of SEA ip (20μg per injection) to induce tolerance and 
compared to samples treated with 1 injection SEA (active) or untreated. CD4 T cells were isolated and 
stained for T-bet and CD44 and expression checked by flow cytometry. Cells were gated on the CD4+ 
population. Data are representative of three individual experiments. 
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Figure 71 T-bet expression within the tolerance setting 
Flow cytometry histogram, showing the kinetic shift of different samples. WT and Egr2-/-Egr3-/- 
deficient mice were treated with 8 injections of SEA ip (20μg per injection) to induce tolerance and 
compared to samples treated with 1 injection SEA (active) or untreated. CD4 T cells were isolated and 
stained for T-bet and CD44 and expression checked by flow cytometry. Cells were gated on the CD4+ 
population. Data are representative of three individual experiments. 
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4.4 Discussion  
Within this chapter we investigated the role of Egr2 and Egr3 within the tolerance induction in 
vivo, where we found Egr2 and Egr3 knockout mice are able to undergo tolerance induction. A 
number of studies have looked at the induction of the tolerance in vivo in regard to Egr2 and 
Egr3, but they did not use the Egr2-/-Egr3-/- mouse model. Our model allows for the Egr2 
deletion within lymphocytes where the CD2 promoter is present in conjunction with the 
systemic deletion of Egr3. Other groups reported that the presence of Egr2 and 3 may be 
required for the induction of tolerance; Zheng et al. used Th1 cell lines in vitro from an Egr2 
knockout model (Zheng et al., 2012). However, it was earlier published that if Egr2 is absent, 
Egr3 is able to functionally compensate. Making the Egr2-/-Egr3-/- model an exceptional 
model to carry out in vivo studies.  
Superantigens are able to stimulate the V beta subsets of T cells and achieve T cell activation 
outside the peptide binding groove and were used to investigate the induction of tolerance in 
the absence of Egr2 and 3. This method has been used by a number of groups such as (Zheng 
et al., 2012). It has been reported that in vivo tolerance results in decreased expression of AP-
1 (Sundstedt et al., 1996). Before use we assessed Egr2-/-Egr3-/- CD4 T cells and found they 
showed a reasonable population following SEA stimulation, similar to that in WT and CHIP 
sequencing data from Egr2-/-Egr3/- CD4 T cells treated with anti-CD3 and anti-CD28 showed 
no changes in the MHC genes related to the Vb3+ T cell subset thus Egr2 and Egr3 have no 
effect on the Vb3 subset. We reported repeated stimulation of Egr2-/-Egr3-/- mice with 
Staphylococcal enterotoxin A (SEA) resulted in decreased production of IL-2 and proliferation 
(Figure 59 and Figure 59) similar to that within the WT mice. Results showed repeated 
stimulation with superantigen causes an initial upregulation of effector cytokine production 
such as IL-2 and IFN-γ and TNF-α (Shwartz, 2003), a sudden decrease in cytokine expression 
takes place after 3 days coupled with apoptosis with the cells being left behind termed 
anergic. However, some studies within tolerance induction in regard to Egr2 and 3 used just 
one injection of superantigen stimulation. As the constant treatment is needed to maintain a 
state of tolerance (Shwartz, 2003), our experimental setting seemed more fitting. Proving Egr2 
and Egr3 are not imperative in the process of tolerance induction.  
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Table 6 In-vivo tolerance induction in regard to Egr2 and Egr3 expression 
 
Tolerant cells had to be identified successfully. On T cell activation CD44 and CD69 are 
expressed while the expression of CD62L is a marker of naïve T cells. In vivo, tolerant T cells 
have been reported to have decreases in activated T cell phenotypes coupled with increases in 
naïve T cell markers (Shwartz, 2003). On tolerance induction we found a similar result within 
our Egr2-/-Egr3-/- CD4 T cells (Figure 61). Both the tolerant Egr2-/-Egr3-/- and WT cells had 
increased expression of CD62L (Figure 63). Thus tolerance can take place within Egr2 and 3 
knockout mice and phenotypically match the phenotype of 
tolerant T cells. We surprisingly found the upregulation of inflammatory cytokine IFN-γ 
following tolerance induction within Egr2-/-Egr3-/- mice compared to the WT (Figure 71). This 
result is in accordance with our in vitro data and has yet to be reported. It was previously 
reported that Egr2-/-Egr3-/- mice showed increased inflammatory cytokine production (Li et 
al., 2012b), and we were curious to see how this is controlled molecularly and what factors 
controlled the high expression of IFN-γ within a tolerant setting, a setting that mimicked that 
of autoimmune disease. Autoimmune disease is found to be due to a breakdown in tolerance, 
Reference Mouse 
model/ cell 
line  
In-vitro 
induction 
using 
anti-CD3 
In-Vivo 
induction 
method 
Egr2 or Egr3 
upregulated 
during 
tolerance? 
Summary of findings Similarity 
to our 
model 
Zha, 2006 TCR-Rag-/- 
mice and IL-2 
luc mice TH1 
clones 
yes antigenic 
administration  
no report Ras reverses anergy in Th1. 
DGK-alpha upregulated in 
anergic th1 cells 
Yes 
Safford, 
2005 
A.E7 6.5 TCR 
transgenic 
C3-HA 
yes Adoptive 
transfer 
yes Overexpression of Egr2 and 
Egr3 inhibit T cell function.  
Yes 
Zheng, 
2012 
Egr2-/- - th1 
clones, and 
mice 
yes Superantigen yes Egr2 is needed for anergy 
induction in vitro and in 
vivo. Egr2 regulates Dgk 
expression on anergy 
induction 
partial 
Egr2-/-
Egr3-/- 
knockout 
model 
Egr2-/-Egr3-/- 
CD4 T cells  
yes Superantigen no Egr2 and 3 do not play a 
role in tolerance induction. 
Egr2 and 3 play a role in 
inflammatory cytokine 
production within the 
tolerant setting.  
- 
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with an  inflammatory environment reported to be one of the major contributors to 
autoimmune disease (Lacotte et al., 2009). The inflammatory setting within our model showed 
the increase of IFN-γ, thus we investigated the role T-bet plays in this state. T bet is a 
transcription factor that is able to control the expression of IFN-γ and differentiation into the 
Th1 subset. On looking at T bet expression within the tolerant setting we found its expression 
to be similar to the WT and Egr2-/-Egr3-/- Tolerant samples (Figure 72), indicating that Egr2 
and 3 play a role in the control of inflammatory cytokine production. In conclusion this chapter 
shows Egr2 and Egr3 do not play a role in in vivo T cell tolerance induction but instead play a 
role in the control of inflammatory cytokine production. 
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Chapter 5. General Discussion 
Self-tolerance is an important function of peripheral T cells. In homeostatic conditions, self-
tolerance of T cells is controlled by extrinsic mechanisms such as regulatory T cells (T reg) and 
also intrinsic mechanisms induced by partially stimulation of T cell receptors (TCR) (Klein et al., 
2009; 2014; Vieira, 2004). Although in animal models the induction of tolerance renders T cells 
resistant to proliferate and produce IL-2, T cells from autoimmune disease patients such as 
lupus show poor proliferative response and impaired IL-2 production in response to TCR 
stimulation, but display hyper-active and inflammatory phenotypes (Kammer et al., 2002). The 
findings from this study demonstrate a novel mechanism for the control of inflammation 
tolerance mediated by Egr2 and 3 in T cells. We demonstrated that tolerant T cells are not only 
resistant to TCR mediated proliferation, but also resistant to inflammatory stimulation. 
Proliferative tolerance refers to the ability of the T cells to proliferate and produce IL-2 on 
tolerance induction while inflammatory tolerance is the ability of CD4 T cells to produce 
inflammatory cytokines under tolerogenic conditions. In this study we have reported that Egr2 
and Egr3 are not essential for the induction of proliferative tolerance, but of inflammation 
tolerance by controlling inflammatory cytokine production. 
5.1 Tolerance induction in the absence of Egr2 and Egr3 
The upregulation of Egr2 and Egr3 has been reported within tolerogenic and mitogenic 
conditions (Du et al., 2014). Anergy induction is reported to result in hindered IL-2 production 
and decrease in proliferation within CD4 T cells (Jenkins et al., 1987b), with the most common 
method of tolerance induction in vitro being the use of stimulation of the TCR with anti-CD3 in 
the absence of co-stimulation or CD28. The mechanism of anergy in vitro is mimicked in vivo 
and referred to as adoptive tolerance. Egr2 and 3 have been found to play a role within 
tolerance with studies showing its upregulation following anergy induction (Safford et al., 
2005). Our Egr2 and 3 knockout mouse model acted as a suitable tool to investigate the role of 
Egr2 and 3 within tolerance as no other group has used a similar double knockout model. We 
have reported decreased IL-2 and proliferation within Egr2 and 3 knockout CD4 T cells in vitro 
following treatment with plate bound anti-CD3 as seen within WT mice (Figure 28 and Figure 
29). Previous reports have demonstrated the use of single knockout models, transfection of 
Egr2 into T cells and T-cell cell lines, however the overexpression of Egr2 has been shown to 
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result in apoptosis which also results in reduced IL-2 and proliferation thus other methods 
result in altered physiological condition (Safford et al., 2005).  
On investigating the hallmarks of anergic cells, reports show anergy induction in vitro involves 
the translocation of NFAT into the nucleus allowing for its expression as we have shown within 
our Egr2-/-Egr3-/- CD4 T cells. Reversal of anergy can be achieved in two ways, firstly by the 
addition of IL-2 into culture and secondly by the addition of cyclosporine A. We found CsA 
addition to result in increased IL-2 and proliferation within Egr2-/-Egr3-/- CD4 T cells. Reports 
have shown that single knockout Egr3 mice cannot undergo anergy induction (Safford et al., 
2005), similarly on knocking out only Egr3 from CD4 T cells we found a similar result, meaning 
Egr2 and 3 play another role within the tolerance setting. Importantly we have shown the 
large role TCR signalling plays on the expression of Egr2. As Egr2 has been found to play 
multiple roles including that of T cell development, further studies are looking into its role 
within T cell differentiation. We reported Egr2 expression decreased with decreasing TCR 
signalling strength which provides a key result to understating the significance of Egr2 within 
promotion of proliferation and in doing so T cell differentiation.  
In vivo tolerance can be induced by the persistence of antigen stimulation causing 
unresponsiveness to further antigenic stimulation (Shwartz, 2003). Similarly, it adopts the 
MAPK and NFKβ pathways with the addition of the mammalian target of rapamycin (MOTR) 
pathway (Krakauer, 2013) which is induced directly by the presence of cytokines (McKay, 
2001). Harris et al. (2004b) reported the upregulation of Egr2 and 3 within the in vivo setting 
as well, while we found tolerance induction to be possible in the absence of Egr2 and 3 
following treatment with Superantigen SEA, similar to that in wild type mice. As Egr2 and 3 
have been found to play a role in this, methodology of tolerance induction may play a role in 
the different outcomes viewed, however with both IL-2 and proliferation levels dropping 
significantly within Egr2 and 3 knockout cells after treatment with superantigen we can say 
tolerance was induced within Egr2 and 3 knockout CD4 T cells. Once again proving Egr2 and 3 
play an alternative role within this mechanism other than that of tolerance induction. 
Within both the in vivo and in vitro tolerance induction we found increased IFN-gamma 
expression within Egr2-/-Egr3-/- tolerant T cells compared to the WT Figure 36 and Figure 67. 
As this is yet to be reported, we looked into the control of said cytokine. T bet is the 
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transcription factor responsible for T cell differentiation into the Th1 subset, allowing for 
inflammation within the body. On inducting tolerance on WT and Egr2-/-Egr3-/- knockout mice 
we discovered expression in tolerant WT to mimic that within tolerant Egr2-/-Egr3-/- CD4 T 
cells, revealing a possible role for Egr2 and Egr3 within the control of inflammatory tolerance.  
A number of anergy associated genes have been investigated within the tolerance setting. We 
have reported that within Egr2-/-Egr3-/- CD4 T cell tolerance induction, there is still high 
expression of tolerance associated genes. This includes E3 ubiquitin ligase genes which carry 
out the final step in the ubiquitination cascade, catalysing transfer of ubiquitin from an E2 
enzyme to form a covalent bond with a substrate lysine. cbl-b and itch have been found to be 
upregulated within anergy. In addition, we looked at the expression of diaglycerol kinase alpha 
(DGK-α) which we found to be upregulated, as did other groups (Zheng et al., 2012). Recently 
the gene Ndrg1 has been investigated with regard to Egr2, and we found similarities between 
the upregulation of cbl-b, itch and dgk alpha. Ndrg1 has been reported to be upregulated 
within the anergy induction. Its overexpression has been shown to result in the induction of a 
state similar to that of anergy. Its expression has been found to fall downstream of Egr2 (Oh et 
al., 2015).  
We looked at the expression of Bach2 which we found to be unchanged within the anergic 
setting in WT and Egr2-/-Egr3-/- CD4 T cells. BACH2 is expressed with T regulatory (Treg) cells 
(CD4+CD25+) and has been reported to be promote tumour immunosuppression 
(Roychoudhuri et al., 2013). It has been reported to be highly expressed within T cells with a 
high affinity for an antigen. Our results confer with previous results from Li et al. in that Treg 
expression remained unchanged within WT and Egr2-/-Egr3-/- CD4 T cells (Li et al., 2012b), 
which correlated with the development of autoimmune disease. It has been reported that 
CD4+CD25+ cells are able to facilitate anergy induction (Ermann et al., 2001). We also assessed 
the expression of TCF-1 and Bhlhe40 and found reduced TCF-1 levels with both Egr2-/-Egr3-/- 
and WT tolerant CD4 T cells. Bhlhe40 has been reported to encourage differentiation toward 
the Th1 lineage (Lin et al., 2014). In activated Egr2-/-Egr3-/-CD4 T cells we found its expression 
to be upregulated, however the expression fell within tolerant Egr2-/-Egr3-/- CD4+ T cells. Egr2 
and 3 knockout CD4+ T cells have been reported to have high levels of Th1 cells with increased 
levels of IFN-γ (Li et al., 2012b). We also found decreased levels of IFN-γ between Egr2-/-Egr3-
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/- activated T cells and Egr2-/-Egr3-/- tolerant T cells that directly correspond to Bhlhe40 
expression.  
5.2 Egr2, Egr3 and inflammation in the tolerant setting 
Inflammation is one of the major mechanisms that lead to tolerance breakdown and thus to 
autoimmune disease (Theofilopoulos and . Bona, 2002). Egr2 and Egr3 have been implicated in 
their roles in inflammation. Li et al. (2012a) found Egr2 and 3 knockout CD4 T cells exhibited 
increased production of inflammatory cytokines such as 1L-17A, 1L-17F and IFN-γ, but 
tolerance within the inflammatory setting had yet to be studied. In doing so we found 
induction of tolerance within Egr2-/-Egr3-/- T cells sustained elevated expression of IFN-γ, 
implying the induction of tolerance has an effect on inflammatory cytokine production control.  
Inflammation has been found to be a significant factor in the development of autoimmune 
diseases such as rheumatoid arthritis, which presents in the joint lining and is associated with 
Th1 expression (Choy et al., 2014). Tolerance induction prevents the activation of self-reactive 
T cells; however self-reactive T cells that lie latent in the periphery can still be activated by 
outside stimulus and result in inflammation. This can be seen in patients with RA, where CD4 T 
cells which lack co-stimulation are activated and skewed toward the Th1 subset resulting in 
the development of arthrosclerosis (Pasceri and Yeh, 1999). Inflammation can also be 
triggered by infection by a pathogen, and subsequent activation of dendritic cells in turn leads 
to the activation of autoreactive T cells eventually leading to autoimmunity (Turley, 2002). This 
can be seen in patients with thyroid autoimmune disorders such as Graves’ disease and 
Hashimoto’s thyroiditis, and allows for autoimmune disease development from an otherwise 
tolerant state (Millar et al., 2003). Thus inflammation is evidently one of the key factors that 
control self-tolerance and is a major factor that causes the breakdown leading to autoimmune 
disease, and multiple studies using mouse models have proven this (see Table 7). 
Essentially, the control of inflammatory cytokines is governed by specific transcription factors. 
The control of IFN-γ is controlled by the expression of T-bet which skews naïve T cells into the 
Th1 subset. With high IFN-γ levels within tolerant Egr2-/-Egr3-/- T cells we found the 
expression of T-bet to remain lowered similar to that in WT tolerant cells. T-bet has been 
implicated in the tolerant setting with studies carried out on T regulatory cells using peptides 
to induce tolerance. It was reported that Egr2 and T bet worked in this system to maintain 
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peptide-induced tolerance. However, both Egr2 and T-bet functioned in different ways to 
maintain this state (Anderson et al., 2006; Anderson et al., 2006; Anderson et al., 2006). With 
Egr2 and 3 deficient cells exhibiting increased IFN-γ in the tolerant state, even though we 
showed decreased T bet expression, this would imply a role for Egr2 and 3 in the control of T-
bet activation. Thus Egr2 and 3 play a role in inflammatory tolerance via the control of 
inflammatory cytokine production. We also viewed decreased expression of RORgt, which is 
the transcription factor that controls Th17 differentiation. These results suggest an alternative 
mechanism for tolerance induction within the inflammatory setting as expression of 
transcription factors do not correlate with cytokine production. 
  
Human disease  Human disease description Mouse model Mouse pathogenesis Inflammatory cytokines  Reference 
Multiple Sclerosis 
(MS) 
Chronic inflammatory autoimmune disease 
with affects in the central nervous system with 
cell infiltration and CNS cell demyelination 
EAE Demyelination in CNS due to 
mononuclear cell infiltration 
Involvement of CD4 T cells with 
Th1 predominant effects 
including increase in IFN-γ. 
TH17 cells promote 
inflammation via IL-17  
(Komiyama et al., 
2006)(McCarthy, Richards 
and Miller, 2012) 
Rheumatoid 
arthritis (RA) 
Chronic disease associated with systemic 
effects characterised by swollen joints, 
autoantibody production to collagen 
CIA-collagen 
induced 
arthritis using 
in DBA/1 mice 
Inflammatory infiltration, 
synovial hyperplasia and 
cartilage and bone erosion 
TNF-α, IL-1, IL-17 and IL-6 play 
biggest roles with IL-6 driving 
neutrophil activation leading to 
inflammation  
(Smolen et al., 
2007)(Asquith et al., 2009) 
Systemic Lupus 
Erythematosus 
(SLE) 
Disease characterised by production of 
antibodies to one or more self-antigens 
leading to polysystemic autoimmunity. 
Associated with renal disease 
(glomerulonephritis, nephritis), skin rash, 
hyperactivation of B and T cells, accumulation 
of inflammatory cells leading to swelling, 
defective clearance of immune complexes 
NZB/W Gene mutation loss of Fas 
ligand interaction thus lack of 
clearance of B and T cells 
promoting inflammation 
 
 
 
Pathology includes 
inflammation expression 
increased IFN-γ, IL-6, IL-17A, IL-
17F and TNF-α leading to 
inflammation.  
(Abraham and Weiss, 
2004; Mok. C.C, 2003) 
(Perry et al., 2011; 
Rottmann and Willis, July 
2010) 
(Li et al., 2012a) 
MRL/lpr high autoantibody titres, 
development of skin rash and 
inflammatory arthritis 
BXSB/Yaa Gene mutation in the Y 
chromosome thus disease 
more susceptible to males 
unlike others. Genetic defect in 
TLR-7.  
CD2-Egr2-/-
Egr3-/- 
Hyperactive B and T cells 
increase in inflammatory 
cytokines IFN-γ, IL-17 A, IL-17F. 
Development of splenomegaly 
and glomerulonephritis  
Table 7 Human inflammatory autoimmune diseases and their corresponding mouse model
  
5.3  Varying Egr2 expression in autoimmune disease 
Egr2 and 3 knockout mice have been found to have high numbers of CD4+CD44+ effector 
phenotypes. These are known to be highly cross-reactive and lead to autoimmune disease 
development (Li et al., 2012). These mice exhibit lupus-like symptoms within 4 weeks and have 
lymphocyte infiltration in multiple organs such as the kidney (Li et al., 2012). It is important to 
differentiate the roles of inflammatory disorders in comparison to breakdowns in inflammation that 
lead to autoimmune disease. Inflammatory proliferative disorders such as inflammatory bowel 
disease (IBD) exhibit normal IL-2 expression and proliferation (Fuss et al., 1996), whereas 
autoimmune disease exhibits decreased IL-2 and proliferation similar to that seen in tolerant Egr2 
and 3 knockout mice. 
Egr2 has been reported to play a role in multiple autoimmune diseases. Dendritic cells DCs play one 
of the major roles in autoimmune disease development with mDCs and PDCs playing a role in 
multiple sclerosis development. Egr2 is reported to be expressed in at the later stages of DC 
development and have decreased expression of SOCS1. Reduced Egr2 expression within DCs has 
been shown to affect IL-12 generation within MDCs (Miah et al., 2013), with Egr2 knockdown DCs 
showing increased levels of MHC class I and II molecules and co-stimulatory molecules (Miah et al., 
2013). This would suggest that the absence of Egr2 in our model would cause autoimmunity through 
the increased production of inflammatory cytokines via increased activation of mDC. It has also been 
reported that Egr2 plays a role in the development of T regulatory cells (Okamura et al., 2012), 
which are important in the maintenance of the immune system to avoid autoimmune disease. 
Interestingly, the production of T reg cells within the Egr2/3 knockout mouse model was found to be 
unchanged (Li et al., 2012b). Our analysis of the BACH2 gene also showed levels of Treg remained 
similar within the tolerant setting in Egr2/3 knockout mice.  
In autoimmune disease, Egr2 has been shown to play roles in systemic Lupus in Japanese 
populations, where polymorphisms within the Egr2 gene are linked to SLE (Myouzen et al., 2010). In 
multiple sclerosis which is a chronic inflammatory demyelinating disorder of the central nervous 
system the levels of Egr2 within patients had decreased and similarly to our model there were 
increased levels of IL-17 (Miao et al., 2013). Interestingly, this is not the pattern with Egr2 within 
autoimmune disease, and in studies on systemic sclerosis (SSc) and scleroderma the expression of 
Egr2 elevated disease severity. It was reported that Egr2 was upregulated in skin biopsies collected 
from SSc patients and the SSC mouse model (Fang et al., 2011). Thus the balance of Egr2 expression 
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within autoimmune disease plays a very important role, proving there is still a way to go with its 
expression in autoimmune disease in relation to therapy.  
Egr2 has been shown to play a role during infection. It was found that CD2-Egr2 knockout mice have 
increased viral load in their lungs compared to WT or Egr1 knockout mice following inflection with 
influenza (Du et al., 2014). We found CD2-Egr2-/-Egr3-/- mice to have increased viral load coupled 
with a decrease in neutralising antibody following viral infection, showing Egr2/3 are important in 
the production of virus specific antibodies that are needed for clearance (Ogbe et al., 2015). 
These results therefore show the importance of Egr2 and Egr3 within the control of inflammation, 
tolerance breakdown and viral clearance. Egr2 can then be applied directly to the treatment of 
patients with autoimmune disorders in the future as in the case of SSC where the addition of TGF-β 
stabilises the expression of Egr2 resulting in normal fibroblast production (Fang et al., 2011). 
Identification of mutations within the Egr2 locus could help not only diagnose the cause of disease 
but within inflammatory disorders it can be applied to better control the severity of ongoing illness. 
In this case Egr2 and 3 can be used in the control of autoimmune disease severity. 
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Chapter 6. Conclusions, limitations and future work 
Our previous work has shown a role for Egr2 and 3 within the development of B and T cells coupled 
with the role of Egr2 in the prevention of autoimmunity. Based on the findings, having already 
shown inflammation within Egr2 and Egr3 knockout mice, we have now shown that tolerance can be 
induced in the absence of transcription factors Egr2 and Egr3 in vitro and in vivo. We found 
tolerance induction in Egr2 and 3 knockout CD4 T cells to be NFAT dependant with Egr2 and 3 
knockout T cells upregulating expression of tolerance associated genes. Thus we found that Egr2 and 
3 play a more important role in preventing inflammation of tolerant T cells, rather than tolerance 
induction.  
We also looked at the control of Egr2 expression within the mitogenic setting and found this to be 
dependent on the strength of antigenic stimulation. This suggests that the expression of Egr2 
through T cell receptor activation can therefore directly influence T cell proliferation and production 
of IL-2 within CD4 T cells. As we have previously reported, the induction of tolerance is possible in 
the absence of Egr2 and 3 as tolerance induction is independent of AP-1 activation. We have also 
shown a possible role of Egr2 and 3 in the control of inflammation within tolerant T cells, as tolerant 
Egr2 and 3 negligent mice still exhibit high expression of IFN-γ. A diagrammatic representation of the 
role of Egr2 and 3 within inflammatory tolerance is shown in Figure 72 . 
In summary the presence of Egr2 and Egr3 is not imperative for tolerance induction to take place. 
We found that TCR signalling governs the expression of Egr2 and thus dictates proliferative function 
in T cells. Egr2 and 3 thus do not play a role in proliferative tolerance. We found Egr2 and 3 functions 
to control inflammation within the tolerant setting, and may play a role in the control of activation 
of T bet. Egr2 and 3 may therefore be able to regulate the effector function of tolerant T cells within 
the inflammatory setting, possibly influencing the inflammatory severity within autoimmune 
disease. 
As tolerance has yet to be studied within an inflammatory setting, the Egr2 and 3 knockout mouse 
model is an appropriate mouse model for this. However, this study was not without limitations. The 
potential role of Egr2 and 3 within inflammatory tolerance has been established, but IFN-γ is only 
one of the factors that give rise to inflammation. In order to truly look into inflammation and 
tolerance the consideration of other inflammatory cytokines such as IL-17, IL-6 and TNF-α needs to 
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be further investigated. Li et al. (2012b) reported that Egr2 and 3 knockout mice presented with 
increased inflammatory cytokines in addition to IFN-γ, but this study did not look into the remaining 
cytokines which may also contribute to inflammatory tolerance. The molecular mechanisms of Egr2 
and 3 direct interactions with that of the transcription factor T bet have also yet to be confirmed. In 
addition, the Egr2 and 3 knockout model provides only one inflammatory setting on which to work 
with, where there are multiple models (as seen in Table 5 and Error! Reference source not found.) 
that can be used for similar inflammatory tolerance studies. As Egr2-/-Egr3-/- mice have been found 
to develop symptoms after 4-6 weeks, autoimmune disease models such as EAE would be more 
stable to work with as these would have established autoimmune disease at any age.  
 
Figure 72 Diagrammatic representation of Egr2 and Egr3 in tolerance inflammation 
On tolerance induction TCR signalling leads to NFAT activation which leads to Egr2 and 3 expression. During 
inflammatory tolerance, the absence of Egr2 and 3 lead to T-bet activation and the production of 
inflammatory cytokine IFN-γ in the tolerant state. This means that Egr2 and 3 play a crucial role in the 
control of inflammatory tolerance.  
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The findings from this study demonstrate a novel tolerogenic mechanism for Egr2 and 3 within the 
control of inflammation. As we have found the expression of Egr2 to be directly linked to the TCR 
signalling, it would be interesting to be able to quantify the true expression of Egr2 and 3 during T 
cell reactions. It would also be interesting to further investigate the expression of other genes within 
the tolerant Egr2 and 3 negligent CD4 T cells, as we found anergy induction to take place in the 
absence of Egr2 and 3. Because the role of tolerance has not been investigated within the 
inflammatory setting, CHIP sequencing or microarray carried out on tolerant Egr2-/-Egr3-/- would 
allow for a larger array of gene expression to further investigate the mechanisms in the control of 
inflammation within the tolerant state and identify new genes involved. Egr2 has also been 
implicated in the expression of ‘anergy associated genes’. It would be interesting to investigate this 
further, especially in terms of the ubiquitin ligase genes and their control within the tolerant setting. 
As we have already carried out an EMSA for the presence of NFAT, in order to confirm NFAT binding 
it would be good to look at a super shift analysis where anti-NFAT oligonucleotides would be 
incorporated to prove the binding of NFAT within the complexes. Egr2-/-Egr3-/- mice have been 
reported to have a decreased number of thymocytes (Li et al., 2011) and this may be because Egr2 is 
required for thymocte development in the DN1 and DN2 stages. However the DN4 and DP stages are 
not affected by Egr2 expression. In order to prove positive selection is completely functional within 
the model under the tolerance conditions, an MHC class II knockout model could be applied, and 
mitogens could be used to rule out defects in negative selection as they allow for weak self-antigen 
monitoring of negative selection.  
Additionally, our group has recently come up with a knockin model of Egr2 (Miao et al (2016)-in 
review). Egr2 knockin has a fluorescence tag to Egr2 expression using GFP. This model opens a whole 
new array of experimental opportunity with the ability to track Egr2 within homeostatic, mitogenic 
and tolerogenic conditions. This means the expression of Egr2 within tolerance induction can 
possibly be shown in vitro as well as in vivo. It would act to confirm what we have already found and 
would show Egr2+CD44 high to have high proliferation and low IFN-γ production against the Egr2-
CD44 high, showing low proliferation and high IFN-γ production. The use of animal models such as 
cblb-/- mice or itch-/- mice would allow the studies of not just inflammation and autoimmune 
disease, but also of tolerance. Monitoring the expression of Egr2 and 3 within such models would 
provide new insight into their role in tolerance induction as well identify novel roles in the control of 
ubiquitin ligase genes within tolerance.  
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In a similar manner this study could be expanded and further confirmed using the most commonly 
used form of pMHC (peptide-major histocompatibility complex) multimurisation called tetramers. 
Tetramers are used to identify specific T cell populations and are fluorochrome conjugated allowing 
easy analysis via flow cytometry (Wooldridge et al., 2009). Tetramers have been used in tolerance 
studies such as by david and group, Where peptide induced tolerance was achieved (David et al., 
2014). However our method differed; Bacterial superantigens have been found to provide a strong 
cross-linking to enable the investigation using pMHCII tetramer use allowing for direct staining of 
samples ex-vivo. Tetramer use would provide identification of TCRs (Massey et al., 2007). This would 
allow for a more specific population to be identified within our model following tolerance induction 
and a much faster analysis. In addition the use of our model backcrossed within the TCR transgenic 
Rag2-/- background would create an excellent environment for the true nature of Egr2 and Egr3 
knockout CD4 T cells. Similarly to safford and group the induction would be monitored within a 
neutral environment. To add to this, the use o EMSA can be adopted within in-vivo treated CD4 
Tcells; by the monitoring of the transcription factors AP-1 and NFκβ. 
Toll-like receptors (TLRs) are pattern recognition receptors that are able to recognise distinct 
pathogen-associated molecular patterns (PAMPS) that are conserved in specific microorganisms. 
Domininguez-Villar et al. (2015) recently showed that TLR7 is able to induce anergy in human CD4+T 
cells by silencing the expression of TLR7 in CD4+ T cells using the HIV-1 infection, as these induce 
high levels of CD4+ T cells. They then went on to investigate the calcium flux where NFATc is 
activated; in doing so they carried out an NFATc knockdown within the CD4 T cells. It would be 
interesting to see the effects of NFAT knockdowns within the tolerance induction models. Their 
investigation took place within a viral environment, but it is not clear what would happen in a 
human autoimmune disease inflammatory environment. Since viruses have been found to be among 
the factors that influence autoimmune disease development, and so it would be something worth 
investigating. 
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Figure 73 IL-2 concentration in naïve CD4 T cells from wild type and CD2-Egr2-/Egr3- mice with WT or Egr2-/-
Egr3-/- negative cells show similar IL-2 production 
IL-2 levels in naïve WT and Egr2
-/-
Egr3
-/- 
CD4
+ 
T cells from mice treated with one (active) or 6 injections 
(tolerant) with SEA and cultured ex vivo in 10μg/ml SEA for 48 hours before IL-2 quantification. WT and Egr2-/-
Egr3-/- CD4 T cells from mice treated just once with SEA showed increased IL-2 expression, with expression 
being increased in the WT. Similarly, samples treated 8 times with SEA from both WT and Egr2-/-Egr3-/- mice 
showed decreased IL-2 concentrations compared to mice treated once. The difference between WT and 
WGr2-/-Egr3-/- CD4 T cells is similar as cells show equal significant change. 
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Figure 74 IL-2 concentration in naïve CD4 T cells from wild type and CD2-Egr2-/Egr3- mice with SEA show 
significant changes compared to those without SEA 
Samples with SEA show IL-2 levels in naïve WT and Egr2
-/-
Egr3
-/- 
CD4
+ 
T cells from mice treated with one (active) 
or 6 injections (tolerant) with SEA and cultured ex vivo in 10μg/ml SEA for 48 hours before IL-2 quantification. 
WT and Egr2-/-Egr3-/- CD4 T cells from mice treated just once with SEA showed increased IL-2 expression, with 
expression being increased in the WT. Similarly, samples treated 6 times with SEA from both WT and Egr2-/-
Egr3-/- mice showed decreased IL-2 concentrations compared to mice treated just once. Samples without SEA 
show no significant difference. 
 
 
